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Abstract 
The next generation of cancer therapeutics will specifically target processes 
responsible for the growth and survival of cancer cells.  Among the most promising of 
these molecularly targeted therapeutics are small interfering RNAs (siRNAs).  These 
siRNAs serve as the effectors of RNA interference, a naturally occurring and highly 
specific mechanism for regulating gene expression through sequence-specific degradation 
of messenger RNA.  While these siRNAs have shown potential in vitro and in preclinical 
animal models, safe and effective systemic delivery remains one of the greatest 
challenges hindering their clinical application.  This thesis describes an engineering 
approach to address the challenge of systemic delivery of siRNAs for cancer therapy. 
 Analysis of the kinetics of siRNA-mediated gene silencing reveals that gene 
inhibition by unmodified siRNAs can last for one week in rapidly dividing cells and up to 
one month in cells with minimal division.  Additionally, chemical modifications to 
enhance siRNA nuclease stability do not prolong intracellular siRNA activity.  These 
data, when used in combination with results from a mathematical model of siRNA 
function, demonstrate that dilution from cell division, and not intracellular nuclease 
stability, is the dominant factor governing the duration of gene inhibition by siRNAs. 
Cyclodextrin-containing polycations (CDP) can self-assemble with siRNAs to 
form nanoparticles with desirable properties for systemic application.  Characterization of 
these nanoparticles demonstrates that they can contain several thousand siRNAs, protect 
the siRNA payload from nuclease degradation, and be modified with transferrin targeting 
ligands that show multivalent binding to cell surface receptors.  
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Multimodality in vivo imaging with positron emission tomography (PET) and 
bioluminescent imaging (BLI) is used to monitor the biodistribution and function of the 
siRNA nanoparticles after intravenous administration in live mice.  Attachment of 
targeting ligands to the surface of the nanoparticles enhances gene inhibition within the 
tumor, although the biodistribution and tumor localization are not dependent on the 
amount of targeting ligand.  The targeting ligand likely serves to augment nanoparticle 
uptake by the tumor cells.  When the siRNA nanoparticles are used to deliver therapeutic 
siRNAs to achieve tumor growth inhibition in disseminated and subcutaneous murine 
cancer models, schedule-dependent anti-tumor effects are observed.
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1 Introduction: Big potential for small interfering RNA in 
cancer therapy 
 
1.1 Small interfering RNAs: A new class of cancer therapeutics 
Significant progress has been made in the war on cancer, evidenced by the decline 
in cancer-related deaths in the US.  According to the National Cancer Institute, 
approximately 65% of patients diagnosed with cancer will live longer than 5 years (1).  
These numbers are expected to improve even more with the advent of novel molecularly 
targeted cancer therapies.  The traditional approach to cancer chemotherapy involves 
injecting highly toxic drugs to interfere with cell division, thereby killing the rapidly 
dividing cancer cells.  However, this non-specific killing of rapidly dividing cells also 
destroys non-cancerous cells such as those in the bone marrow, leading to potentially 
serious side effects and providing a very narrow therapeutic index.  As a result of an 
increased understanding of the molecular mechanisms underlying cancer development 
and progression, a new generation of cancer therapeutics are being developed to 
specifically interfere with molecules that are responsible for driving the growth and 
survival of the cancer cells (2).  These molecularly targeted therapies have the potential 
to exert much more selective killing of cancer cells and may substantially reduce the 
often serious complications associated with current cancer treatments. 
Small interfering RNA (siRNA) molecules are a promising new class of therapeutic 
agents that are perfectly suited for molecularly targeted cancer therapy.  The siRNA 
molecules are double-stranded nucleic acids approximately 19-21 bp in length that act as 
the effectors of RNA interference (RNAi), a naturally occurring mechanism for post-
transcriptional gene silencing (3).  siRNAs interact with their cognate mRNAs through 
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Watson-Crick base pairing and subsequently trigger degradation of the target mRNAs in 
a sequence-specific fashion.  The consequence of the mRNA degradation is a reduction in 
protein expression.  This mechanism can be exploited therapeutically to inhibit the 
expression of a wide variety of disease-associated targets (4,5).  Furthermore, because the 
RNAi mechanism results in sequence-specific mRNA degradation, it has the potential to 
help realize the goal of developing novel cancer therapies that specifically attack cancer 
cells while minimizing the effect on normal healthy cells. 
1.2 Opportunities for siRNA in cancer therapy 
 Cancer is the number one cause of death for people under age 65 in the United 
States, accounting for nearly 25% of all deaths in 2001 (6).  It is predicted that half of all 
men and a third of all women in the United States will develop cancer at some point in 
their lifetimes.  According to the World Health Organization, death rates from cancer are 
expected to increase by 104% worldwide by 2020 (7).  Needless to say, the war on cancer 
is still raging and the development of more-effective and less-toxic cancer therapeutics is 
urgently needed.  siRNA molecules have the potential to revolutionize cancer therapy by 
providing highly potent and specific cancer cell killing with drastically reduced side 
effects.  Some of the most promising targets for siRNA-based cancer therapy involve 
oncogenic fusion proteins resulting from chromosomal translocations, overexpressed or 
mutated oncogenes, or molecules controlling cell survival or division (8). 
1.2.1 Targeting chromosomal translocations 
In human cells, genetic information is stored in DNA molecules that are 
assembled into 23 pairs of protein:nucleic acid complexes called chromosomes.  
Typically, these chromosomal structures act to compact the DNA (which is nearly 3 
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meters long end to end), protect it from degradation or damage, help to control when 
particular genes are transcribed, and ensure proper replication and distribution of the 
genetic code during cell division.  Sometimes, however, these chromosomal structures 
can be disrupted by rearrangements that cause part of one chromosome to break off and 
attach to a different chromosome, a process called translocation.  Transcription factors 
and kinases involved in cell signaling, cycling, and death are common targets of the 
chromosomal translocations that can lead to cancer.  This chromosomal rearrangement 
can result in the production of an oncogenic fusion protein or it can place a gene under 
the control of a new promoter; in either case, the product can cause a cell to become 
cancerous through processes such as overexpression of certain proteins and/or 
constitutive activation of cellular processes. 
Several translocation breakpoints have been implicated in specific cancers 
including leukemias and lymphomas.  One of the most notable cases of chromosomal 
translocation is the t(9:22) that leads to the altered Philadelphia chromosome 22 in 
chronic myelogenous leukemia (CML).  This leads to production of the Bcr-Abl fusion 
protein that acts as an unregulated protein tyrosine kinase and is involved in neoplastic 
transformation.  In 2001, Novartis received FDA approval for Gleevec (imatinib 
mesylate, STI 571), a small-molecular inhibitor of this Bcr-Abl fusion protein.  Gleevec 
blocks the ATP-binding pocket of the tyrosine kinase domain of the fusion protein, 
thereby blocking its kinase activity.  This method of specifically targeting the fusion 
product represents a powerful new technique for the treatment of cancers caused by 
chromosomal translocations. 
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RNA interference is a promising therapy for these cancers because it can 
specifically target and degrade the mRNA transcript corresponding to these aberrant 
fusion genes.  Instead of blocking the action of the fusion protein itself, as performed by 
Gleevec, RNAi would degrade the transcript before translation could occur.  
Additionally, because RNAi is highly specific (even a few mismatches can abrogate 
function), it can target degradation of these unwanted fusion transcripts while leaving the 
normal versions untouched.  This means that degradation will only occur in cancer cells 
where this fusion transcript is produced. 
Another type of cancer characterized by a chromosomal translocation, t(11:22), is 
the Ewing’s family of tumors (EFT), a poorly differentiated mesenchymal malignancy 
that arises in bone or soft tissue.  It is the second most common primary osseous 
malignancy in childhood and adolescence (9).  The translocation t(11;22) is commonly 
detected in EFT and produces the chimeric EWS-FLI1 fusion gene found in 85% of EFT 
patients(10).  The EWS domain replaces the normal transcriptional activator domain in 
the 5’ region of the FLI1 DNA-binding protein, leading to altered transcriptional 
activation that contributes to the tumorigenic phenotype (9).  Reduction of the EWS-FLI1 
protein in EFT cells in vitro or in subcutaneous xenograft tumors by antisense 
oligonucleotides complementary to EWS-FLI1 mRNA results in decreased proliferation 
(11-13), suggesting a potential therapeutic intervention directed at this tumor-specific 
chimeric gene. Small interfering RNAs (siRNAs) have recently been shown to silence the 
EWS-FLI1 gene and suppress proliferation of an EFT cell line in vitro (14-16). 
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1.2.2 Reducing the expression of overexpressed or mutated oncogenes 
While fusion genes such as EWS-FLI1 represent ideal targets for RNAi because 
the sequence-specific degradation will only occur in cells expressing the fusion transcript, 
RNAi can also be used to treat cancers characterized by gene amplification and 
overexpression.  Gene amplification can result when chromosomal replication goes awry, 
leading to the production of multiple copies of certain regions in the chromosomes.  This 
can lead to the cancerous state if an oncogene such as K-ras, myc, or HER2/neu is 
included in this amplified region.  Cancer cells may also have amplification of the 
multiple drug resistance (mdr) genes, causing them to develop resistance to many 
chemotherapeutic drugs.  In 1998, Genentech received FDA approval for its drug 
Herceptin, a monoclonal antibody against the human epidermal growth factor receptor 2 
(HER2), for the treatment of advanced-stage breast cancer.  While antibodies represent a 
promising therapy for targeting cancer-specific molecules like the HER2 protein, RNA 
interference also holds promise as an effective therapy because of its ability to 
specifically degrade the transcripts of these amplified oncogenes before the proteins are 
produced.  A recent in vitro study by Faltos et al. demonstrated the use of RNAi for 
sequence-specific decrease in HER2/neu mRNA and protein levels, leading to 
antiproliferative and apoptotic responses in cells overexpressing HER2/neu (17).  This 
indicates that RNAi therapy may be a feasible treatment for cancers that are characterized 
by overexpression of certain genes. 
Another promising target for siRNA-based cancer therapy is the mutated K-ras 
gene found in over 85% of pancreatic cancers.  Currently, the five-year survival rate of 
pancreatic cancer patients is only 4.4% (1).  One of the reasons that this type of cancer is 
so deadly is that it has the ability to infiltrate nearby tissue and metastasize at an early 
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stage.  New treatment modalities are required to treat the advanced stages of this disease.  
On a positive note, much progress has been made with respect to the molecular basis of 
pancreatic cancers, revealing the prevalence of the mutated K-ras gene.  Ras proteins are 
GTPases that participate in signal transduction from growth factor receptors on the cell 
surface; a point mutation in this gene can lead to its constitutive activation that causes the 
cell to continuously receive a signal for proliferation.  Recent studies have shown that 
reduction of K-ras levels in pancreatic cancer tumors leads to loss of anchorage-
dependent growth and tumorigenesis (18,19). 
1.2.3 Controlling cell survival and death 
One of the hallmarks of cancer cells is their ability to avoid the normal regulatory 
signals that control cell growth and death (20).  Although normal cell growth and division 
is characterized by a finely tuned balance between cell division and apoptotic cell death, 
the ability of cancer cells to perturb this steady-state allows them to accumulate and 
develop into invasive tumors.  Anti-apoptotic proteins such as bcl-2 and survivin are 
overexpressed in many cancer cells.  The Bcl-2 protein helps govern mitochondrial death 
signaling, a key step in the apoptotic mechanism.  Inhibition of bcl-2 expression using 
siRNA can lead to apoptosis in vitro and slow the growth of tumor xenografts (21,22).  
Likewise, survivin has been show to help regulate cell death mechanisms by interacting 
with caspases and also helping control mitotic spindle formation.  Survivin represents a 
promising target for molecularly targeted therapies since it is upregulated in many 
cancers but minimally expressed in normal tissues (8).   Survivin inhibition by siRNAs 
can lead to cell arrest in the G2/M phase and inhibition of clonogenic survival of cancer 
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cells (23).  In other cancer types, siRNA directed against survivin can induce apoptosis 
and significantly inhibit the growth of xenograft tumors in vivo (24). 
Other possible targets are proteins that are necessary for processes involved in cell 
division.  Although these molecular targets are not necessarily unique to cancer cells, 
they are often overexpressed in rapidly dividing cancerous cells with minimal expression 
in non-mitotic cells.  Ribonucleotide reductase is an attractive target for cancer therapies 
since it catalyzes the reduction of ribonucleotides into deoxyribonucleotides necessary for 
DNA replication and repair.  Several potent siRNA inhibitors of the M2 subunit of RNR 
(RRM2) have been identified, and these siRNAs have demonstrated the ability to inhibit 
the growth of tumor cell lines after transfection in vitro and transplantation into mice 
(25).  A recent study by Avolio et al. also demonstrated the in vitro and in vivo efficacy 
of an siRNA targeting ribonucleotide reductase (26). 
1.3 The challenge of systemic siRNA delivery  
Despite the promises and hype surrounding siRNA therapeutics for cancer, the 
clinical realization of siRNA therapeutics faces several significant hurdles, foremost of 
which may be a safe and effective delivery method (27).  Naked siRNA molecules are 
rapidly degraded by nucleases present in the bloodstream, and their small size leads to 
first-pass renal clearance (4).  Chemically modified siRNAs can be designed to maintain 
functional efficacy while increasing their stability against nuclease degradation.  
Furthermore, attachment of specific targeting ligands can induce binding to protein 
carriers or uptake by the desired population of cells to be treated.  For example, siRNA 
conjugated to targeting ligands such as cholesterol and antibodies have shown efficacy 
both in vitro and in vivo (28,29).  While these methods for nuclease stabilization and 
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covalent attachment of targeting ligands are promising, nanoparticle-mediated delivery 
methods may provide functions not achievable with naked nucleic acids or direct 
attachment to targeting moieties. 
The design of nanoparticle carriers for systemic siRNA delivery aptly highlights 
the challenges and intricacies associated with attempts to manipulate biological systems.  
Many times, therapeutic interventions thought to act through a certain mechanism may 
turn out to achieve the effect through an entirely different mechanism.  Additionally, 
modifications designed to overcome a certain problem may only reveal a still more 
challenging barrier to success. 
Surface decoration with hydrophilic polymers such as polyethylene glycol (PEG) 
has been used to minimize uptake by the reticuloendothelial system (RES) and stabilize 
nanoparticles against aggregation in physiological environments (30,31).  Moreover, 
addition of targeting ligands to the surface helps to increase uptake of the injected 
nanoparticles by a specific cell type such as tumor cells (32).  However, recent studies 
have demonstrated that these modifications do not necessarily achieve the expected 
results after systemic delivery.  For example, polycationic nucleic acid carriers, even 
when coated with PEG for stabilization, exhibit extremely rapid clearance from the 
bloodstream after intravenous administration (33).  Studies have also indicated that 
addition of tumor-specific targeting ligands to the surface of the nanoparticles does not 
increase the amount of the injected dose that reaches the tumor compared to non-targeted 
nanoparticles.  Nevertheless, the targeted nanoparticles show significantly greater 
efficacy in terms of gene expression (plasmid DNA delivery) or target gene knockdown 
leading to tumor growth inhibition (siRNA delivery) (34,35).  It is hypothesized that the 
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targeting ligands do not necessarily enhance the tumor localization of the injected 
nanoparticles, but instead act to enhance the internalization by the tumor cells once the 
nanoparticles achieve tumor localization. 
There exists the potential that the short circulation times of these nanoparticle 
carriers could limit the potential differences that might arise between targeted and non-
targeted forms if circulation times were extended.  Longer circulation times have been 
achieved for nanoparticles that are cross-linked after formation, but irreversible cross-
linking will inhibit the release of the payload after cell internalization.  The use of 
reversible cross-linking systems that can respond to the reducing environment inside a 
cell represents a clever approach to the design of nanoparticle carriers that can be stable 
for prolonged circulation in the blood yet willingly release the payload when inside the 
cell (36). 
Even if the nanoparticles do navigate the complex milieu of the bloodstream and 
begin to be internalized by the target cells of interest, a completely new set of barriers 
exist to potentially block therapeutic efficacy.  Upon internalization, the nanoparticles 
must escape the vesicular compartment in which they were internalized.  Smart polymer 
systems help address the barrier of endosomal escape by responding to changes in pH in 
the endosomes, leading to nucleic acid release and endosomal disruption (37,38).  If the 
delivered therapeutic molecule exerts its effect in the cytosol (e.g., siRNA), then it has 
reached its site of action.  However, many therapeutic molecules (e.g., plasmid DNA) 
must reach the nucleus to have their effect.  This requires intracellular trafficking to the 
nuclear compartment, a process that can be severely diffusion-limited but may be aided 
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by the use of nuclear localization signals or peptides  designed to harness the dynein 
motor complex (39,40). 
1.4 An engineering approach for the design of siRNA therapeutics 
 An engineer desires to not only learn how a given system works but also how it 
can be manipulated to achieve a desired goal.  Oftentimes, this is accomplished by 
dismantling the system and analyzing the component systems individually in a 
methodical and quantitative fashion.  Once the nature and function of these component 
systems is sufficiently understood, they can be assembled into systems with higher levels 
of complexity that possess properties suitable for their intended application.  In this way 
an engineer does not act as a passive observer, but instead actively seeks ways to apply 
new knowledge and improve existing technologies.  This thesis describes an engineering 
approach to address the challenge of systemic delivery of small interfering RNA (siRNA) 
molecules for cancer therapy. 
 The analysis begins at the molecular level with an attempt to understand the 
properties and function of individual siRNA molecules.  Chapters 2 and 3 focus on the 
behavior of siRNA molecules in vitro and in vivo, with a specific emphasis on 
understanding factors governing the magnitude and persistence of the inhibition after 
siRNA treatment.  The results demonstrate that the rate of cell division is one of the most 
important factors governing the activity of siRNAs, and therapies targeting rapidly 
dividing cells will require different dosing schedules than therapies targeting non-mitotic 
cell populations.  
Chapter 4 addresses the next level of complexity when these siRNA molecules are 
assembled into nanoparticles using cyclodextrin-containing polycations (CDP).  The 
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siRNA and CDP self-assemble to yield macromolecular nanoparticles with distinct 
properties that emerge from the interactions between the individual components within 
the assembled system.  Extensive physicochemical and biological characterization of 
these siRNA nanoparticles reveals how their properties can be tuned to make them 
suitable for systemic delivery of siRNA in vivo. 
Chapters 5 through 7 examine the in vivo behavior and function of the siRNA 
nanoparticles.  In Chapter 5, noninvasive live-animal imaging with positron emission 
tomography (PET) and bioluminescent imaging (BLI) is used to monitor the in vivo 
biodistribution and function of the siRNA nanoparticles in mice, providing important 
insights into the behavior of these nanoparticles inside a living organism.  In Chapters 6 
and 7, the nanoparticles are used to deliver therapeutic siRNAs to achieve tumor growth 
inhibition in disseminated and subcutaneous murine cancer models. 
Finally, recommendations for future work in the area of systemic siRNA delivery 
for cancer therapy are offered in Chapter 8. 
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2 Insights into the kinetics of siRNA-mediated gene silencing 
from live-cell and live-animal bioluminescent imaging† 
 
2.1 Abstract 
Small interfering RNA (siRNA) molecules are potent effectors of post-
transcriptional gene silencing.  Using noninvasive bioluminescent imaging and a 
mathematical model of siRNA delivery and function, the effects of target-specific and 
treatment-specific parameters on siRNA-mediated gene silencing are monitored in cells 
stably expressing the firefly luciferase protein.  In vitro, luciferase protein levels recover 
to pre-treatment values within <1 week in rapidly dividing cell lines, but take longer than 
3 weeks to return to steady-state levels in nondividing fibroblasts.  Similar results are 
observed in vivo, with knockdown lasting ~10 days in subcutaneous tumors in A/J mice 
and 3-4 weeks in the nondividing hepatocytes of BALB/c mice.  These data indicate that 
dilution due to cell division, and not intracellular siRNA half-life, governs the duration of 
gene silencing under these conditions.  To demonstrate the practical use of the model in 
treatment design, model calculations are used to predict the dosing schedule required to 
maintain persistent silencing of target proteins with different half-lives in rapidly dividing 
or nondividing cells.  The approach of bioluminescent imaging combined with 
mathematical modeling provides useful insights into siRNA function and may help 
expedite the translation of siRNA into clinically relevant therapeutics for disease 
treatment and management. 
                                                 
† Reproduced with permission from:  Bartlett, D.W. and Davis, M.E. (2006) Insights into the kinetics of 
siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res, 
34, 322-333.  Published by Oxford University Press. 
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2.2 Introduction 
 RNA interference (RNAi) refers to the ability of double-stranded RNA (dsRNA) 
to cause sequence-specific degradation of complementary mRNA molecules.  Since its 
discovery in C. elegans in 1998 (1), it has rapidly attracted attention from researchers in 
fields ranging from genetics to clinical medicine.  A natural intracellular process likely 
involved in cell-based defense against mobile genetic elements such as viruses and 
transposons (2), RNAi promises to be an invaluable tool for gene function analysis as 
well as a powerful therapeutic agent that can be used to silence pathogenic gene products 
associated with diseases including cancer, viral infections, and autoimmune disorders (3-
8). 
A central component of RNAi is a double-stranded siRNA molecule that is 21-23 
nucleotides in length with 2-nt long 3’ overhangs (9).  These siRNA effector molecules 
can be introduced into cells directly as synthetic siRNAs or indirectly as precursor long 
dsRNAs or short hairpin RNAs (shRNA).  RNA polymerase II- or III-driven expression 
cassettes can be used for constitutive expression of shRNA molecules (10).  Both the 
long dsRNAs and shRNAs are cleaved by Dicer (RNase III family of endonucleases) into 
the appropriately sized siRNA effectors.  Although the presence of dsRNA >30 
nucleotides can elicit an interferon response in mammalian cells (11), Elbashir and 
colleagues demonstrated that synthetic 21-mer siRNAs evaded the interferon response 
and yet were still effective mediators of sequence-specific gene silencing in mammalian 
cells (9).  Here, we have chosen to focus on the use of synthetic 21-mer siRNA duplex 
molecules in mammalian cells for transient gene silencing. 
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 Because synthetic siRNA molecules must be transported into the cells before they 
can function in RNAi, successful delivery of siRNA is of central importance.  Delivery 
vehicles must protect the siRNA from nucleases in the serum or extracellular media, 
enhance siRNA transport across the cell membrane, and guide the siRNA to its proper 
location through interactions with the intracellular trafficking machinery.  While naked 
siRNA molecules have been shown to enter cells, significantly more siRNA can be 
delivered using carrier vehicles (12,13).  Both viral and nonviral vectors deliver siRNA 
into cells, although viral vectors are limited to delivering siRNA-expressing constructs 
such as shRNA.  Commercially available cationic lipids such as Oligofectamine can 
effectively deliver siRNA molecules into cells in vitro with transfection efficiencies 
approaching 90% (9).  However, the high toxicity of cationic lipids limits their use for 
systemic delivery in vivo.   Recent studies from our laboratory have shown that 
cyclodextrin-containing polycations (CDP) can achieve safe and effective systemic 
delivery of siRNA in mice (14).  Here, we consider the nonviral delivery of siRNA using 
cationic lipids or polymers. 
A challenge for the successful application of siRNA will be to determine the 
dosing schedule required for efficacy, making insights into the kinetics of siRNA-
mediated gene silencing foundational for the future clinical use of siRNA.  Without a 
proper understanding of the kinetics of the process and the parameters that can affect the 
resulting gene silencing, application of RNAi will be governed largely by trial and error.  
The ability to specifically tailor and optimize the treatment for each particular system 
would save significant time and resources, especially given the high cost of synthetic 
siRNA molecules and the amount of material required for in vivo studies.  Mathematical 
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modeling using simple kinetic equations for each step in the RNAi process can shed light 
on many of these questions regarding the kinetic aspects of RNAi.  To our knowledge, 
there are only a few published examples of such studies looking at the kinetics of the 
intracellular RNAi process (15-18).  Of these studies, none has combined the delivery 
process and the interaction with the RNAi machinery in mammalian cells.  Bergstrom 
and colleagues proposed a unidirectional amplification method in their mathematical 
model of RNAi-mediated gene silencing (15).  Because no RNA-dependent RNA 
polymerase has yet been found in mammalian cells, they acknowledged that their model 
did not address the silencing mechanisms observed in mammals.  Groenenboom and 
colleagues recently proposed a mathematical model for RNAi that contained several 
extensions to the core RNAi pathway, providing for siRNA degradation by RNase as well 
as primed amplification (16).  Their model aimed to explain transgene- or virus-induced 
gene silencing and avoidance of self-reactivity, but did not consider any steps in the 
delivery process.  Similarly, Raab and Stephanopoulos looked at the dynamics of gene 
silencing by siRNA given at different doses and at various times relative to plasmid 
transfection, but did not incorporate siRNA delivery (17).  Arciero and colleagues created 
a mathematical model to investigate tumor-immune evasion and siRNA treatment (18).  
Although this model provided insights into how siRNA can be used in cancer treatment, 
it did not examine the delivery process and there were no experimental data from in vitro 
or in vivo studies.  Here, we use bioluminescent imaging and mathematical modeling to 
investigate the steps of RNAi from siRNA delivery to intracellular function with the aim 
of enabling the practical application and design of siRNA-based treatment strategies both 
in vitro and in vivo.  Because the imaging is noninvasive and nondestructive, the same set 
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of cells or animals can be followed for the entire study.  These results will complement 
investigations using more traditional analytical methods to monitor mRNA or protein 
knockdown and hopefully serve to encourage the rational design of experimental and 
clinical siRNA-based treatments.   
2.3 Materials and methods 
2.3.1 Production of luciferase-expressing cell lines by lentiviral transduction 
Cell lines were incubated with viral supernatant containing SMPU-R-MNCU3-
LUC, a lentiviral vector based on HIV-1 that transduces the firefly luciferase gene.  The 
backbone vector SMPU-R has deletions of the enhancers and promoters of the HIV-1 
long terminal repeat (SIN), has minimal HIV-1 gag sequences, contains the cPPT/CTS 
sequence from HIV-1, has three copies of the UES polyadenylation enhancement element 
from SV40, and has a minimal HIV-1 RRE (gift of Paula Cannon, Children’s Hospital 
Los Angeles, Los Angeles, CA; (19)).  The vector has the U3 region from the MND 
retroviral vector as an internal promoter driving expression of the firefly luciferase gene 
from SP-LUC+ (Promega, Madison, WI; (20)). 
2.3.2 siRNA duplexes 
 All siRNA molecules were ordered purified and pre-annealed (“Option C”) from 
Dharmacon Research, Inc. (Lafayette, CO).  siGL3 (sense, 5’-
CUUACGCUGAGUACUUCGAdTdT-3’; antisense, 5’-
UCGAAGUACUCAGCGUAAGdTdT-3’) is an unmodified siRNA duplex that targets 
the luciferase gene, while siCONTROL non-targeted siRNA #1 (siCON1; sense, 5’-
UAGCGACUAAACACAUCAAUU-3’; antisense, 5’-
UUGAUGUGUUUAGUCGCUAUU-3’) is an unmodified siRNA duplex 
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bioinformatically designed to minimize the potential for targeting any known human or 
mouse genes. 
2.3.3 In vitro transfections 
Cells were seeded in 24-well plates 2-3 days prior to transfection at 2x104-1x105 
cells per well and grown in media supplemented with 10% fetal bovine serum (FBS) and 
antibiotics (penicillin/streptomycin).  siRNA was complexed with Oligofectamine 
(Invitrogen, Carlsbad, CA) according to manufacturer’s instructions and applied to each 
well in a total volume of 200 µL Opti-MEM I (Invitrogen).  Transfection media was 
removed and replaced with complete media after 5 hours.  
2.3.4 Formation of subcutaneous tumors in mice 
Luciferase-expressing Neuro2A (Neuro2A-Luc) cells were grown to confluence 
in media supplemented with 10% FBS and antibiotics (penicillin/streptomycin).  
Immediately prior to injection, cells were washed with phosphate-buffered saline (PBS), 
trypsinized, and resuspended in serum-free media at 2x106 cells/mL.  Each mouse 
received 0.5 mL of the resulting cell suspension by subcutaneous injection. 
2.3.5 Low-pressure tail-vein (LPTV) injection of formulated siRNA nanoparticles 
All nanoparticles were made with siRNA and an imidazole-modified CDP (CDP-
Im) synthesized as described previously (21,22).  Before addition to siRNA, CDP-Im was 
mixed with an adamantane-PEG5000 (AD-PEG) conjugate and an AD-PEG-transferrin 
(Tf) conjugate such that the total moles of AD-PEG or AD-PEG-Tf equaled the number 
of moles of β-CD.  Tf-targeted nanoparticles contained 1% AD-PEG-Tf relative to AD-
PEG.  This mixture was added to an equal volume of siRNA at a charge ratio (positive 
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charges from CDP-Im to negative charges from siRNA backbone) of 3:1 (+:-).  An equal 
volume of 10% (w/v) glucose in water was added to the resulting nanoparticles to yield a 
5% (w/v) glucose (D5W) solution suitable for injection.  Each mouse was injected with 
200 µL of this nanoparticle solution containing 50 µg siRNA per 20-g mouse (2.5 mg/kg 
siRNA). 
2.3.6 High-pressure tail-vein (HPTV) co-injection of plasmid and siRNA 
 Hydrodynamic, or HPTV, injection of nucleic acids can achieve significant levels 
of nucleic acid in the hepatocytes of mice (23,24).  A. McCaffrey and M. Kay kindly 
donated a plasmid (pApoEHCRLuc) containing the firefly luciferase gene under the 
control of the human α1-antitrypsin promoter and the apolipoprotein E locus control 
region.  For HPTV co-injection studies in BALB/c mice, each 20-g mouse received a 
10% w/v injection of a D5W solution containing 0.25 mg/kg of the luciferase-containing 
plasmid and 2.5 mg/kg siRNA. 
2.3.7 Bioluminescent imaging 
Cell culture plates or mice containing the luciferase-expressing cells were imaged 
using the Xenogen IVIS 100 Imaging System (Xenogen, Alameda, CA).  D-luciferin 
(Xenogen) was dissolved in PBS at 15 g/L.  For in vitro assays in 24-well plates, 50 µL 
of the 15 g/L luciferin solution was added to each well containing 1 mL of media.  Light 
emission was measured 2-3 minutes after addition of the luciferin.  For in vivo 
experiments, 0.2 mL of the 15 g/L luciferin solution was injected intraperitoneally 10 
minutes before measuring the light emission.  Mice were anesthetized with an initial dose 
of 5% isoflurane followed by a maintenance dose of 2.5% isoflurane.  Bioluminescent 
signal intensities were quantified using Living Image software (Xenogen). 
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2.3.8 Mathematical model 
The model presented here was designed to allow the user to specifically study the 
impact of parameter values on gene silencing by RNAi.  When designing an siRNA-
based treatment, the main controllable parameters are the delivery method (naked siRNA, 
formulated with vector, chemically modified) and dosing schedule.  These choices must 
be governed by parameters such as the target mRNA half-life, target protein half-life, 
threshold for reduction (in either target mRNA or protein), number of target cells, and 
desired knockdown duration.  The model’s design criteria therefore included the ability to 
enable user-defined values for these parameters that characterize each experimental 
system.   
A simplified schematic of the major processes included in the model is shown in 
Figure 2.1.  Model variables (Table 1) and parameters (Table 2) were used to develop a 
set of ordinary differential equations for the steps involved in siRNA delivery to and 
function within mammalian cells in vitro and in vivo.  The differential equations 
governing each major process from the delivery of siRNA to its intracellular interaction 
with the RNAi machinery are grouped into modules that can be changed independently to 
modify the model complexity as desired. 
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Figure 2.1.  Simplified schematic of the key steps required for siRNA delivery to and function within 
mammalian cells.  Steps 1-3 are unique to in vivo application of siRNA, whereas steps 4-9 represent the 
general processes on the level of an individual cell and are therefore common to both in vivo and in vitro 
application of siRNA. 
 
 
Table 2.1.  Model variables. 
Model Variables 
Name Model Compartment Description (units) 
Bcf Plasma Free complex in circulation (# vol-1) 
Bcb Plasma Bound complex in circulation (# vol-1) 
Ec Extracellular Extracellular complex in local vicinity (# vol-1) 
Enc Intracellular Endosomal complex (# vol-1) 
Enna Intracellular Endosomal free siRNA (# vol-1) 
Cc Intracellular Cytoplasmic complex (# vol-1) 
Cna Intracellular Cytoplasmic free siRNA (# vol-1) 
R Intracellular Activated RISC complex (# vol-1) 
C Intracellular Activated RISC complex bound to mRNA (# vol-1) 
M Intracellular Target mRNA (# vol-1) 
P Intracellular Target protein (# vol-1) 
Z Intracellular Number of cells (#) 
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Table 2.2.  Model parameters.  For parameters common to both in vitro and in vivo applications, the in vivo 
parameter values are shown in italics below the in vitro parameter values. 
 
Model Parameters 
Name Description (units)  Determination Value 
max Maximum # of cells (#) Determined experimentally Fit to each 
system 
partition Effective fraction of dose available to target cells Estimated from experimental data 1x10-3 
rtot Total available amount of RISC protein 
complexes (# L-1) 
Literature (25-27) 1.9x1015 
Ve Extracellular volume (L) Specified experimentally in vitro, 
Estimated from experimental data  
and literature (28,29) 
2x10-4 
1x10-5 
Vi Intracellular volume (L) Literature (30) 4x10-12 
Vp Plasma volume, mouse (L) Literature (31) 1.5x10-3 
kbloodbind Complex binding to blood components (hr-1) Estimated from experimental data 1x10-4 
kblooddis Complex dissociation from blood components 
(hr-1) 
Estimated from experimental data 1x10-2 
kcleavage Cleavage of target mRNA by activated RISC 
complex (hr-1) 
Literature (27) 7.2 
kdegendna Endosomal siRNA degradation (hr-1) Literature (32-35) 5x10-1 
kdeginna Intracellular siRNA degradation (hr-1) Estimated from experimental data 
and literature (34) 
2.9x10-2 
kdegmRNA Target mRNA degradation (hr-1) Literature (36-39) 2 
kdegprot Target protein degradation, Luciferase (hr-1) Literature (40) 3.5x10-1 
kdegRISC Activated RISC complex degradation (hr-1) Estimated from experimental data 7.7x10-2 
kdisRISC Dissociation of activated RISC complex (hr-1) Chosen to be negligible once 
activated RISC is formed 
1x10-9 
kdisRISCm Dissociation of activated RISC complex and 
target mRNA (hr-1) 
Literature (25-27) 1 
kelimec Extracellular complex degradation (hr-1) Estimated from experimental data 8.7x10-2 
2.9x10-2 
kelimpl Plasma complex degradation (hr-1) Estimated from experimental data 5.8x10-2 
kescendna Endosomal escape for siRNA (hr-1) Estimated from experimental data 
and literature (41) 
6x10-2 
kescendvec Endosomal escape for complex (hr-1) Estimated from experimental data 
and literature (41) 
1x10-2 
kformmRNA Formation of target mRNA (# L-1 hr-1) Literature (36,37) 5.2x1013 
kformprot Formation of target protein (hr-1) Literature (36,37) 5.2x102 
kformRISC Formation of activated RISC complex (L #-1 hr-1) Estimated from experimental data 2x10-19 
kformRISCm Formation of activated RISC/mRNA complex (L 
#-1 hr-1) 
Literature (25-27) 1.1x10-14 
kgrowth Cell growth rate (hr-1) Determined experimentally Fit to each 
system 
kint Internalization (hr-1) Literature (12,13,42) 1x10-5 
5x10-7 
ktransblood Transport from plasma to extracellular fluid (hr-1) Estimated from experimental data 1x10-2 
kunpackcyt Cytosolic complex unpackaging (hr-1) Estimated from experimental data 5x10-1 
6x10-2 
kunpackend Endosomal complex unpackaging (hr-1) Estimated from experimental data 1x10-4 
1x10-3 
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All of the equations for intracellular siRNA-associated species contain a term to 
account for dilution due to cell division, where dilution is equal to the ratio of new cells 
divided by the total number of cells.  For example, if the number of cells doubles in one 
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day, then dilution would equal 0.5 and the concentration of the intracellular species 
would likewise be reduced by 50%.  For the sake of calculation simplicity, only species 
involving the delivered siRNA molecules are diluted by this factor; all other intracellular 
species (i.e., target mRNA and target protein) are assumed to not change after cell 
division because they are produced intracellularly by both of the daughter cells.  The net 
effect of this is that the siRNA-associated species are diluted equally between the two 
daughter cells after each cell division. 
The set of ODEs was solved with MATLAB (The MathWorks, Inc., Natick, MA) 
using the stiff ODE15s solver.  The ODE15s solver is a variable-order solver based on 
the numerical differentiation formulas.  Parametric sensitivity analysis was performed 
using SENS_SYS written by V. M. Garcia Molla.  This MATLAB routine is an extension 
to the ODE15s solver that calculates the derivatives of the solution with respect to the 
parameters. 
2.4 Results 
In vitro and in vivo experiments were conducted to gain insights into the general 
kinetics of siRNA-mediated gene silencing in cell lines that constitutively express the 
luciferase gene.  Constitutively expressed genes, in contrast to genes expressed 
transiently by plasmids, provide a more realistic model for clinical application in which 
an endogenous gene, such as an oncogene, is the target for a therapeutic siRNA.  The 
Xenogen IVIS 100 Imaging System allowed us to monitor luciferase activity in 
luciferase-expressing cells growing in 24-well plates or present in subcutaneous tumors 
or livers in live mice; because the imaging was noninvasive, luciferase activity was 
measured in the same plate of cells or the same animals over the entire duration of the 
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study.  Monitoring the kinetics of siRNA-mediated gene silencing in the same population 
of cells helps to avoid variability introduced when using different cell populations for 
each time point as required in luminometer-based luciferase detection or flow cytometry 
(for fluorescent reporters).  Additionally, firefly luciferase has a short half-life of 
approximately 2 hours, so that its level should change concomitantly with the level of 
mRNA (40,43).  This enables the use of bioluminescent imaging of luciferase protein 
activity as an indicator of mRNA transcript degradation by the delivered siRNA 
molecules. 
2.4.1 Effect of siRNA dose on luciferase knockdown in vitro 
The amount of siRNA applied to the extracellular media has a significant impact 
on the magnitude of the gene silencing but a minimal impact on the overall duration 
(Figure 2.2A).  Using the baseline parameters given in Table 2, the mathematical model 
predicts the trends observed experimentally (Figure 2.2B).  Similar trends are observed 
with these siRNA doses in other luciferase-expressing cell lines (data not shown). 
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Figure 2.2.  Effect of siRNA dose on the duration and magnitude of luciferase knockdown by siRNA in 
nondividing cells.  (A) Experimental results using Oligofectamine to deliver siRNA to luciferase-
expressing, nondividing fibroblasts with 1.5x105 cells per well in a 24-well plate.  Data points represent the 
ratio of the average luciferase signal intensity from triplicate wells receiving siGL3 and siCON1 on day 0.  
Squares = 10 nM, Diamonds = 25 nM, Triangles = 50 nM, Circles = 100 nM. (B) Luciferase knockdown 
after siRNA transfection predicted by the mathematical model using the baseline in vitro parameters given 
in Table 2.2 with the number of cells held constant at 1.5x105, a transfection time of 5 hours, and a 
transfection efficiency of 90%. 
2.4.2 Effect of cell doubling time on luciferase knockdown in vitro 
The majority of studies examining the kinetics of siRNA-mediated gene silencing 
in vitro have used rapidly dividing cell lines that typically have doubling times of ~1 day.  
Using these cell lines, the silencing effect generally lasts for ~1 week (44,45).  To 
investigate whether this duration of silencing is intrinsic to siRNA or a result of dilution 
due to cell division, siRNA-mediated gene silencing was monitored in four luciferase-
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expressing cell lines with different observed doubling times:  Neuro2A-Luc (0.8 days), 
LNCaP-Luc (1.4 days), HeLa-Luc (1.6 days), and CCD-1074Sk-Luc (nondividing).  The 
cells were plated in 24-well plates and transfected under identical conditions to enable 
direct observation of the effect of cell doubling time alone.  The experimental results in 
Figure 2.3A reveal that the dilution effect from cell division can alter the duration of gene 
silencing.  Consistent with previous observations, the duration of gene silencing in 
rapidly growing cell lines is ~1 week; however, cell lines with slower doubling times 
show a corresponding increase in the duration of silencing.  Figure 2.3B shows the 
predicted effect of cell doubling time when the experimental transfection parameters are 
input into the mathematical model.  The model predictions confirm that the dilution effect 
due to cell doubling time alone can account for the decreased duration of gene silencing 
in dividing cells.  It is interesting to note that the duration of gene silencing in 
nondividing cells is ~3 weeks.  This duration is consistent with the kinetics observed in 
two previous reports looking at siRNA-mediated gene silencing in nondividing 
mammalian neurons and primary macrophages (46,47).  In nondividing cells, the duration 
of gene silencing is not controlled by dilution from cell division but by the intrinsic 
stability of siRNA within the cell. 
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Figure 2.3.  Effect of cell doubling time on the duration of luciferase knockdown by siRNA in vitro.  (A) 
Experimental results using Oligofectamine to deliver 100 nM siRNA to luciferase-expressing cells with a 
range of doubling times (dt).  Data points represent the ratio of the average luciferase signal intensity from 
triplicate wells receiving siGL3 and siCON1 on day 0.  Squares = Neuro2A-Luc (dt = 0.8 d), Diamonds = 
LNCaP-Luc (dt = 1.4 d), Triangles = HeLa-Luc (dt = 1.6 d), Circles = CCD-1074Sk-Luc (nondividing). (B) 
Luciferase knockdown after siRNA transfection predicted by the mathematical model using the baseline in 
vitro parameters given in Table 2.2 with the initial number of dividing and nondividing cells equal to 5x104 
and 1.5x105, respectively, a transfection time of 5 hours, and a transfection efficiency of 90%. 
 
2.4.3 Kinetics of luciferase knockdown by siRNA in subcutaneous tumors 
Many tumors exhibit rapid growth with doubling times on the order of only a few 
days, and the duration of gene silencing should be limited by this rapid cell division.  To 
test this hypothesis, subcutaneous tumors were created in A/J mice using luciferase-
expressing Neuro2A-Luc cells.  Since the goal was to observe the kinetics of gene 
silencing and not an actual therapeutic effect on the growth rate of the cells, siRNA 
  
31
against the luciferase gene (siGL3) and a control siRNA (siCON1) were used to show the 
sequence-specificity of the luciferase knockdown.  Each mouse received three 
consecutive daily LPTV injections of transferrin-targeted nanoparticles containing 2.5 
mg/kg siRNA.  After quantifying the luciferase activity in each tumor using the Xenogen 
camera, data were used to create a predicted logistic growth curve (Figure 2.4A).  
Because the siRNA targets only the luciferase gene, the growth rate of the cells should be 
unaffected; as a result, a decrease in luciferase signal intensity indicates a change in the 
luciferase protein level.  Normalization to predicted growth curves allowed estimation of 
the knockdown resulting from siRNA treatment (Figure 2.4B).  By adjusting only the 
parameters for the circulation/extracellular transport of the siRNA nanoparticles, very 
good agreement was obtained between the model’s predictions and the experimental data.   
The observed knockdown duration after three consecutive injections was around 10 days, 
consistent with the in vitro data for cell lines with similar observed growth rates. 
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Figure 2.4.  Kinetics of luciferase knockdown by siRNA in Neuro2A-Luc subcutaneous tumors in A/J 
mice.  (A) Experimental and predicted results for luciferase knockdown after three consecutive LPTV 
injections on days 6, 7, and 8 of transferrin-targeted CDP-Im nanoparticles containing 50 µg siRNA per 20-
g mouse.  Experimental data points are shown for a mouse receiving siCON1 (squares) and a mouse 
receiving siGL3 (circles).  Solid lines represent the predicted luciferase signal with siRNA treatment and 
dashed lines represent the predicted luciferase signal in the absence of siRNA treatment.  (B) 
Normalization of the observed luciferase signal in the siGL3-treated mouse to the predicted luciferase 
signal in the absence of treatment.   Circles indicate the normalized experimental data points, while the 
solid line represents the response predicted by the mathematical model using the baseline in vivo 
parameters given in Table 2.2 and assuming that 50% of the total cells are reached with each dose. 
 
2.4.4 Kinetics of luciferase knockdown by siRNA in hepatocytes 
While cells in subcutaneous tumors are dividing rapidly (e.g., once per day), most 
of the hepatocytes in a normal mouse liver are in a state of growth arrest (48).  Therefore, 
it was hypothesized that gene silencing by siRNA would exhibit different kinetics in 
hepatocytes versus tumors.  Each BALB/c mouse received a single HPTV injection of 
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0.25 mg/kg plasmid and 2.5 mg/kg siGL3 on day 0, and the Xenogen camera was used to 
follow the luciferase signal in each mouse liver.  Normalization to the signal intensity in 
mice that received plasmid only (no siRNA) allowed quantification of the percent 
knockdown by siRNA.  Figure 2.5 shows the experimental data together with the model 
predictions.  Similar to the in vitro results for gene silencing in nondividing cells, the 
duration of gene silencing lasts for ~3-4 weeks in the hepatocytes after a single dose of 
siRNA. 
 
Figure 2.5.  Kinetics of luciferase knockdown by siRNA in nondividing hepatocytes in BALB/c mice.  
Experimental and predicted results are shown for luciferase knockdown after hydrodynamic tail-vein co-
injection of 5 µg pApoEHCRLuc and 50 µg siRNA per 20-g mouse on day 0.  Circles represent the ratio of 
the average luciferase signal intensity from three mice receiving plasmid + siRNA to the luciferase signal 
intensity from three mice receiving plasmid alone.  The predicted luciferase knockdown, given by the solid 
line, was calculated using the baseline in vivo parameters given in Table 2.2 with the following 
modifications to account for hydrodynamic injection of naked siRNA without a delivery vehicle:  eliminate 
steps involving the nanoparticles (kescendvec, kunpackend, kunpackcyt), modify uptake and intracellular 
trafficking to match observed kinetics (partition = 1x10-2, ktransblood = 1, kint = 1x10-3 hr-1, kescendna = 
1x10-2 hr-1, kdegendna = 5x10-3 hr-1), and modify extracellular volume (Ve = 1.5x10-5 L).  The kescendna 
and kdegendna may no longer represent endosomal processes as hydrodynamically injected naked siRNA 
may be internalized through different vesicles or partitioned into a separate intracellular compartment (e.g., 
nucleus) that exhibits different degradation and release kinetics than in standard or receptor-mediated 
endocytosis of siRNA-containing nanoparticles.  The total number of hepatocytes was chosen to be 5x107, 
on the same order of magnitude as the number of hepatocytes in a mouse liver (49,50). 
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2.4.5 Effect of siRNA stability on luciferase knockdown by siRNA 
Because both double-stranded and single-stranded nucleic acids are rapidly 
degraded in serum, current efforts in the field of nucleic-acid based therapeutics seek to 
enhance the stability of the nucleic acids with the goal of increasing the duration of gene 
silencing by boosting their bioavailability and possibly prolonging their persistence 
intracellularly (32-34).  Layzer and colleagues studied the kinetics of gene silencing in 
HeLa cells using 2’-F-modified siRNA and unmodified 2’-OH siRNA.  Although the 2’-
F-modified siRNA led to a significant increase in serum stability, it appeared to have no 
effect on the duration of gene silencing after transfection.  This suggests that the 
intracellular stability of siRNA molecules is not the limiting factor controlling the 
duration of gene silencing in rapidly dividing cells; instead, dilution due to cell division 
limits how long gene silencing can occur under these conditions.  If the intracellular half-
life of siRNA molecules is already around 24 hours, then even modifications to increase 
the half-life to >72 hours have an insignificant effect on the duration of gene silencing 
(Figure 2.6).  These model predictions corroborate the experimental results obtained by 
Layzer and colleagues (34).  On the other hand, the outcome of using modified siRNA 
may be different in slowly dividing or nondividing cells since the intracellular siRNA 
half-life will be shorter than the cell doubling time, meaning dilution due to cell division 
will no longer be the dominant factor.  Increasing the persistence of siRNA within the 
cell might prolong the duration of gene silencing.  Results from such studies in 
nondividing cells should be interpreted carefully since the apparent intracellular stability 
of siRNA molecules may be caused by association with other intracellular components or 
localization to specific compartments, both of which could lead to degradation kinetics 
independent of the properties of the siRNA molecules alone.  In that case, modified 
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siRNA would not necessarily increase the duration of gene silencing relative to 
unmodified siRNA even in nondividing cells. 
 
Figure 2.6.  Effect of intracellular siRNA half-life on the duration of siRNA-mediated gene silencing in 
vitro.  Curves represent model predictions for luciferase knockdown after transfection with 100 nM siRNA 
against luciferase on day 0 with a cell doubling time of 1 day (kgrowth = 0.0.029 hr-1) and intracellular 
siRNA half-lives of 24, 48, and 72 hours (kdeginna = 0.029, 0.014, and 0.01 hr-1).  The initial number of 
cells was 5x104, transfection time was 5 hours, transfection efficiency was 90%, and all other parameters 
were kept at their baseline in vitro values given in Table 2.2. 
 
2.4.6 Multiple doses to prolong luciferase knockdown by siRNA in nondividing cells 
The previous studies have looked at the transient knockdown of the luciferase 
reporter gene by 1-3 injections of siRNA over a short-term period; even in nondividing 
cells, the maximum duration of silencing using typical siRNA doses is ~3-4 weeks.  
However, a clinically relevant treatment regimen using siRNA may require that a gene be 
silenced for a prolonged period of time.  Some have attempted to solve this problem by 
using lentiviral delivery of expressed short-hairpin siRNAs (shRNA) to achieve sustained 
gene silencing in vitro and in vivo (51,52).  Precise control of the intracellular level of 
siRNA and having a means to turn off its production when treatment is no longer 
necessary represent two major challenges to this use of shRNA.  On the other hand, the 
intrinsically transient nature of siRNAs makes them more amenable to disease treatments 
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in which the treatment is given over a period of time and then stopped once the desired 
therapeutic outcome (e.g., regression of a tumor or inhibition of viral growth) is achieved.  
To illustrate how properly timed doses of siRNA can prolong gene silencing by siRNA, 
nondividing CCD-1074Sk-Luc cells were transfected with a second dose of siRNA four 
days after the initial dose (Figure 2.7A).  With a second dose of 100 nM siRNA, the 
luciferase protein levels remained at <40% of the steady-state value for an additional four 
days.  If the trends continue in such a fashion, a 100-nM dose every four days could lead 
to persistent gene silencing as shown by model calculations in Figure 2.7B. 
 
Figure 2.7.  Effect of siRNA dose frequency on the duration of luciferase knockdown by siRNA in 
nondividing cells.  (A) Experimental results using Oligofectamine to deliver siRNA to luciferase-
expressing nondividing fibroblasts in vitro.  Data points represent the ratio of the average luciferase signal 
intensity from triplicate wells receiving siGL3 and siCON1.  To facilitate comparison of the knockdown 
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kinetics, the data points are normalized such that all three curves exhibit the same magnitude of knockdown 
for the first four days since all three received the same treatment over this period.  This normalization 
permits comparison of the kinetics of gene silencing observed with different treatments even though the 
absolute magnitude of the knockdown varied slightly in each experiment.  Squares = 100 nM (day 0), 
Diamonds = 100 nM (day 0) + 10 nM (day 4), Triangles = 100 nM (day 0) + 100 nM (day 4).  (B) 
Luciferase knockdown after siRNA transfection predicted by the mathematical model using the baseline in 
vitro parameters given in Table 2.2 with the number of cells equal to 1.5x105, a transfection time of 5 
hours, and a transfection efficiency of 90%. 
 
2.4.7 Considerations for siRNA-based treatments that require a threshold knockdown 
for efficacy 
Because siRNA treatment of rapidly dividing cells requires treating more cells 
over time while also having to deal with dilution effects, the amount of target gene or 
protein knockdown will be less than that observed in slowly dividing or nondividing 
cells.  More frequent dosing is required to overcome these barriers.  Cancer is one 
example of a disease often characterized by rapid cell division that may require target 
gene knockdown lasting longer than that which can be achieved with a single dose of 
siRNA.  To address this situation, the mathematical model was used to estimate siRNA 
dosing schedules needed to maintain a given gene below a threshold value for an 
extended period of time in dividing cells.  While the magnitude of target gene (or protein) 
reduction or the duration of knockdown relative to the steady-state value in the absence 
of treatment can be relatively good indicators of the success of an siRNA treatment, the 
therapeutic efficacy of an siRNA treatment regimen should perhaps be judged by the 
length of time it is able to maintain the target gene or protein level below a given 
threshold.  Although a short, substantial knockdown of certain targets may be sufficient 
to trigger a cascade of downstream effects, other situations may require considerably 
longer knockdown to achieve the desired therapeutic effect.  Additionally, this 
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therapeutic effect may only be seen when the target protein is reduced below a threshold, 
or some fraction of its pre-treatment value.  
The data in Figure 2.8 show how the mathematical model can be used to simulate 
the effects of cell doubling time and target protein half-life during treatment with siRNA.  
To avoid unnecessary complications, the calculations ignore the circulation/extracellular 
transport and consider each siRNA dose already in the local extracellular environment of 
the cells (analogous to the in vitro situation).   Figures 2.8A-D give results that 
demonstrate how target protein half-life can impact the observed dynamics of protein 
knockdown with once- or twice-weekly dosing in rapidly dividing or nondividing cells.  
For a target protein with a short half-life in rapidly dividing cells, even twice-weekly 
dosing still can result in significant oscillations which may hinder the ability to cause a 
phenotypic change in the target cells (Figure 2.8A).  If the target protein has a long half-
life, then twice-weekly dosing is able to maintain steady knockdown at ~50% of the 
steady-state level, but this magnitude of protein knockdown is not achieved until about a 
week after the first dose of siRNA (Figure 2.8B).  In nondividing cells, once-weekly 
dosing is adequate to maintain persistent silencing at ~20% of the steady-state value 
(Figures 2.8C-D).  Again, this protein knockdown can only be achieved after more than a 
week from the initial siRNA dose if the target protein half-life is very long (Figure 2.8D).  
The fraction of the total treatment time during which a target protein is below a threshold 
(e.g., 50% steady-state value) can be used as a metric to compare the efficacy of different 
treatment regimens.  The data illustrated in Figure 2.8E reveal how cell growth rate and 
target protein half-life can affect protein knockdown when siRNA is administered once 
on day 0, once-weekly, or twice-weekly over the 25-day treatment.  As expected, cell 
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growth rate has a large impact on the duration of knockdown, directly affecting the 
fraction of the total time that the target protein level can be reduced below the threshold 
of 50%. 
 
Figure 2.8.  Effect of cell doubling time and target protein half-life on the ability to maintain persistent 
gene silencing.  All plots represent predicted mRNA (dashed lines) and protein (solid lines) knockdown in 
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transfected cells using the baseline in vitro parameters given in Table 2.2, a transfection time of 5 hours, 
and an initial number of dividing and nondividing cells equal to 5x104 and 1.5x105, respectively.  (A) Dose 
of 100 nM siRNA every 3 days with a target protein half-life of 2 hours (kdegprot = 0.35 hr-1) in cells with 
a doubling time of 1 day (kgrowth = 0.029 hr-1).  (B) Dose of 100 nM siRNA every 3 days with a target 
protein half-life of 48 hours (kdegprot = 0.014 hr-1) in cells with a doubling time of 1 day (kgrowth = 0.029 
hr-1).  (C) Dose of 100 nM siRNA every 7 days with a target protein half-life of 2 hours (kdegprot = 0.35 
hr-1) in nondividing cells.  (D) Dose of 100 nM siRNA every 7 days with a target protein half-life of 48 
hours (kdegprot = 0.014 hr-1) in nondividing cells.  (E) Effect of variations in cell doubling time and target 
protein half-life on the ability to maintain a target protein level below a threshold of 50% its pre-treatment 
value over the 25-day period.  I = 100 nM (day 0), II = 100 nM (days 0, 7, 14), III = 100 nM (days 0, 3, 7, 
10, 14, 17, 21, 24).   Surface vertices represent the fraction of the total time during which the relative 
protein level is below the 50% threshold. 
 
2.5 Discussion 
A more thorough understanding of the factors affecting the kinetics of siRNA-
mediated gene silencing should prove to be invaluable for experimental and clinical 
applications of siRNA.   Given the relatively recent discovery of RNAi, details of its 
action are still being elucidated, and many of the current siRNA dosing schedules used in 
literature are based on precedence rather than being optimized for each system.  The high 
cost of siRNA molecules, especially for in vivo studies, limits systematic exploration of 
the parameter space needed to achieve the most effective siRNA dosing schedule for each 
model system.  This situation can be partially rectified by using mathematical modeling 
to give insights that help direct experimental studies.  Here, we employed bioluminescent 
imaging and mathematical modeling to investigate the effects of target-specific and 
treatment-specific parameters on siRNA-mediated gene silencing in vitro and in vivo. 
The experimental data presented here show the effects of cell doubling time, 
siRNA dosing schedule, and siRNA delivery method on luciferase reporter-protein 
knockdown and aid in developing mathematical models of siRNA delivery to and 
function within mammalian cells.  Luciferase knockdown in cell lines engineered to 
constitutively express luciferase was used to mimic the knockdown of an endogenously 
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expressed gene, analogous to an oncogene whose presence in a cell can lead to 
tumorigenicity.  The luciferase-expressing cell lines were used in cell culture experiments 
or injected into mice and then monitored for luciferase expression using noninvasive 
bioluminescent imaging with the Xenogen Imaging System.  The duration of gene 
silencing lasted for ~1 week in rapidly dividing cells but longer than three weeks in 
nondividing cells both in vitro and in vivo, supporting the hypothesis that dilution due to 
cell division is the major factor controlling the duration of luciferase knockdown in 
rapidly dividing cells. 
The duration of gene silencing by siRNA can be longer than that achieved with 
other nucleic-acid based gene inhibition strategies, such as antisense, whose knockdown 
typically lasts only on the order of 1-2 days.  Bertrand and colleagues studied antisense- 
and siRNA-mediated inhibition of GFP in HeLa cells and showed that while antisense-
mediated inhibition diminished after only 1 day, the siRNA-mediated inhibition was still 
increasing (32).  This significant difference in the duration of gene silencing could 
become important when trying to use either antisense or siRNA molecules as therapeutic 
agents.  In fact, the short duration of gene silencing by certain nucleic-acid based gene 
inhibition strategies could preclude their ability to alter cellular behavior if the target 
gene is not silenced for an adequate amount of time.  This would be particularly apparent 
if the target protein has a long intracellular half-life; then, knockdown of the target 
mRNA may not result in target protein knockdown if the mRNA levels can be restored 
before a significant amount of protein has degraded. 
The findings presented here highlight several key considerations for experimental 
design when evaluating the efficacy of siRNA against certain genes that produce proteins 
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with long half-lives.  If the knockdown phenotype does not become apparent until the 
protein is below a certain threshold, then observation at early time points may not reveal 
any effect.  This is crucial for in vitro studies aimed at testing the ability of a therapeutic 
siRNA to induce apoptosis or growth arrest in certain cell lines.  Common practice is to 
look at time points within 48 to 72 hours; here, model predictions suggest that these time 
points may be too early if the target protein half-life is any longer than a couple of days.  
Similar considerations should be made when deciding dosing schedules for in vivo 
studies using siRNA for protein knockdown in tumors (e.g., an oncogenic fusion protein), 
since proteins with longer half-lives will show a slower initial response to the therapy but 
will require less frequent dosing for persistent silencing.  An important area for future 
research will be to determine to what extent a gene or protein needs to be knocked down 
before the intended therapeutic effect is realized.  Such information can be combined 
with mathematical models like the one presented here to more accurately determine the 
required treatment regimen needed to achieve efficacy.  Although the model in its current 
form does not allow for treatment effects other than target gene knockdown, the simple 
addition of a death parameter to the cell growth equation could provide a target cell death 
rate that depends on the reduction of the target protein level below a certain threshold.  
Other slightly more complicated modifications to the current set of equations could 
incorporate recruitment of immune effector cells, effects on angiogenesis, or even 
sensitization to other treatments including chemotherapy.  
While the mathematical model can predict many of the trends observed 
experimentally for the systems used here, confidence in the actual magnitude and 
duration of the predicted gene silencing in hypothetical situations can still be greatly 
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increased as more accurate parameter values become available.  Parametric sensitivity 
analysis was performed using the SENS_SYS modification of the ODE15s solver in 
MATLAB.  Parameters governing RISC formation (kformRISC) and binding to target 
mRNA (kformRISCm) have a significant impact on target mRNA or protein levels.  
Although studies of the RISC complex are rapidly elucidating details of its mechanism 
and kinetics, these parameters will need to be refined as more data become available.  
Additional equations will be needed to model a multi-step RISC formation process, or the 
lumped rate constants currently used can be modified to provide reasonable estimates of 
the overall kinetics.  As expected, target mRNA and protein levels are also sensitive to 
parameters governing the siRNA delivery process, such as cellular uptake, endosomal 
escape, and vector unpackaging.  It will be important to determine these parameters for 
each individual delivery vehicle since such rates will vary from system to system.  With 
knowledge of these different parameters, the model can be used to mimic delivery by a 
variety of methods including naked siRNA (by high-pressure or low-pressure tail-vein 
injection) or formulation into liposomes, lipoplexes, or polyplexes.  Such comparisons 
may reveal how the characteristics of each delivery method specifically affect the kinetics 
of gene silencing.  This information may help to focus design improvements for delivery 
vehicles or improve the efficacy of treatment regimens employing them, as suggested in 
general for gene delivery by Varga and colleagues (53).  Of the parameters intrinsic to the 
target cells, the most important are the cell growth rate (dilution effect), compartment 
volumes (that control the concentration of siRNA available to drive uptake or association 
processes), and the stability of the target mRNA and protein molecules.  The current set 
of model equations predicts that the stability of the mRNA transcript has a greater effect 
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on the magnitude and duration of gene silencing than the absolute transcript number.  
This is because the relative knockdown is controlled largely by the relative sizes of the 
two mRNA degradation terms:  natural turnover within the cell and degradation by 
RNAi.  Therefore, the contribution from RNAi leads to greater deviation from the steady-
state mRNA level for more stable mRNA molecules.  Similar reasoning can be applied to 
other gene inhibition strategies, such as antisense, that act at the mRNA level (54). 
Based on these findings and the literature to date, siRNA appears to be the most 
potent and effective nucleic acid-based therapeutic aimed at post-transcriptional gene 
silencing.  The siRNA molecules can achieve >80% target protein inhibition at 
nanomolar concentrations, and their enhanced intracellular stability enables knockdown 
that can last for weeks in nondividing cells.  It is shown here that an optimized siRNA-
based treatment schedule can be designed to achieve prolonged gene silencing by 
properly timed injections of siRNA.  Mathematical modeling can help to realize these 
optimized treatments at a fraction of the time and cost that would be required by 
experimentation alone.  Although there is no substitute for experimental data, especially 
for highly variable and not completely definable biological systems, model calculations 
can help to guide effective experimental design and aid in data interpretation.  With the 
burgeoning interest in nucleic acid-based therapeutics such as siRNA, development of 
mathematical models such as the one presented here may expedite their translation into 
clinically relevant therapeutics for disease treatment and management. 
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3 Effect of siRNA nuclease stability on the in vitro and in vivo 
kinetics of siRNA-mediated gene silencing†  
 
3.1 Abstract 
Small interfering RNA (siRNA) molecules achieve sequence-specific gene 
silencing through the RNA interference (RNAi) mechanism.  Here, live-cell and live-
animal bioluminescent imaging (BLI) is used to directly compare luciferase knockdown 
by unmodified and nuclease-stabilized siRNAs in rapidly (HeLa) and slowly (CCD-
1074Sk) dividing cells to reveal the impact of cell division and siRNA nuclease stability 
on the kinetics of siRNA-mediated gene silencing.  Luciferase knockdown using 
unmodified siRNAs lasts approximately 1 week in HeLa cells and up to 1 month in CCD-
1074Sk cells.  There is a slight increase in the duration of luciferase knockdown by 
nuclease-stabilized siRNAs relative to unmodified siRNAs after cationic lipid 
transfection, but this difference is not observed after electroporation.  In BALB/cJ mice, a 
four-fold increase in maximum luciferase knockdown is observed after hydrodynamic 
injection (HDI) of nuclease-stabilized siRNAs relative to unmodified siRNAs, yet the 
overall kinetics of the recovery after knockdown are nearly identical.  By using a 
mathematical model of siRNA-mediated gene silencing, the trends observed in the 
experimental data can be duplicated by changing model parameters that affect the 
stability of the siRNAs before they reach the cytosolic compartment.  Based on these 
findings, we hypothesize that the stabilization advantages of nuclease-stabilized siRNAs 
                                                 
† Reproduced with permission from:  Bartlett, D.W. and Davis, M.E. (2007) Effect of siRNA nuclease 
stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng, DOI 
10.1002/bit.21285.  Copyright 2006 Wiley Periodicals, Inc.. 
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originate primarily from effects prior to and during internalization before the siRNAs can 
interact with the intracellular RNAi machinery. 
3.2 Introduction 
Small interfering RNA (siRNA) molecules are potent triggers of sequence-
specific gene silencing through RNA interference (RNAi) (1,2).  Because the duration of 
gene inhibition by siRNA is a primary factor in determining the dosing schedules 
required to achieve therapeutic effects, insights into the kinetics of siRNA-mediated gene 
silencing are crucial to the design of effective siRNA-based treatment strategies. 
We have previously reported on the kinetics of unmodified siRNAs in cultured 
cells and in mice, observing that unmodified siRNA molecules can achieve luciferase 
knockdown that lasts for around 1 week in rapidly dividing cell lines and as long as 1 
month in slowly dividing fibroblasts (3).  This prolonged duration of gene silencing by 
siRNA in vitro has also been observed with primary macrophages and mammalian 
neurons, both of which exhibit minimal cell proliferation (4,5).  Additionally, we showed 
that the in vivo kinetics of gene silencing in mice were comparable to those observed in 
vitro (3).   Recently, Zimmermann et al. reported that siRNAs can achieve long-lasting 
target inhibition in the livers of mice and non-human primates, suggesting that the trends 
in gene silencing are not species-specific (6).  These results support the claim that 
dilution of intracellular siRNAs by cell division is a major factor limiting the duration of 
siRNA-mediated gene silencing in dividing cells.  Furthermore, the prolonged duration of 
gene inhibition by unmodified siRNAs in slowly or nondividing cells suggests an 
enhanced intracellular stability of these molecules and is consistent with previous reports 
showing the extended intracellular persistence of double-stranded siRNAs in living cells 
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(5,7).  The ability of unmodified siRNAs to produce such lengthy gene inhibition implies 
that they are somehow protected against intracellular nucleases.  One possibility is that 
capture by the RNA-induced silencing complex (RISC) sequesters siRNA and blocks 
nuclease attack.  If unmodified siRNAs have high intracellular stability, then nuclease 
stability may not be a limiting factor once siRNAs enter the cell.  This would be in 
contrast to the situation observed with antisense oligonucleotides, where it has been 
demonstrated that the nuclease resistance of the oligonucleotide correlates with the 
magnitude and duration of the gene silencing effect in vitro after cationic lipid 
transfection (8). 
For siRNAs to retain their functional activity, they must also resist degradation 
prior to cellular internalization.  The half-life reported for unmodified siRNAs in serum 
ranges from several minutes to around an hour (2,6,9,10).  The susceptibility to 
degradation by nucleases present in serum appears to preclude the systemic application of 
naked, unmodified siRNAs through clinically feasible administration routes.  Chemical 
modifications to the nucleotides (e.g., 2’-F, 2’-OMe, LNA) or the backbone (e.g., 
phosphorothioate linkages) have been used successfully to enhance nuclease stability and 
prolong siRNA half-life in serum while still enabling siRNA function (9-14).  The effects 
of nuclease stabilization should be most dramatic in situations where the siRNAs can 
directly interact with nucleases present in the extracellular environment such as the 
bloodstream.  However, transfection of cultured cells is accomplished most effectively 
using carrier-mediated delivery, often through cationic lipid encapsulation of the siRNAs 
to enhance cellular uptake.  Because the siRNAs are protected by the carrier prior to 
cellular uptake, in vitro studies most aptly highlight the effects of intracellular processes 
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on the activity of transfected siRNAs.  A similar situation should be expected in vivo 
when delivery vehicles are used to transport the siRNAs to the target cells.  However, 
hydrodynamic injection (HDI) provides a unique situation in which naked siRNAs can be 
successfully delivered systemically in vivo (15).  The duration of the exposure to the 
bloodstream prior to cellular uptake by cells such as hepatocytes is not precisely known, 
although the rapid degradation of unmodified siRNAs in serum indicates that even a short 
exposure can be sufficient to degrade a portion of the injected unmodified siRNAs, while 
nuclease-stabilized siRNAs should be affected to a much lesser extent by this serum 
exposure. 
The studies by Chiu and Rana and Layzer et al. both examined the kinetics of 
reporter gene inhibition in vitro after cationic lipid transfection of HeLa cells with 
unmodified and nuclease-stabilized siRNAs (10,11).  Chiu and Rana asserted that a 
nuclease-stabilized, 2’-F modified siRNA against EGFP slightly prolonged EGFP 
knockdown relative to an unmodified siRNA.  Layzer et al. used unmodified and 2’-F-
modified siRNAs against luciferase and observed no significant difference in the 
magnitude or duration of luciferase knockdown in cultured HeLa cells.  The slight 
differences in the observed kinetics by these two studies could be attributed to variations 
in the methods used, such as the transfection agent, or the effects of transient versus 
constitutive reporter gene expression. 
As mentioned previously, an additional complexity of direct serum exposure is 
introduced during systemic delivery of naked siRNAs in vivo.  Two previously published 
reports comparing unmodified and nuclease-stabilized siRNAs in vivo utilized HDI to 
deliver naked siRNAs to liver cells (9,10).  Layzer et al. observed no substantial 
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difference in either the magnitude or duration of luciferase knockdown after injection of 
unmodified or nuclease-stabilized siRNAs (10).  On the other hand, Morrissey et al. saw 
considerably greater knockdown of HBV DNA or surface antigen levels after 72 hours by 
nuclease-stabilized siRNAs compared to unmodified siRNAs (9). 
To further examine these questions regarding the efficacy of unmodified versus 
nuclease-stabilized siRNAs, we employed live-cell and live-animal bioluminescent 
imaging (BLI) and mathematical modeling to directly compare the kinetics of siRNA-
mediated gene silencing using unmodified and nuclease-stabilized siRNAs.  The primary 
objective of our study is to determine how siRNA nuclease stability affects gene 
inhibition kinetics both in vitro and in vivo.  We explore whether siRNA-mediated gene 
silencing kinetics are affected by chemical modifications to enhance nuclease resistance 
and whether the kinetics strongly depend on cell doubling times like we observed with 
unmodified siRNAs (3).  To our knowledge, this is the first study to directly compare 
unmodified and nuclease-stabilized siRNAs delivered under identical conditions in both 
rapidly and slowly dividing cells, allowing us to concurrently address the impact of cell 
division and siRNA nuclease stability on the kinetics of siRNA-mediated gene silencing.  
Our findings indicate that while nuclease stability is important to prevent siRNA 
degradation in the extracellular environment, such as the bloodstream after systemic 
administration, it is not a dominant factor controlling the persistence of siRNAs that have 
already been internalized into the cytosolic compartment of cells. 
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3.3 Materials and methods 
3.3.1 Luciferase-expressing cell lines 
Cell lines were incubated with viral supernatant containing SMPU-R-MNDU3-
LUC, a lentiviral vector based on HIV-1 that transduces the firefly luciferase gene 
(16,17).  The backbone vector SMPU-R has deletions of the enhancers and promoters of 
the HIV-1 long terminal repeat (SIN), has minimal HIV-1 gag sequences, contains the 
cPPT/CTS sequence from HIV-1, has three copies of the USE polyadenylation 
enhancement element from SV40, and has a minimal HIV-1 RRE (gift of Paula Cannon, 
Children’s Hospital Los Angeles).  The vector has the U3 region from the MND 
retroviral vector as an internal promoter driving expression of the firefly luciferase gene 
from SP-LUC+ (Promega). 
3.3.2 siRNA duplexes 
 siGL3, siLuc1, and siLuc2 target the firefly luciferase gene, siEGFP targets the 
enhanced green fluorescent protein (EGFP) gene, and siCON1 is a control sequence that 
is bioinformatically designed to minimize the potential for targeting any known human or 
mouse genes: 
 
siGL3: 
sense:      5’- CUUACGCUGAGUACUUCGAdTdT –3’ 
antisense:  5’- UCGAAGUACUCAGCGUAAGdTdT -3’ 
 
siLuc1: 
sense:      5’- GGUUCCUGGAACAAUUGCUUUUAdCdA –3’ 
antisense:  5’- UGUAAAAGCAAUUGUUCCAGGAACCAG -3’ 
 
siLuc2: 
sense:      5’- GUGCCAGAGUCCUUCGAUAGG –3’ 
antisense:  5’- UAUCGAAGGACUCUGGCACAA -3’ 
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siEGFP: 
sense:      5’- GACGUAAACGGCCACAAGUUC –3’ 
antisense:  5’- ACUUGUGGCCGUUUACGUCGC -3’ 
 
siCON1: 
sense:      5’- UAGCGACUAAACACAUCAAUU –3’ 
antisense:  5’- UUGAUGUGUUUAGUCGCUAUU -3’ 
 
Unmodified siLuc1 and siLuc2 were synthesized by Integrated DNA Technologies, 
unmodified siEGFP was synthesized by Dharmacon, and unmodified and siSTABLEv2 
versions of siGL3 and siCON1 were synthesized by Dharmacon.  The siSTABLEv2 
siRNAs contain Dharmacon’s proprietary chemical modifications that provide enhanced 
nuclease resistance. 
3.3.3 siRNA serum stability 
1.5 µL of a 20 µM solution of unmodified or nuclease-stabilized siGL3 in water 
were added to 13.5 µL of active mouse serum (Sigma) and incubated at 37°C and 5% 
CO2.  After incubation for the desired amount of time, 3 µL loading buffer was added and 
15 µL of each sample was loaded into a 2% agarose gel.  Bands were visualized by 
ethidium bromide staining and quantified using ImageJ image analysis software. 
3.3.4 In vitro transfection 
Oligofectamine Transfection 
Cells were seeded at 2x104 cells per well in 24-well plates 2 days prior to 
transfection and grown in media supplemented with 10% fetal bovine serum (FBS) and 
antibiotics (penicillin/streptomycin).  siRNA was complexed with Oligofectamine 
(Invitrogen) according to manufacturer’s instructions and applied to each well in a total 
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volume of 200 µL Opti-MEM I (Invitrogen).  Transfection media was removed and 
replaced with complete media after 5 h. 
Electroporation 
 Cells growing in a 25 cm2 flask were trypsinized, counted, and resuspended in 
Opti-MEM I at 2x106 cells mL-1.  100 µL of this suspension were added to an 
electroporation cuvette (Bio-Rad) with a 0.2-cm gap width and incubated on ice for 15 
minutes.  5 µL of each 20 µM siRNA stock solution were added to the individual 
cuvettes to give a final siRNA concentration of 952 nM.  Each cuvette was then placed in 
the ShockPod of a Gene Pulser Xcell with a CE module (Bio-Rad), and the protocol for 
HeLa cells was used to apply an exponential decay pulse (160 V, 500 µF).  After 
electroporation, the cells in the cuvette were allowed to recover for 15 minutes at room 
temperature and then plated in 1 mL pre-warmed complete media at 6x104 cells per well 
in a 24-well plate. 
3.3.5 Hydrodynamic co-injection of plasmid DNA and siRNA 
 The plasmid, pApoEHCRLuc, contains the firefly luciferase gene under a 
hepatocyte-specific promoter.  For kinetic studies in BALB/cJ mice, a 5% glucose 
solution containing 0.25 mg kg-1 of the luciferase-containing plasmid and 2.5 mg kg-1 
siRNA was injected by hydrodynamic tail-vein injection (2 mL per 20-g mouse).  Mice 
were restrained in a holding device while the entire volume (~2 mL) was injected into a 
lateral tail vein over a 5-second period.  At the time of injection, the BALB/cJ mice were 
7 weeks old and had an average body weight of 18 g. 
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3.3.6 Bioluminescent imaging (BLI) 
Cell culture plates or mice were imaged using the Xenogen IVIS 100 imaging 
system (Xenogen).  D-luciferin (Xenogen) was dissolved in PBS at 15 g L-1.  For in vitro 
assays in 24-well plates, 50 µL of the 15 g L-1 luciferin solution was added to each well 
containing 1 mL of media.  Light emission was measured 2-3 minutes after addition of 
the luciferin.  For in vivo experiments, 0.2 mL of the 15 g L-1 luciferin solution was 
injected i.p. 10 minutes before measuring the light emission.  Mice were anesthetized 
with an initial dose of 5% isoflurane followed by a maintenance dose of 2.5% isoflurane.  
Bioluminescent signals were quantified using Living Image software (Xenogen). 
The relative luciferase knockdown for in vitro and in vivo experiments was 
calculated by taking the ratio of the change in luciferase expression resulting from an 
siRNA against luciferase to the change in luciferase expression resulting from a non-
targeting control siRNA.  This normalization to an identically transfected control siRNA 
should help to minimize artifacts from nonspecific effects that have been observed with 
siRNA transfection (18,19). 
3.3.7 Mathematical modeling 
We employed the mathematical model of siRNA-mediated gene silencing 
described previously to determine which parameters may be responsible for the 
differences in gene silencing using unmodified and nuclease-stabilized siRNAs (3).  The 
majority of the parameters were left unchanged from those described previously, and an 
explanation of which parameters were changed and why is provided in more detail in the 
Results section. 
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3.4 Results 
3.4.1 Verification of luciferase knockdown by multiple siRNA sequences 
siRNA sequences can be designed to cleave at different regions within a given 
mRNA transcript with the same end result of mRNA cleavage and a concomitant 
reduction in protein levels.  Therefore, three different siRNAs were designed that target 
three separate regions on the luciferase mRNA transcript.  Both siGL3 and siLuc2 have a 
standard 19-bp duplex region, while the siLuc1 sequence is designed to have a 25-bp 
duplex region that may aid in processing by the Dicer component of the RNAi pathway 
(20).  Luciferase-expressing HeLa and CCD-1074Sk fibroblast cells were transfected 
under identical conditions with these three different siRNA sequences against luciferase 
(siGL3, siLuc1, and siLuc2) and two control siRNA sequences (siCON1 and siEGFP).  
The results shown in Figure 3.1 represent the luciferase knockdown by each sequence 
relative to siCON1 at doses of 25 nM and 100 nM.  The lack of knockdown by 100 nM 
siEGFP in Figure 3.1B indicates that cells transfected with siEGFP show nearly identical 
luciferase expression to cells transfected with siCON1, validating the use of siCON1 as a 
nonspecific control.  On the other hand, all three siRNA sequences targeting luciferase 
gave nearly identical luciferase knockdown kinetics, with negligible variations in both the 
magnitude and duration of knockdown at all concentrations tested.  The knockdown 
lasted slightly over 1 week in HeLa cells, which exhibited average cell doubling times of 
1-2 days.  On the other hand, the luciferase levels did not recover to control levels for up 
to 1 month in the fibroblasts, which exhibited average cell doubling times of 15-20 days.  
These results corroborate our previous findings and provide further evidence supporting 
the claim that cell division directly impacts the duration of siRNA-mediated gene 
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silencing (3).  The slightly longer duration of gene silencing for the fibroblasts in this 
study compared to our previous study may be attributed to the averaging of a greater 
number of data points that are now available or variations in the initial lipoplex 
formulation and cell passage number.  Given the variability inherent to these systems, the 
consistency of the observed knockdown between multiple independent experiments is 
encouraging.  The nearly identical results with multiple sequences targeting independent 
sites on the luciferase mRNA indicate that the observed kinetics of the luciferase 
knockdown are not specific to only a certain sequence. 
 
Figure 3.1.  Validation of luciferase-targeting and control siRNA sequences in rapidly dividing (HeLa) and 
slowly dividing (CCD) luciferase-expressing cells after Oligofectamine transfection.  (A) HeLa, 25 nM 
siRNA, (B) HeLa, 100 nM siRNA, (C) CCD-1074Sk, 25 nM siRNA, (D) CCD-1074Sk, 100 nM siRNA.  
Luciferase knockdown is reported relative to the luciferase activity from cells transfected with equal doses 
of the siCON1 control sequence.  Squares = siEGFP, circles = siGL3, diamonds = siLuc1, triangles = 
siLuc2. 
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3.4.2 Serum stability of unmodified and nuclease-stabilized siRNAs 
The siGL3 and siCON1 sequences were used as the luciferase-targeting and non-
targeting siRNAs, respectively, for the remainder of the in vitro and in vivo studies.  
Previously, we examined the kinetics of luciferase downregulation by unmodified 
siRNAs; here, we expand this investigation to include nuclease-stabilized siRNAs.  There 
are several commercially available modified siRNAs that are purported to have increased 
nuclease stability.  Dharmacon’s siSTABLEv2 modified siRNAs were used in these 
studies because their reported half-life in human serum exceeds several days and because 
the unmodified siGL3 and siCON1 were also purchased from Dharmacon.  A serum 
stability assay was conducted to verify that the siSTABLEv2 siRNAs from Dharmacon 
exhibited enhanced nuclease stability.  2 µM of unmodified and nuclease-stabilized 
siGL3 were incubated in 90% active mouse serum for 1 to 24 hours at 37°C and 5% CO2 
and subsequently visualized by ethidium bromide staining after gel electrophoresis.  
Nuclease stability can be judged from the relative intensity of the bands at each time 
point, with degradation indicated by the disappearance of the bands over time.  As shown 
by the data given in Figure 3.2, unmodified siGL3 degrades rapidly in the presence of 
serum, with the bands becoming undetectable by 6 hours.  On the other hand, there is 
little detectable degradation of the nuclease-stabilized siGL3 after 6 hours, and a band is 
still clearly visible after 24 hours.  The relative changes in the band intensities for both 
unmodified and nuclease-stabilized siGL3 are also plotted in Figure 3.2.  By fitting an 
exponential curve to these data, an estimated half-life for each siRNA species under these 
conditions can be calculated.  Whereas the unmodified siGL3 had a half-life of around 1 
hour, the nuclease-stabilized siGL3 had an observed half-life of almost 1 day.  The 
  
62
observed half-life for the nuclease-stabilized siGL3 is shorter than the half-life of several 
days reported by Dharmacon, but this discrepancy could be the result of different serum 
preparations (e.g., mouse vs. human) and/or the result of the quantification method used.  
Regardless, these results confirm that the modified siRNAs display enhanced nuclease 
resistance relative to unmodified siRNAs. 
 
Figure 3.2.  Nuclease stability of unmodified and nuclease-stabilized siRNAs after incubation at 37°C and 
5% CO2 in 90% mouse serum.  After gel electrophoresis, band intensities were quantified with ImageJ 
software and plotted versus time to estimate the half-life of the unmodified (solid circles) and nuclease-
stabilized (open circles) siGL3. 
 
3.4.3 In vitro activity of unmodified and nuclease-stabilized siRNAs in rapidly and 
slowly dividing cells  
 The cationic lipid transfection reagent, Oligofectamine, can deliver siRNA to 
luciferase-expressing HeLa and CCD-1074Sk cells (3).  Luciferase knockdown by 
unmodified and nuclease-stabilized siRNAs was first studied in rapidly dividing HeLa 
cells.  The cells were transfected with 25 nM or 100 nM of each siRNA species and then 
the luciferase activity was monitored through live-cell BLI.  Since the exact 
modifications of the nuclease-stabilized siRNAs may also introduce some nonspecific 
effects, a nuclease-stabilized version of the siCON1 control siRNA was used for 
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normalization of the cells receiving nuclease-stabilized siGL3.  This should minimize any 
artifacts from nonspecific effects that may arise from sequence-independent mechanisms.  
The results shown in Figure 3.3A-B represent the average of duplicate or triplicate wells 
per transfection condition, and the data from at least four independent experiments are 
represented at the 100 nM dose.  There was a slight increase in the duration of luciferase 
knockdown for the nuclease-stabilized siGL3 as seen by the shift in the knockdown 
curve, indicating that the inhibition lasts approximately 1-2 days longer under these 
conditions. 
 
Figure 3.3.  In vitro luciferase knockdown by unmodified and nuclease-stabilized siGL3 in rapidly dividing 
(HeLa) and slowly dividing (CCD) luciferase-expressing cells after Oligofectamine transfection.  (A) 
HeLa, 25 nM siRNA, (B) HeLa, 100 nM siRNA, (C) CCD-1074Sk, 25 nM siRNA, (D) CCD-1074Sk, 100 
nM siRNA.  Luciferase knockdown is reported relative to the luciferase activity from cells transfected with 
equal doses of the unmodified or nuclease-stabilized siCON1 control sequence.  Solid circles = unmodified 
siGL3, open circles = nuclease-stabilized siGL3. 
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The CCD-1074Sk fibroblast cell line has constitutive luciferase expression and 
divides very slowly, providing a system for examining the effects of enhanced siRNA 
nuclease stability in the absence of significant cell division.  The observed average cell 
doubling time during these experiments was 15-20 days, meaning the cells essentially 
were nondividing relative to the rapidly dividing HeLa cells that divide once every 1-2 
days.  Under these conditions, the amount of siRNA dilution that occurs in the fibroblast 
cell line should be low, allowing other processes, such as nuclease degradation, to 
possibly become limiting.  The cells were transfected with 25 nM or 100 nM of the 
unmodified and nuclease-stabilized siRNAs and the luciferase activity of the cells was 
monitored over time with live-cell BLI.  The data shown in Figure 3.3C-D represent the 
average of duplicate or triplicate wells per transfection condition, and the data from at 
least two independent experiments are represented at the 100 nM dose.  While the 
magnitude of the knockdown remained nearly the same for the unmodified and nuclease-
stabilized siRNAs, there was again a slight increase in the duration of the knockdown for 
the nuclease-stabilized siGL3, this time shifting the curve by 5-10 days at its maximum 
point of difference.  Since similar trends are again observed at both 25 nM and 100 nM 
even though the magnitude of the knockdown is lower for the 25 nM dose, it appears that 
the trends are not caused by saturation of the RNAi machinery. 
To explore whether the use of a transfection reagent affects the observed kinetics, 
we used electroporation to achieve intracellular localization of the unmodified and 
modified siRNAs in HeLa cells.  The results shown in Figure 3.4 represent the average of 
triplicate wells per transfection condition.  The kinetics of the luciferase knockdown after 
electroporation were similar to those observed after Oligofectamine transfection, with the 
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knockdown again lasting slightly over a week in the rapidly dividing HeLa cells.  
However, there was no noticeable increase in the duration of the knockdown when using 
nuclease-stabilized siGL3.  
 
Figure 3.4.  In vitro luciferase knockdown by unmodified and nuclease-stabilized siGL3 in HeLa cells after 
electroporation.  Luciferase knockdown is reported relative to the luciferase activity from cells that 
received equal doses of the unmodified or nuclease-stabilized siCON1 control sequence.  Solid circles = 
unmodified siGL3, open circles = nuclease-stabilized siGL3. 
 
 Although the nuclease-stabilized siRNAs did not appear to provide significant 
advantages in terms of the magnitude or the duration of gene silencing in vitro, the 
situation may be vastly different in vivo.  Specifically, the enhanced resistance of 
nuclease-stabilized siRNAs to degradation in the extracellular environment can increase 
the amount of the injected dose that remains intact for uptake and ultimately intracellular 
function.   
3.4.4 In vivo activity of unmodified and nuclease-stabilized siRNAs after 
hydrodynamic injection (HDI) 
Systemic delivery of naked nucleic acid molecules such as siRNAs can be 
achieved using HDI through the tail vein in mice.  Because HDI leads to substantial 
uptake by cells in the liver, it was used to compare the function of unmodified and 
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nuclease-stabilized siRNAs in vivo.  A plasmid containing the firefly luciferase gene 
driven by a hepatocyte-specific promoter was co-injected with siRNAs through HDI.  
Uptake of the plasmid by liver hepatocytes leads to a strong luciferase signal in the liver 
that can be followed using BLI.  When an siRNA sequence that targets luciferase is co-
injected with the plasmid, the total liver luciferase signal is decreased relative to the 
signal in mice that receive the plasmid and a non-targeting control siRNA sequence.  As 
in the in vitro experiments, a nuclease-stabilized version of the control siCON1 was used 
for determining the relative luciferase knockdown in the group of mice receiving 
nuclease-stabilized siGL3.  The luciferase signals of the mice were followed by BLI for 7 
weeks.  Bioluminescent images of representative mice from each treatment group after 2, 
12, and 30 days are shown in Figure 3.5, and the average integrated luciferase signals 
over the entire experiment are shown in Figure 3.6A.  The rapid decline in luciferase 
signals over the first several weeks followed by a non-zero steady-state value that persists 
for months is reproducibly observed after HDI of this plasmid.  The inherent variability 
from mouse to mouse leads to inevitable deviations in the final steady-state values 
reached by the mice in each group; therefore, normalization of these final values 
facilitates comparison between groups (Figure 3.6B).  Since the final normalized steady-
state values in Figure 3.6B are the same for all treatment groups, division of the signal for 
the siGL3-treated mice by the signal for the siCON1-treated mice gives a relative 
luciferase knockdown at each time point. 
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Figure 3.5.  Bioluminescent images of BALB/cJ mice after hydrodynamic co-injection of a plasmid 
containing the firefly luciferase gene under a hepatocyte-specific promoter and unmodified (siCON1, 
siGL3) or nuclease-stabilized (siCON1stbl, siGL3stbl) siRNAs.  One representative mouse was chosen 
from each of the four treatment groups and images are shown of each mouse after (A) 2 days, (B) 12 days, 
and (C) 30 days. 
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Figure 3.6.  Luciferase activity in BALB/cJ mice after hydrodynamic co-injection of a plasmid containing 
the firefly luciferase gene under a hepatocyte-specific promoter and unmodified or nuclease-stabilized 
siRNAs.  (A) Average raw luciferase signals and (B) average normalized luciferase signals are shown for 
mice co-injected with the plasmid and either unmodified siCON1 (solid squares, n = 3), unmodified siGL3 
(solid circles, n = 4), nuclease-stabilized siCON1 (open squares, n = 4), or nuclease-stabilized siGL3 (open 
circles, n = 5).  Normalization was performed by multiplying all data points of the raw luciferase signals for 
each group by an adjustment factor such that the final steady-state luciferase signals are equal for all four 
groups. 
 
The curves in Figure 3.7A represent the relative luciferase knockdown for the 
unmodified and nuclease-stabilized siGL3-treated mice relative to their respective 
controls.  The maximum magnitude of knockdown by each treatment can be assessed 
directly from Figure 3.7A.  The nuclease-stabilized siGL3 achieved a four-fold greater 
reduction in luciferase activity than the unmodified siGL3, reaching 5% of control 
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luciferase activity after 2 days compared to 20% of control luciferase activity for 
unmodified siGL3.  Determination of the duration of luciferase knockdown is more 
complicated because the nuclease-stabilized siGL3 gave a greater degree of knockdown.  
For example, if the luciferase signals for each treatment group recover at the same rate, 
the one that exhibits greater knockdown will take longer to return to the steady-state 
value.  Therefore, even though the results in Figure 3.7A indicate that the relative 
luciferase knockdown by nuclease-stabilized siGL3 lasts longer than the knockdown by 
unmodified siGL3, this may not necessarily imply different overall kinetics.  One 
approach to answering this question is shown in Figure 3.7B.  The curve for unmodified 
siGL3 is identical to the one shown in Figure 3.7A; however, the curve for nuclease-
stabilized siGL3 is shifted so that the knockdown after 2 days is equivalent for both.  
Such data analysis allows direct comparison of the kinetics at points of equivalent 
knockdown.  It is remarkable that the curves for both the unmodified and nuclease-
stabilized siRNAs nearly coincide over the duration of the knockdown, revealing that the 
overall kinetics are essentially identical in both cases. 
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Figure 3.7.  In vivo luciferase knockdown by unmodified and nuclease-stabilized siGL3 in BALB/cJ mice 
after hydrodynamic co-injection with a plasmid containing the firefly luciferase gene under a hepatocyte-
specific promoter.  (A) Relative luciferase knockdown for mice treated with unmodified siGL3 (solid 
circles, n = 4) or nuclease-stabilized siGL3 (open circles, n = 5).  Relative knockdown is calculated by 
dividing the normalized luciferase signals for the siGL3-treated mice by the normalized luciferase signals 
for the siCON1-treated mice.  (B) Comparison of the kinetics of luciferase knockdown by unmodified 
siGL3 (solid circles, n = 4) and nuclease-stabilized siGL3 (open circles, n = 5) at points of equivalent 
knockdown. 
 
3.4.5 Model predictions for the effect of siRNA nuclease stability 
Further analysis of these data using a mathematical model of siRNA-mediated 
gene silencing supports the notion that siRNA nuclease stabilization has its primary effect 
prior to cellular internalization and cytosolic localization.  The mathematical model 
enabled us to calculate how changes in certain parameters, such as intracellular or 
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extracellular siRNA half-life, could affect the kinetics of gene silencing.  The goal was to 
find which set of parameters must be varied to match the experimental results in Figures 
3.3 and 3.7.  If we assume that the differences between the curves for the unmodified and 
nuclease-stabilized siGL3 in Figure 3.3 are not just due to inherent variability, then the 
model must predict that the nuclease-stabilized siRNAs will slightly increase the duration 
of gene silencing without significantly impacting its magnitude when applied in vitro 
using Oligofectamine.  The model must also predict that HDI of nuclease-stabilized 
siRNAs will increase the magnitude of gene silencing, but not the kinetics of the 
recovery, relative to that achieved by unmodified siRNAs.  These goals can be achieved 
by changing relatively few parameters in the mathematical model described previously 
(3).  The rate of intracellular siRNA degradation, kdeginna, was kept constant for both 
unmodified and nuclease-stabilized siRNAs, although the rate of degradation was 
decreased to 7.2x10-3 h-1 to more closely match the experimental data now available.  
Additionally, the rate for the target mRNA degradation, kdegmRNA, was fixed at 0.69 h-1 
for both in vitro and in vivo models to provide the best approximation of the observed 
magnitude of luciferase knockdown.  For the in vitro version of the model, the value for 
vector endosomal unpackaging, kunpackend, was increased to 5x10-2 h-1 after 
Oligofectamine transfection and the value for siRNA endosomal degradation 
(kdegendna) was adjusted to reflect the nuclease stability of the unmodified (0.58 h-1) and 
nuclease-stabilized (0.03 h-1) siRNAs.  These changes result in a greater amount of naked 
(unpackaged) siRNA that has the potential to be degraded before it can enter the cytosolic 
compartment and interact with the intracellular machinery, such as the RISC components, 
that might contribute to its enhanced stability.  For the in vivo version of the model, the 
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rate of naked siRNA internalization, kint, after HDI was reduced to 1x10-8 h-1 to reflect a 
situation where some of the injected siRNA is not internalized immediately by the 
hepatocytes but remains in the extracellular environment where it is still susceptible to 
nuclease degradation (21).  The volume of this extracellular environment, such as the 
sinusoidal space in the liver, can be estimated to be around 300 µL for a mouse liver with 
50 million hepatocytes (22).  The partition parameter, controlling the effective amount of 
the injected dose that reaches this extracellular space, was adjusted to 5x10-3 from 1x10-2 
to match the magnitude of the knockdown by both unmodified and nuclease-stabilized 
siRNAs.  Unlike siRNAs internalized after Oligofectamine transfection, siRNAs 
internalized after HDI were assumed to not undergo any degradation in internalizing 
vesicles such as endosomes.  This enabled us to focus specifically on the differences in 
extracellular stability after HDI since all intracellular parameters were kept identical for 
unmodified and nuclease-stabilized siRNAs.  Finally, the rates for siRNA plasma 
elimination (kelimpl) and siRNA extracellular degradation (kelimec) were adjusted to 
reflect the nuclease stability of the unmodified and nuclease-stabilized siRNAs.  We 
assumed a relatively rapid plasma siRNA elimination with kelimpl = 0.1 h-1 for all 
siRNAs since renal clearance and nuclease degradation will both lead to plasma 
elimination.  The siRNA extracellular degradation and endosomal degradation rates were 
chosen to match the results from Figure 3.2, with values of 0.58 h-1 and 0.03 h-1 for 
unmodified and nuclease-stabilized siRNAs, respectively. 
Model simulations for luciferase knockdown by unmodified and nuclease-
stabilized siRNAs are shown in Figures 3.8 and 3.9.  The curves in Figure 3.8 represent 
the model predictions for luciferase knockdown in HeLa and CCD-1074Sk cells by 
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unmodified and nuclease-stabilized siRNAs, analogous to the experimental results shown 
in Figures 3.3B and 3.3D.  The differences between the two curves result only from the 
different degradation rates of the unmodified and nuclease-stabilized siRNAs prior to 
endosomal escape and interaction with the RNAi machinery; all other parameters are the 
same.  The intracellular siRNA degradation rate, reflecting the stability of the siRNAs in 
the cytosolic compartment, remains constant for both types of siRNA. 
 
Figure 3.8.  Model predictions for luciferase knockdown in luciferase-expressing (A) HeLa cells and (B) 
CCD-1074Sk cells after Oligofectamine transfection with 100 nM of unmodified siGL3 (solid line) or 
nuclease-stabilized siGL3 (dashed line).  In these simulations, the intracellular siRNA degradation rate 
remains constant while the parameters governing the stability of the siRNAs before cytosolic localization 
are changed as described in the Results. 
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The curves in Figure 3.9, corresponding to the experimental data shown in Figure 3.7, 
represent the luciferase knockdown predicted after HDI using unmodified and nuclease-
stabilized siRNAs.  The magnitude of the luciferase knockdown by the nuclease-
stabilized siRNAs is predicted to be greater than that by unmodified siRNAs, yet the 
kinetics of the overall knockdown are very similar as shown in Figure 3.9B.  Again, the 
intracellular siRNA degradation rate was kept constant, and this time only the 
extracellular siRNA degradation rate was altered to reflect the enhanced nuclease 
stability of the stabilized siRNAs. 
 
Figure 3.9.  Model predictions for luciferase knockdown in BALB/cJ mice after HDI.  (A) Relative 
luciferase knockdown after injection of unmodified siGL3 (solid line) or nuclease-stabilized siGL3 (dashed 
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line).  (B) Comparison of the kinetics of luciferase knockdown by unmodified siGL3 (solid line) and 
nuclease-stabilized siGL3 (dashed line) at points of equivalent knockdown.  In these simulations, the 
intracellular siRNA degradation rate remains constant while the parameters governing the stability of the 
siRNAs before cytosolic localization are changed as described in the Results. 
 
The model simulations shown in Figure 3.10 provide further justification for our 
decision to maintain a constant intracellular siRNA degradation rate.  The rate of 
intracellular siRNA degradation, kdeginna, was varied from 1.4x10-2 h-1 to 3.6x10-3 h-1 to 
reflect a situation in which nuclease stabilization prolongs the intracellular siRNA half-
life.  However, the parameters governing the stability of the siRNAs prior to cytosolic 
localization were kept constant.  The model predictions for luciferase knockdown in 
rapidly dividing HeLa cells (Figure 3.10A) appear reasonably close to what was observed 
experimentally (Figure 3.3B), yet the predictions for luciferase knockdown in the slowly 
dividing CCD-1074Sk cells (Figure 3.10B) or mouse liver hepatocytes after HDI (Figure 
3.10C) do not provide reasonable approximations to the experimental trends. 
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Figure 3.10.  Model predictions for the effect of intracellular siRNA degradation rate (kdeginna) on 
luciferase knockdown in (A) HeLa cells after transfection with 100 nM siGL3, (B) CCD-1074Sk cells after 
transfection with 100 nM siGL3, and (C) mouse liver hepatocytes after HDI of a luciferase-expressing 
plasmid and siGL3. 
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3.5   Discussion 
Although numerous studies have been conducted in a variety of animal models to 
investigate the efficacy of siRNAs as therapeutic agents, there has been less attention 
devoted to dosing schedule considerations that will depend upon how long knockdown 
lasts after a given dose of siRNA.  We previously showed that unmodified siRNAs can 
achieve luciferase downregulation for extended periods of time, lasting approximately 1 
week in rapidly dividing cells and 1 month in cells with minimal cell division (3).  These 
results help to guide the design of more effective dosing schedules by highlighting the 
importance of cell division.  Here, we extend the analysis of the kinetics of siRNA-
mediated gene silencing to include nuclease-stabilized siRNAs.   
Because of the rapid degradation of naked siRNAs in serum, it is clear that some 
form of protection will be required for systemic delivery.  This can be achieved either by 
the use of a delivery vehicle or by chemical modification of the siRNA itself.  Several 
studies have shown that chemically modified siRNAs can be highly resistant to nuclease 
degradation yet still function as effectors of RNA interference (9-14).  As a result, 
nuclease-stabilized siRNAs have been touted as holding great promise for in vivo 
applications where exposure to serum in the extracellular environment would rapidly 
degrade unmodified siRNAs.  A question that remains is whether or not nuclease 
stabilization also affects the kinetics of siRNA-mediated gene silencing.  If enhanced 
nuclease stability allows the siRNAs to remain intact longer inside the cell, it might lead 
to an increase in the duration of gene inhibition.  For example, Monia et al. observed a 
correlation between the nuclease resistance of antisense oligonucleotides and the 
magnitude and duration of the antisense effect (8).  Even though the 2’-methoxy modified 
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oligonucleotides with phosphodiester backbones had higher affinity for the target mRNA, 
the more nuclease-resistant 2’-pentoxy modified oligonucleotides displayed the greatest 
antisense activity, with a significant increase in both the magnitude and duration of Ha-
ras mRNA silencing.  On the other hand, Layzer et al. observed no significant difference 
in the magnitude or duration of gene silencing by unmodified or nuclease-stabilized 
siRNAs after cationic lipid transfection in cultured HeLa cells or in mice after HDI of 
naked siRNAs (10).  It is important to note that the studies with antisense 
oligonucleotides were also performed using a cationic lipid transfection reagent, 
indicating that the lack of apparent differences between the unmodified and nuclease-
stabilized siRNAs is not likely an artifact of the use of a transfection reagent.  Because 
cell division is a dominant factor that could govern the intracellular persistence of siRNA 
species in rapidly dividing cells, it is possible that nuclease-stabilized siRNAs are still 
diluted rapidly enough by cell division to limit prolonged gene silencing.  However, cell 
division cannot explain the lack of differences observed after HDI since liver hepatocytes 
divide very slowly.  The simplest explanation of these results is that the intrinsic nuclease 
stability of the individual siRNAs, unlike with antisense oligonucleotides, does not 
control their intracellular persistence.  To test this hypothesis, we compared the activities 
of unmodified and nuclease-stabilized siRNAs in both rapidly and slowly dividing cells 
in vitro to determine if the nuclease-stabilized siRNAs would affect the magnitude or 
duration of gene silencing.  Then, we used HDI to co-deliver a luciferase-expressing 
plasmid and either unmodified or nuclease-stabilized siRNAs in BALB/cJ mice, and we 
compared the kinetics of luciferase knockdown by the respective siRNAs using BLI. 
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The data presented here directly address the impact of nuclease stabilization on 
siRNA activity in vitro in rapidly and slowly dividing cells and in vivo after HDI in mice.  
There was a slight increase in the duration of luciferase knockdown by nuclease-
stabilized siRNAs relative to unmodified siRNAs after cationic lipid transfection, but this 
difference was not observed after electroporation.  In BALB/cJ mice, a four-fold increase 
in maximum luciferase knockdown was observed after hydrodynamic injection (HDI) of 
nuclease-stabilized siRNAs relative to unmodified siRNAs, yet the overall kinetics of the 
recovery after knockdown were nearly identical. 
These experimental results, combined with the mathematical model predictions, 
imply that the differences in the knockdown observed with nuclease-stabilized siRNAs 
result chiefly from processes that occur during internalization before the siRNAs have the 
chance to interact with the intracellular RNAi machinery.  For example, the predicted 
curves shown in Figure 3.8 can be made to closely match the experimental trends if the 
nuclease-stabilized siRNAs are more stable than unmodified siRNAs during 
internalization yet have similar degradation kinetics as unmodified siRNAs once 
localized to the cytosol.  It should be noted that for these conditions the model also 
predicts a slight change in the magnitude of knockdown that was not observed 
experimentally, but this difference is likely caused by intricacies of the RNAi process that 
are not captured by our simplified model.  Furthermore, there were no observed 
differences after electroporation of unmodified and nuclease-stabilized siRNAs, where 
the rapid entry of the siRNAs directly into the cytosol of the cells would allow both types 
of siRNAs to quickly associate with the intracellular machinery.  This is exactly the result 
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predicted by the model if the intracellular siRNA degradation rate is constant and there is 
no opportunity for degradation in internalizing vesicles before escape into the cytosol. 
Additionally, the in vivo results presented here are consistent with those reported 
by Morrissey et al. who observed much stronger knockdown after HDI by nuclease-
stabilized siRNAs relative to unmodified siRNAs after 72 hours (9).  Exposure to serum 
prior to uptake by the hepatocytes can lead to an appreciable degradation of the injected 
unmodified siRNAs, especially given the rapid degradation kinetics observed in the 
serum stability assay shown in Figure 3.2.  Lecocq et al. reported that a significant 
portion of hydrodynamically injected plasmid DNA remained bound to the outer surface 
of hepatocytes for at least 1 hour after injection (21).  If similar distribution patterns 
occur with siRNAs, then nuclease degradation of this portion of the injected dose that is 
not internalized rapidly could also lead to the greater magnitude of knockdown by 
nuclease-stabilized siRNAs relative to unmodified siRNAs after HDI of equivalent doses.  
Changes only in this extracellular siRNA degradation rate for the unmodified and 
nuclease-stabilized siRNAs can account for the observed experimental trends, as revealed 
by the model predictions shown in Figure 3.9.  Although the overall kinetics of the 
luciferase knockdown are similar for unmodified and nuclease-stabilized siRNAs, the 
nuclease-stabilized siRNAs are predicted to increase the absolute magnitude of the 
knockdown.  However, the degree to which this difference in effective dose that 
ultimately is internalized by the hepatocytes will affect the magnitude of knockdown will 
depend on the initial dose applied.  If the magnitude of knockdown is already at its 
maximum using the unmodified siRNAs, then even a higher effective dose resulting from 
using nuclease-stabilized siRNAs cannot further reduce gene expression since the RNAi 
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machinery is saturated.  This maximum administered dose will vary from one system to 
another since it can be affected by parameters such as the target mRNA degradation rate 
and the percent of the injected dose that reaches the target cells. 
 Further support for the idea that the intracellular nuclease stability of siRNAs is 
not a dominant factor controlling the kinetics of siRNA-mediated gene silencing comes 
from the model simulations shown in Figure 3.10.  Although changes in the intracellular 
degradation rate can reasonably approximate the experimental results obtained using 
HeLa cells, this cannot account for the observed luciferase knockdown by unmodified 
and nuclease-stabilized siRNAs in slowly dividing fibroblasts or liver hepatocytes.  
Without cell division, the intracellular siRNA degradation rate plays a more dominant 
role in the duration of the inhibition.  A mere two-fold reduction in the rate of 
intracellular siRNA degradation leads to a larger change in the duration of the 
knockdown (Figure 3.10B) than we observed experimentally between the unmodified and 
nuclease-stabilized siRNAs (Figure 3.3D), even though there was an approximately 20-
fold difference in the observed serum stability of the unmodified and nuclease-stabilized 
siRNAs (Figure 3.2).  Therefore, the intracellular siRNA degradation rate does not appear 
to be the parameter that is responsible for the observed differences.  Moreover, the model 
predictions for luciferase knockdown after HDI in mice (Figure 3.10C) reveal that 
changes in the intracellular siRNA degradation rate alone cannot account for our 
observations showing that nuclease-stabilized siRNAs led to a greater magnitude of 
luciferase knockdown without affecting the overall kinetics (Figure 3.7).  In fact, changes 
in the intracellular siRNA degradation rate alone do the exact opposite, leaving the 
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magnitude of the luciferase knockdown essentially unchanged while instead affecting the 
kinetics of the recovery back to the steady-state value. 
 Of practical importance, this comparison of the kinetics of gene silencing by 
unmodified and nuclease-stabilized siRNAs may serve as an additional method to 
confirm whether an observed knockdown phenotype is a result of an RNAi or an 
antisense mechanism.  While nuclease-stabilized antisense oligonucleotides have been 
shown to enhance both the magnitude and duration of gene silencing, unmodified and 
nuclease-stabilized siRNAs do not exhibit significantly different functional behavior once 
inside cells.  If the observed kinetics of gene silencing are nearly identical using both 
unmodified and modified siRNAs, then this would support the notion that the siRNAs are 
acting through an RNAi mechanism. 
It is also important to consider under what circumstances nuclease-stabilized 
siRNAs can provide a significant benefit relative to unmodified siRNAs.  Our 
observations indicate that nuclease-stabilized siRNAs do not provide considerable 
advantages in vitro with regard to either the magnitude or duration of gene silencing.  In 
fact, nuclease-stabilized siRNAs are more costly to produce and frequently show 
decreased activity relative to unmodified siRNAs of the same sequence.  However, the 
added costs and the potential for decreased activity of nuclease-stabilized siRNAs may be 
outweighed by other factors for in vivo applications.  Recent reports have indicated that 
chemical modifications can modulate the immunostimulatory properties of siRNAs (23).  
Moreover, chemical modifications to confer added nuclease stability can increase the 
bioavailability of an injected siRNA species by protecting it from the rapid nuclease 
degradation that occurs with unmodified siRNAs.  If siRNAs are injected locally, as in 
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intratumoral or intramuscular injection, the added nuclease stability may increase the 
time during which siRNAs can be internalized by the target cells.  Systemic 
administration of siRNAs through hydrodynamic tail-vein injection, as employed in this 
study, or standard intravenous injection can also benefit from siRNA nuclease 
stabilization.  Standard intravenous injection of relatively high doses (up to 30 mg kg-1) 
of nuclease-stabilized siRNAs reduced hepatitis B virus (HBV) DNA levels in a mouse 
model of HBV (9).  However, since the rapid renal clearance of naked siRNAs is a result 
of their small size, nuclease-stabilized siRNAs are still cleared rapidly from the 
bloodstream after systemic administration (2).  To address both limitations of renal 
clearance and nuclease stability, Soutschek et al. showed that nuclease-stabilized, 
cholesterol-targeted siRNAs had a lower plasma clearance than unconjugated siRNAs 
after intravenous injection, presumably due to enhanced binding to serum proteins that 
slowed renal filtration (24).  These nuclease-stabilized, cholesterol-targeted siRNAs were 
able to silence endogenous apolipoprotein B levels after standard intravenous injection, 
albeit at a high dose of 50 mg kg-1.  Development of nucleic acid delivery vehicles that 
encapsulate and protect siRNAs until internalization by the target cells represents another 
promising approach to avoid rapid removal of systemically administered siRNAs by renal 
filtration and nuclease degradation.  Not only can carrier-mediated siRNA delivery 
considerably lower the required siRNA dose for efficacy, but it also permits the use of 
unmodified siRNAs even for systemic administration, as indicated by the multitude of 
published studies showing efficacy after intravenous injection of delivery vehicles 
containing unmodified siRNAs (25,26). 
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3.6 Conclusions 
The results presented here indicate that the most significant impact of siRNA 
nuclease stability on gene silencing involves processes that occur prior to cellular 
internalization.  The magnitude and duration of luciferase knockdown in vitro were not 
affected by the siRNA nuclease stability after electroporation, and only a slight increase 
in the duration of knockdown was observed after Oligofectamine transfection in both 
rapidly and slowly dividing cells.  Moreover, use of nuclease-stabilized siRNAs led to a 
greater observed magnitude of luciferase knockdown after HDI in mice, but the kinetics 
of the knockdown were unaffected.  By employing a mathematical model of siRNA-
mediated gene silencing, we showed that only changes in the siRNA stability before 
cytosolic entry would lead to predicted luciferase knockdown curves consistent with all 
of the available experimental data.  These findings suggest that nuclease-stabilized 
siRNAs do not offer any significant advantages over unmodified siRNAs with respect to 
either the magnitude or the duration of gene silencing once they achieve cytosolic 
localization in cells. 
  
85
3.7 Acknowledgments 
We are grateful to D. Petersen and D. Kohn (Children’s Hospital Los Angeles) for 
performing the lentiviral transductions of the luciferase-expressing cell lines and A. 
McCaffrey and M. Kay (Stanford University) for donating the luciferase-containing 
plasmid, pApoEHCRLuc.  This material is based upon work supported by a National 
Science Foundation Graduate Research Fellowship.  This publication was made possible 
by Grant Number 1 R01 EB004657-01 from the National Institutes of Health (NIH).  Its 
contents are solely the responsibility of the authors and do not necessarily represent the 
official views of the NIH. 
 
 
 
 
  
86
3.8 References 
1. Bertrand, J.-R., Pottier, M., Vekris, A., Opolon, P., Maksimenko, A. and Malvy, 
C. (2002) Comparison of antisense oligonucleotides and siRNAs in cell culture 
and in vivo. Biochem Biophys Res Commun, 296, 1000-1004. 
2. Dykxhoorn, D.M., Palliser, D. and Lieberman, J. (2006) The silent treatment: 
siRNAs as small molecule drugs. Gene Ther, 13, 541-552. 
3. Bartlett, D.W. and Davis, M.E. (2006) Insights into the kinetics of siRNA-
mediated gene silencing from live-cell and live-animal bioluminescent imaging. 
Nucleic Acids Res, 34, 322-333. 
4. Omi, K., Tokunaga, K. and Hohjoh, H. (2004) Long-lasting RNAi activity in 
mammalian neurons. FEBS Lett, 558, 89-95. 
5. Song, E., Lee, S.-K., Dykxhoorn, D.M., Novina, C., Zhang, D., Crawford, K., 
Cerny, J., Sharp, P.A., Lieberman, J., Manjunath, N. et al. (2003) Sustained small 
interfering RNA-mediated human immunodeficiency virus type I inhibition in 
primary macrophages. J Virol, 77, 7174-7181. 
6. Zimmermann, T.S., Lee, A.C.H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, 
M.N., Harborth, J., Heyes, J.A., Jeffs, L.B., John, M. et al. (2006) RNAi-mediated 
gene silencing in non-human primates. Nature, 441, 111-114. 
7. Raemdonck, K., Remaut, K., Lucas, B., Sanders, N.N., Demeester, J. and De 
Smedt, S.C. (2006) In situ analysis of single-stranded and duplex siRNA integrity 
in living cells. Biochemistry, 45, 10614-10623. 
8. Monia, B.P., Johnston, J.F., Sasmor, H. and Cummins, L.L. (1996) Nuclease 
resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J 
Biol Chem, 271, 14533-14540. 
9. Morrissey, D.V., Blanchard, K., Shaw, L., Jensen, K., Lockridge, J.A., Dickinson, 
B., McSwiggen, J.A., Vargeese, C., Bowman, K., Shaffer, C.S. et al. (2005) 
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus 
replication. Hepatology, 41, 1349-1356. 
10. Layzer, J.M., McCaffrey, A.P., Tanner, A.K., Huang, Z., Kay, M.A. and 
Sullenger, B.A. (2004) In vivo activity of nuclease-resistant siRNAs. RNA, 10, 
766-771. 
11. Chiu, Y.-L. and Rana, T.M. (2003) siRNA function in RNAi: a chemical 
modification analysis. RNA, 9, 1034-1048. 
12. Choung, S., Kim, Y.J., Kim, S., Park, H.O. and Choi, Y.C. (2006) Chemical 
modification of siRNAs to improve serum stability without loss of efficacy. 
Biochem Biophys Res Commun, 342, 919-927. 
13. Elmén, J., Thonberg, H., Ljungberg, K., Frieden, M., Westergaard, M., Xu, Y., 
Wahren, B., Liang, Z., Ørum, H., Koch, T. et al. (2005) Locked nucleic acid 
(LNA) mediated improvements in siRNA stability and functionality. Nucleic 
Acids Res, 33, 439-447. 
14. Czauderna, F., Fechtner, M., Dames, S., Aygun, H., Klippel, A., Pronk, G.J., 
Giese, K. and Kaufmann, J. (2003) Structural variations and stabilising 
modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res, 31, 
2705-2716. 
  
87
15. McCaffrey, A.P., Meuse, L., Pham, T.-T.T., Conklin, D.S., Hannon, G.J. and 
Kay, M.A. (2002) RNA interference in adult mice. Nature, 418, 38-39. 
16. Challita, P.-M., Skelton, D., El-Khoueiry, A., Yu, X.-J., Weinberg, K. and Kohn, 
D.B. (1995) Multiple modifications in cis elements of the long terminal repeat of 
retroviral vectors lead to increased expression and decreased DNA methylation in 
embryonic carcinoma cells. J Virol, 69, 748-755. 
17. Bahner, I., Kearns, K., Hao, Q., Smogorzewska, E. and Kohn, D. (1996) 
Transduction of human CD34+ hematopoietic progenitor cells by a retroviral 
vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 
replication in myelomonocytic cells produced in long-term culture. J Virol, 70, 
4352-4360. 
18. Persengiev, S.P., Zhu, X. and Green, M.R. (2004) Nonspecific, concentration-
dependent stimulation and repression of mammalian gene expression by small 
interfering RNAs (siRNAs). RNA, 10, 12-18. 
19. Huppi, K., Martin, S.E. and Caplen, N.J. (2005) Defining and assaying RNAi in 
mammalian cells. Mol Cell, 17, 1-10. 
20. Rose, S.D., Kim, D.-H., Amarzguioui, M., Heidel, J.D., Collingwood, M.A., 
Davis, M.E., Rossi, J.J. and Behlke, M.A. (2005) Functional polarity is introduced 
by Dicer processing of short substrate RNAs. Nucleic Acids Res, 33, 4140-4156. 
21. Lecocq, M., Andrianaivo, F., Warnier, M., Wattiaux-De Coninck, S., Wattiaux, R. 
and Jadot, M. (2003) Uptake by mouse liver and intracellular fate of plasmid 
DNA after a rapid tail vein injection of a small or a large volume. J Gene Med, 5, 
142-156. 
22. Reinoso, R.F., Telfer, B.A., Brennan, B.S. and Rowland, M. (2001) Uptake of 
teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic 
distribution. Drug Metab Dispos, 29, 453-349. 
23. Judge, A.D., Bola, G., Lee, A.C.H. and MacLachlan, I. (2006) Design of 
noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol 
Ther, 13, 494-505. 
24. Soutschek, J., Akinc, A., Bramiage, B., Charisse, K., Constien, R., Donoghue, M., 
Elbashir, S., Geick, A., Hadwiger, P., Harborth, J. et al. (2004) Therapeutic 
silencing of an endogenous gene by systemic administration of modified siRNAs. 
Nature, 432, 173-178. 
25. Behlke, M.A. (2006) Progress towards in vivo use of siRNAs. Mol Ther, 13, 644-
670. 
26. Hu-Lieskovan, S., Heidel, J.D., Bartlett, D.W., Davis, M.E. and Triche, T.J. 
(2005) Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery 
of small interfering RNA inhibits tumor growth in a murine model of Ewing's 
sarcoma. Cancer Res, 65, 8984-8992. 
  
88
4 Physicochemical and biological characterization of 
targeted, nucleic acid-containing nanoparticles†  
 
4.1 Abstract 
Nucleic acid-based therapeutics have the potential to provide potent and highly 
specific treatments for a variety of human ailments.  However, systemic delivery 
continues to be a significant hurdle to success.  Multifunctional nanoparticles are being 
investigated as systemic, nonviral delivery systems, and here we describe the 
physicochemical and biological characterization of cyclodextrin-containing polycations 
(CDP) and their nanoparticles formed with nucleic acids including plasmid DNA 
(pDNA) and small interfering RNA (siRNA).  These polycation/nucleic acid complexes 
can be tuned by formulation conditions to yield nanoparticles with sizes ranging from 60-
150 nm, zeta potentials from 10-30 mV, and molecular weights from ~7x107-1x109 g 
mol-1 as determined by light scattering techniques.  Inclusion complexes formed between 
adamantane (AD)-containing molecules and the β-cyclodextrin molecules enable the 
modular attachment of polyethylene glycol (AD-PEG) conjugates for steric stabilization 
and targeting ligands (AD-PEG-transferrin) for cell-specific targeting.  A 70-nm 
nanoparticle can contain ~10,000 CDP polymer chains, ~2,000 siRNA molecules, ~4,000 
AD-PEG5000 molecules, and ~100 AD-PEG5000-Tf molecules; this represents a significant 
payload of siRNA and a large ratio of siRNA to targeting ligand (20:1).  The 
nanoparticles protect the nucleic acid payload from nuclease degradation, do not 
                                                 
† Reproduced  with permission from:  Bartlett, D.W. and Davis, M.E. (2007) Physicochemical and 
biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjugate Chem, 18, 456-
468.  Copyright 2007 American Chemical Society. 
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aggregate at physiological salt concentrations, and cause minimal erythrocyte aggregation 
and complement fixation at the concentrations typically used for in vivo application.  
Uptake of the nucleic acid-containing nanoparticles by HeLa cells is measured by flow 
cytometry and visualized by confocal microscopy.  Competitive uptake experiments 
show that the transferrin-targeted nanoparticles display enhanced affinity for the 
transferrin receptor through avidity effects (multi-ligand binding).  Functional efficacy of 
the delivered pDNA and siRNA is demonstrated through luciferase reporter protein 
expression and knockdown, respectively.  The analysis of the CDP delivery vehicle 
provides insights that can be applied to the design of targeted nucleic acid delivery 
vehicles in general. 
4.2 Introduction 
Nucleic acid-based therapeutics are envisioned to play a significant role in the 
next generation of treatments for a variety of diseases such as cancer.  In addition to the 
classic gene therapy approach of delivering DNA to replace mutated or absent genes, 
nucleic acid molecules can also be used to regulate the production of disease-associated 
proteins at both the transcriptional and translational levels.  These nucleic acid-based 
drugs have received significant attention as promising new therapeutics, yet their 
application in vivo has been largely limited by the challenge of delivery; this has been 
particularly true for systemic delivery. 
Naked nucleic acid molecules are rapidly degraded by ubiquitous nucleases 
present in the bloodstream.  Double-stranded nucleic acid molecules ranging in size from 
small-interfering RNAs (siRNAs) to plasmids (pDNA) have a half-life of less than one 
hour in serum (1-3).  Selective chemical modification of nucleic acids can increase 
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nuclease resistance and enable systemic delivery of naked siRNA molecules with 
functional efficacy in vivo (1,4).  However, even nuclease-stabilized nucleic acids must 
still overcome other elimination barriers such as renal clearance that severely limit the 
efficacy of systemically delivered, small nucleic acid therapeutics (5).  Attachment of 
specific targeting ligands can induce binding to protein carriers or uptake by the desired 
population of cells to be treated.  Bioconjugates of the nucleic acid therapeutics 
covalently attached directly to targeting ligands such as cholesterol and antibodies have 
shown efficacy both in vitro and in vivo (4,6).  While these methods for nuclease 
stabilization and covalent attachment of targeting ligands are promising for small nucleic 
acid therapeutics, the use of lipid- or polymer-based delivery vehicles is an approach for 
systemic delivery that can provide functions not achievable with naked nucleic acids or 
their covalent attachment to targeting moieties. 
Carrier-mediated delivery has several advantages over the delivery of individual 
nucleic acid molecules.  Encapsulation of the payload within a lipid bilayer or through 
electrostatic interactions is nonspecific, so these delivery vehicles can be used for 
generalized nucleic acid delivery.  The use of a carrier enables delivery of many nucleic 
acid molecules per uptake event (this is especially important if the uptake involves highly 
specific cell-surface receptors since they are typically low in number), and isolation from 
exposure to the systemic environment can permit the use of unmodified nucleic acids (7).  
Modularly designed delivery vehicles can also take advantage of covalent or non-
covalent attachment of hydrophilic polymers for steric stabilization and/or targeting 
ligands for cell-specific delivery, two critical features for systemic delivery (7,8).  Such 
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modifications can affect the resulting biodistribution of delivery vehicles through passive 
and/or active targeting (7-10). 
Passive targeting occurs as a result of the intrinsic physicochemical properties of 
the delivery vehicle.  For example, the charge and size of the delivery vehicle alone can 
bias its biodistribution.  The charge of the delivery vehicle significantly impacts its 
interaction with components of the bloodstream; highly charged particles can lead to 
complement activation, while near-neutral particles exhibit reduced phagocytic uptake 
(11,12).  Specifically, cationic polymers such as polylysine and polyethylenimine have 
been shown to activate the complement system, and increasing polycation length and 
surface charge density lead to higher complement activation (11).  Rapid binding of 
charged molecules by complement proteins or other opsonins can lead to immune 
stimulation and rapid clearance of the delivery vehicles from the bloodstream.  The size 
of the delivery vehicle also matters for systemic delivery.  Based on measured sieving 
coefficients for the glomerular capillary wall, it is estimated that the threshold for first-
pass elimination by the kidneys is approximately 10 nm (diameter) (13), placing a lower 
size limit on the assembled delivery vehicles.  On the other end of the size spectrum, 
macromolecular complexes preferentially accumulate in tumors through the enhanced 
permeability and retention (EPR) effect.  However, large macromolecules or delivery 
vehicles exhibit limited diffusion in the extracellular space, such as the tumor 
interstitium, and in the complex intracellular environment (14); in both situations, 
restricted movement will severely limit efficacy by preventing uptake by a sufficient 
number of cells or hindering the ability of the delivered nanoparticles to localize to 
intracellular compartments such as the nucleus.  Other restrictions limiting the maximum 
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size of delivery vehicles can also be imposed by the selectivity of receptors on certain 
cell types.  For example, a study by Rensen et al. demonstrated that nanoparticles larger 
than 70 nm in diameter were not recognized by the asialoglycoprotein receptor (ASGPR) 
(15), placing an upper size limit on the nanoparticles that can be delivered to hepatocytes 
through this receptor. 
Recent efforts toward targeted delivery have focused on decorating the surface of 
delivery vehicles with cell surface receptor-specific targeting ligands as a means of active 
targeting.  Hydrophilic polymers, such as polyethylene glycol (PEG), can be attached to 
the surface of the delivery vehicles to mask surface charge and prevent nonspecific 
interactions, helping to prevent unwanted binding to components of the bloodstream, 
slow uptake by the reticuloendothelial system (RES), and alter the cellular uptake 
patterns (8,16).  Further addition of entities that can interact with cell surface receptors, 
such as the receptors’ natural ligands, antibodies, or antibody fragments, allows the 
delivery vehicle to target particular cell types and undergo receptor-mediated endocytosis 
upon binding to the surface receptor (7,8,15).  
In light of these considerations, a successful delivery vehicle must be engineered 
to have the following characteristics: (i) be small enough to extravasate and exhibit 
adequate tissue penetration, yet avoid rapid renal clearance; (ii) minimize nonspecific 
interactions and opsonization while providing specific targeting to a given cell; and (iii) 
protect the nucleic acid from degradation, but willingly release it upon arrival at the 
proper site.  Over the past few years, we have been developing a synthetic delivery 
system based on a cyclodextrin-containing polycation (CDP) that has demonstrated some 
success in delivering nucleic acid payloads that include pDNA, siRNA, and DNAzymes 
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(7,17-20).  This delivery system is the first to be de novo designed for systemic delivery 
of nucleic acids and completely formulated by self-assembly (17).  Here, we describe the 
physicochemical and biological characterization of the cyclodextrin-containing 
polycation delivery system and its formulation with nucleic acids.  We illustrate issues of 
importance when designing any polycation composite with nucleic acids through the use 
of the CDP and point out when the conclusions are specific to this system only. 
4.3 Materials and methods 
4.3.1 Formulation of nucleic acid nanoparticles 
 The chemical structure of the cyclodextrin-containing polycation is shown in 
Figure 4.1A.  This short, linear polycation can be synthesized with (CDP-Im) or without 
(CDP) the imidazole groups on the terminal amines (17,18).  A schematic showing 
nanoparticle formation using CDP-Im and nucleic acid is shown in Figure 4.1B; 
nanoparticles are formed by mixing equal volumes of CDP-Im and nucleic acid.  The 
ratio of positive (+) charges (2 moles of positive charge per CDP-Im monomer; denoted 
β-CD) to negative (-) charges (1 mole of negative charge per nucleotide) is defined as the 
formulation charge ratio (+/-).  Polyethylene glycol (PEG) molecules containing 
adamantane (AD) on the proximal end and either methoxy (AD-PEG) or a targeting 
ligand such as transferrin (AD-PEG-Tf) on the distal end can be attached to the surface of 
the nanoparticles via inclusion complex formation between adamantane and the β-CD 
molecules on the polycation backbone (16,17).  The molecular weight of the PEG chain 
is typically 5,000 daltons (PEG5000). 
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Figure 4.1.  Formation of nucleic acid-containing nanoparticles using CDP-Im.  (A) Schematic of the 
chemical structure of CDP-Im.  (B) Schematic of nanoparticle assembly. 
 
4.3.2 Formulation of PEGylated/targeted nucleic acid nanoparticles 
Pre-complexation (self-assembly)  
Before addition to the nucleic acid, the CDP or CDP-Im was mixed with an AD-
PEG conjugate at a 1:1 AD-PEG:β-CD (mol:mol) ratio in water.  Targeted nanoparticles 
also require the addition of ligand-modified AD-PEG-X (e.g., AD-PEG-Tf (7,19,20)) as a 
percentage of the total AD-PEG in the mixture.  For example, 1 mol% AD-PEG-Tf 
nanoparticles contain 0.01 moles AD-PEG-Tf for every 0.99 moles AD-PEG.  The 
mixture of CDP (or CDP-Im), AD-PEG, and AD-PEG-Ligand in water was then added to 
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an equal volume of nucleic acid in water such that the ratio of positive charges from CDP 
or CDP-Im to negative charges from the nucleic acid was equal to the desired charge 
ratio.  A schematic of this assembly process is shown in Figure 4.1B.  Unless specified 
otherwise, all PEGylated or targeted nucleic acid nanoparticles used in these studies were 
prepared through the pre-complexation method. 
Post-complexation 
 Particles were initially formulated in water by mixing equal volumes of nucleic 
acid and the cyclodextrin-containing polycation.  After nanoparticles had formed, the 
AD-PEG and AD-PEG-Tf conjugates were added directly to the formulation mixture at 
the desired ratio of AD-PEG:β-CD (mol:mol).  A schematic of this assembly process is 
shown in Figure 4.1B. 
4.3.3 Electrophoretic mobility shift assay 
siRNA-containing nanoparticles were formulated at different charge ratios by 
changing the amount of CDP added to 1 µg of siRNA.  CDP was first dissolved in 10 µL 
water and then added to an equal volume of water containing 1 µg of nucleic acid.  After 
a 30-min incubation at room temperature, 10 µL of each formulation was run on a 1% 
agarose gel and visualized by ethidium bromide staining. 
4.3.4 Individual nanoparticle charge ratio 
siRNA nanoparticles were formulated in 40 µL water at charge ratios from 5 to 30 
(+/-).  After formulation, the nanoparticles were separated from the free components by 
addition of 400 µL PBS, to cause nanoparticle aggregation, followed by centrifugation to 
pellet the aggregated nanoparticles.  Since the CDP is terminated by primary amines, 
quantitation of polycation content was accomplished by measuring the amount of primary 
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amines as follows.  400 µL of the supernatant was removed and combined with 200 µL 
of 0.01% w/v 2,4,6-trinitrobenzenesulfonic acid (Sigma).  After incubating these samples 
for 2 h at 37°C, 200 µL 10% SDS and 100 µL of 1 N HCl were added to each sample 
before measuring the absorbance at 335 nm with a spectrophotometer.  The amount of 
CDP in each sample was determined by comparison to a standard curve of CDP.  The 
total positive charge present in each sample was calculated from the mass of CDP present 
using the fixed charge density of 0.0014 moles “+” per gram.  This gave the number of 
unbound “+” charges present, so the number of bound “+” charges in the nanoparticles 
could be determined by subtracting the number unbound from the total “+” charges added 
during formulation.  Assuming 100% incorporation of the nucleic acid into the 
nanoparticles at a formulation charge ratio of 3 (+/-) (based on the electrophoretic 
mobility shift assays; see Results), the ratio of CDP to nucleic acid within each 
nanoparticle is equal to the number of bound “+” charges divided by the total number of 
“-” charges from the nucleic acid. 
4.3.5 Serum stability 
Particles were formulated in water at a charge ratio of 3 (+/-) with an siRNA 
concentration of 0.05 g L-1.  10 µL of 100% mouse serum (Sigma) were added to 10 µL 
of the nanoparticle formulation and subsequently incubated for 4 h at 37°C and 5% CO2.  
0.25 µg naked siRNA in 5 µL water were added to 5 µL of 100% mouse serum and also 
incubated for 4 h at 37°C and 5% CO2.  For comparison to the t = 4 h samples, identical 
amounts of naked siRNA or siRNA nanoparticles were exposed to 50% mouse serum 
immediately before gel loading (t = 0 h).  10 µL of each sample (containing 0.25 µg 
siRNA) were loaded per well of a 1% agarose gel.  Displacement of the nucleic acid from 
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the nanoparticles was achieved by adding 1% sodium dodecyl sulfate (SDS) to the 
sample immediately prior to gel loading.  Gel electrophoresis was performed by applying 
100 V for 30 min, and the bands were visualized by ethidium bromide staining. 
4.3.6 Dynamic light scattering (DLS) 
Particle formulations were diluted to a volume of 1.4 mL, placed in a cuvette, and 
inserted into a ZetaPALS (Brookhaven Instruments Corporation) instrument to measure 
both the size and zeta potential.  Reported effective hydrodynamic diameters represent 
the average values from a total of 5-10 runs of 30 seconds each, while zeta potentials 
represent the average of 10 runs each. 
4.3.7 Transmission electron microscopy (TEM) 
 Particles containing CDP-Im and siRNA (0.1 g L-1) and PEGylated nanoparticles 
containing CDP-Im, AD-PEG (1:1 AD-PEG:β-CD mole ratio), and siRNA (0.5 g L-1) 
were formulated in water at a charge ratio of 3 (+/-).  Samples were stained with 2% 
uranyl acetate and then examined with an EM201C electron microscope (Philips). 
4.3.8 Atomic force microscopy (AFM) 
 Particles containing CDP-Im and siRNA (0.1 g L-1) and PEGylated nanoparticles 
containing CDP-Im, AD-PEG (1:1 AD-PEG:β-CD mole ratio), and siRNA (0.5 g L-1) 
were formulated in water at a charge ratio of 3 (+/-).  20 µL of each formulation solution 
were dropped on a freshly cleaved mica disc (Ted Pella, Inc.) and dried with pressurized 
air.  Images were acquired with a Digital Instruments MultiMode AFM with a Nanoscope 
IV controller in tapping mode at a scan rate of 1 Hz using a BS Multi75 probe 
(BudgetSensors) with a resonant frequency of 75 kHz and a force constant of 3 N m-1.  
Height images were flattened and processed for visualization with the derivative matrix 
  
98
convolution filter using WSxM scanning probe microscopy software (Nanotec 
Electronica). 
4.3.9 Isothermal titration calorimetry (ITC) 
A MicroCal MCS titration calorimeter was used to investigate the thermodynamic 
properties of the interaction between AD-PEG conjugates and the β-cyclodextrin 
molecules on the CDP-Im backbone.  CDP-Im (free or in nanoparticles) at 0.22 mM total 
β-CD in water was placed in the sample cell of the instrument.  The reference cell 
contained water alone without CDP-Im.  Small amounts of an AD-PEG stock solution at 
a concentration of 2.2 mM in water were titrated into the sample cell in 25 separate 10-
µL increments.  Titrations were performed at 30°C.  The measured parameters were δn, 
the number of moles of ligand (AD-PEG) added to the sample cell, and q, the amount of 
heat released or absorbed.  The Simplex algorithm in the Origin data analysis software 
was used to determine the following parameters:  K, the equilibrium binding constant; n, 
the number of available binding sites; and ∆H, the change in enthalpy.  A more in-depth 
description of the thermodynamic analysis applied to ITC is provided by Blandamer et al. 
(21). 
4.3.10 Percentage of AD-PEG5000 bound after formulation 
The small molecule, lactose (Lac), was attached to the end of AD-PEG5000 to 
enable quantification using the Amplex Red Galactose Oxidase Assay Kit (Molecular 
Probes).  Nanoparticles were formulated in a total volume of 100 µL water by adding a 
50 µL solution containing CDP-Im and AD-PEG5000-Lac (1:1 mole ratio of AD-PEG5000-
Lac: β-CD) in water to a 50 µL solution of siRNA in water.  Control formulations were 
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created by mixing CDP-Im and AD-PEG5000-Lac without siRNA in 100 µL water.  
Nanoparticles and control formulations were filtered with Biomax (Millipore) centrifugal 
filtration devices with a 50 kDa MWCO to separate free and bound components.  The 
Amplex Red Galactose Oxidase Assay Kit (Molecular Probes) was used to quantify the 
amount of AD-PEG5000-Lac in the filtrate and retentate of all samples.  Concentrations 
were determined by comparison to a standard curve of AD-PEG5000-Lac.  The percentage 
of AD-PEG5000-Lac bound to the nanoparticles was determined by subtracting the 
fraction of recovered AD-PEG5000-Lac in the filtrate of the nanoparticle samples from the 
fraction of recovered AD-PEG5000-Lac in the filtrate of the control samples. 
4.3.11 Percentage of AD-PEG5000-Tf bound after formulation 
 Tf-targeted nanoparticles were formulated in a total volume of 100 µL water by 
adding a 50 µL solution of CDP-Im, AD-PEG5000, and AD-PEG5000-Tf (1:1 mole ratio of 
AD-PEG5000-X:β-CD where AD-PEG5000-X was composed of either 1 mol% or 5 mol% 
AD-PEG5000-Tf and the remainder AD-PEG5000) in water to a 50 µL solution of siRNA in 
water.  Control formulations were created by mixing CDP-Im, AD-PEG5000, and AD-
PEG5000-Tf without siRNA in 100 µL water.  Nanoparticles and control formulations 
were filtered with Nanosep (Millipore) centrifugal filtration devices with a 300 kDa 
MWCO to separate free and bound components.  Total protein content in the filtrate 
(unbound AD-PEG5000-Tf) and retentate (bound AD-PEG5000-Tf) was determined using 
the BioRad DC protein assay.  The percentage of AD-PEG5000-Tf bound to the 
nanoparticles was determined by subtracting the fraction of recovered AD-PEG5000-Tf in 
the filtrate of the nanoparticle samples from the fraction of recovered AD-PEG5000-Tf in 
the filtrate of the control samples. 
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4.3.12 Multi-angle light scattering (MALS) 
Particle formulations were loaded into a 10-mL syringe connected to a syringe 
pump to control the flow rate into a Dawn EOS (Wyatt Technology) multi-angle light 
scattering instrument.  The typical flow rate used was 1 mL min-1.  Data were fit by the 
Astra software to the Debye model with a detector fit degree of 2.  The dn/dc value for 
the nanoparticles was determined to be 0.14 mL g-1, and the mass concentration used in 
the calculations was determined from the total amount of CDP-Im and nucleic acid 
incorporated into the nanoparticles assuming an individual nanoparticle charge ratio of 
1.1 (+/-) and complete incorporation of the nucleic acid added during formulation. 
4.3.13 Individual nanoparticle stoichiometry 
An estimate for the stoichiometry of each nanoparticle (i.e., number of CDP, 
nucleic acid, AD-PEG, and AD-PEG-Tf molecules) can be calculated from the following 
equations. 
TfPEGCDPbppart MWTfMWPEGMWCDPMWbpNAMW ×+×+×+××= #####  (4.1) 
bpNA
CDPCR
##
#
×=  (4.2) 
( )
CR
FRPRCDPTffPEG PEG ×××−×= #%%100#  (4.3) 
CR
FRPRCDPTffTf Tf ××××= #%#  (4.4) 
where #NA is the number of nucleic acid molecules in the nanoparticle, #CDP is the 
number of CDP monomers (β-CD) in the nanoparticle, #PEG is the number of AD-PEG 
molecules in the nanoparticle, #Tf is the number of AD-PEG-Tf molecules in the 
nanoparticle, MWpart is the molecular weight of an individual nanoparticle (determined by 
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MALS), #bp is the number of base pairs per nucleic acid molecule (e.g., 21 for siRNA), 
MWbp is the average molecular weight of each nucleic acid base pair (~650 Da as an 
approximation), MWCDP is the molecular weight of each CDP monomer (~1,460 Da), 
MWPEG is the molecular weight of each AD-PEG molecule (~5,200 Da for AD-PEG5000), 
MWTf is the molecular weight of each AD-PEG-Tf molecule (~85,000 Da for AD-
PEG5000-Tf), fPEG is the fraction of the AD-PEG molecules that bind to nanoparticles 
during formulation, PR is the mole ratio of AD-PEG to β-CD during formulation, FR is 
the formulation charge ratio (+/-), CR is the charge ratio (+/- = 1.1) of each individual 
nanoparticle, fTf is the fraction of the AD-PEG-Tf molecules that bind to nanoparticles 
during formulation, and %Tf is the mole percent AD-PEG-Tf during formulation. 
4.3.14 Salt stability 
Particle formulations were diluted to a volume of 1260 µL, placed in a cuvette, 
and inserted into a ZetaPALS (Brookhaven Instruments Corporation) instrument.  Kinetic 
studies of aggregation were performed by recording the effective diameters at 1 minute 
intervals after the addition of 1/10 volume 10X PBS to achieve a final concentration of 
1X PBS, corresponding to physiological salt concentration. 
4.3.15 Erythrocyte aggregation 
Erythrocytes were obtained from whole bovine calf blood (Rockland 
Immunochemicals, Inc.) by multiple rounds of centrifugation at 700xg and 4°C for 10 
min followed by removal of the supernatant and resuspension of the pellet of erythrocytes 
in cold PBS (Cellgro) until the supernatant became clear.  Finally, the erythrocytes were 
resuspended at a concentration of 1% (v/v).  The free polycations or formulated 
nanoparticles were added to a 24-well plate and diluted with PBS to a volume of 100 µL.  
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Subsequently, 100 µL of the erythrocyte suspension were added to each well and the 
plate was incubated for 1 h at 37°C.  Images were taken of each well using a CCD-
IRIS/RGB (Sony) video camera attached to an Eclipse TE-300 (Nikon) inverted 
microscope to visually determine the degree of aggregation. 
4.3.16 Complement fixation 
To test the complement fixation by polycations or CDP-based nanoparticles, 
antibody-sensitized sheep erythrocytes were used in a CH50 assay modified from Plank 
et al. (11).  25 µL human complement sera (Sigma) in gelatin veronal buffer (Sigma) 
were added in a 1:1.5 dilution series across a row of wells in a 96-well plate.  To this 
same row of wells were added 25 µL of the desired concentration of polycation in its free 
form or complexed with calf thymus DNA (CT-DNA).  A different concentration of the 
polycations or nanoparticles was added to each row of wells.  After a 30-min incubation 
at 37°C, 1.25x107 antibody-sensitized sheep erythrocytes (Sigma) were added to each 
well and the plate was incubated with shaking for 1 h at 37°C.  Finally, the plate was 
centrifuged at 2,000 RPM for 10 min, 100 µL of the supernatant from each well was 
transferred to a new 96-well plate, and the absorbance at 410 nm was determined using a 
SpectraMax 190 (Molecular Devices) microplate reader.  This wavelength corresponds to 
an absorbance peak for the hemoglobin that is released after lysis of the erythrocytes.  
The CH50 unit is used to define the serum dilution required to achieve 50% lysis of the 
antibody-sensitized sheep erythrocytes.  If the substance being tested binds complement 
proteins to an appreciable degree, it will sequester these complement proteins and prevent 
them from binding to and lysing the erythrocytes.  As a result, a lower serum dilution 
(CH50) will be required to achieve 50% erythrocyte lysis under these conditions.  The 
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reported %CH50max represents the ratio of the CH50 for the substance being tested to 
the CH50 determined for the complement sera alone (CH50max). 
4.3.17 Cellular uptake 
Method 1:  Flow cytometry 
A FACSCalibur (BD Biosciences) flow cytometer was used to detect the uptake 
of FL-siRNA (fluorescein attached to the 5’ end of the sense strand) delivered with or 
without the CDP-Im delivery vehicle.  HeLa cells were seeded at 2x104 cells per well in 
24-well plates 2-3 days prior to transfection and grown in medium supplemented with 
10% fetal bovine serum (FBS) and antibiotics (penicillin/streptomycin).  The growth 
medium was removed from each well and replaced with 200 µL Opti-MEM I 
(Invitrogen), 200 µL Opti-MEM I with 100 nM FL-siRNA, or 200 µL Opti-MEM I with 
100 nM FL-siRNA formulated into CDP-Im nanoparticles at a charge ratio of 3 (+/-).  
After incubation for 2 h at 37°C and 5% CO2, the transfection medium was removed and 
the cells were trypsinized and resuspended in Hanks Balanced Salt Solution (HBSS) with 
1% bovine serum albumin (BSA) and 10 µg mL-1 propidium iodide to detect cell 
viability. 
Method 2:  Confocal microscopy 
 HeLa cells were seeded at 2x104 cells per well in a LabTek II Chamber Slide 2 
days prior to transfection and grown in medium supplemented with 10% FBS and 
antibiotics (penicillin/streptomycin).  The growth medium was removed from each well 
and replaced with 200 µL Opti-MEM I containing 100 nM FL-siRNA formulated into 
CDP-Im nanoparticles at a charge ratio of 3 (+/-).  After incubation for 2 h at 37°C and 
5% CO2, cells were fixed for 15 min at room temperature using 4% paraformaldehyde in 
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PBS.  F-actin was stained with rhodamine phalloidin (Invitrogen) according to 
manufacturer’s instructions.  Cells were mounted with Biomeda Gel/Mount according to 
manufacturer’s instructions and the coverslips were subsequently sealed using nail polish.  
Fluorescent images were acquired using a Zeiss LSM 510 Meta laser scanning confocal 
microscope with a 40X water-immersion objective. 
4.3.18 Competitive uptake 
 Competitive uptake studies were conducted to determine the impact of free holo-
transferrin (holo-Tf) on the relative uptake of transferrin-targeted (containing 1 mol% 
AD-PEG5000-Tf) or non-targeted nanoparticles.  By formulating the nanoparticles with 
Cy3-siRNA (Cy3 attached to the 5’ end of the sense strand), a Tecan 
SPECTRAFluorPlus plate reader could be used to measure the total cell-associated 
fluorescence after transfection.  Cells were seeded at 2x104 cells per well in 24-well 
plates 2-3 days prior to transfection and grown in medium supplemented with 10% FBS 
and antibiotics (penicillin/streptomycin).  The growth medium was removed from each 
well and replaced with 200 µL Opti-MEM I containing 100 nM Cy3-siRNA formulated 
in nanoparticles.  After incubation for 30 min at 37°C and 5% CO2, the transfection 
medium was removed and the cells were lysed in 100 µL cell lysate buffer (Promega).  
Total fluorescence in the 100 µL lysate per well was measured with the 
SPECTRAFluorPlus plate reader and the number of siRNA molecules was estimated 
from a standard curve of Cy3-siRNA.  Cells in two wells that were not transfected were 
trypsinized and counted to provide an estimate for the average number of cells per well. 
4.3.19 Avidity effects 
Method 1:  Competitive cell-surface transferrin receptor (TfR) binding assay  
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 Competitive uptake experiments were performed using flow cytometry to detect 
the uptake of fluorescently labeled holo-Tf.  Unlabeled holo-Tf, Tf conjugates (AD-
PEG5000-Tf), or Tf-targeted siRNA nanoparticles (1 mol% AD-PEG5000-Tf) were used to 
compete for uptake by the transferrin receptors on the surface of HeLa cells.  Cells were 
seeded at 2x104 cells per well in 24-well plates 2-3 days prior to transfection and grown 
in medium supplemented with 10% FBS and antibiotics (penicillin/streptomycin).  The 
growth medium was removed from each well and replaced with 200 µL Opti-MEM I 
containing 1% BSA, 20 nM AlexaFluor488-labeled holo-Tf (AF488-Tf), and the desired 
unlabeled Tf competitor.  After incubation for 1 h at 37°C and 5% CO2, the transfection 
medium was removed and the cells were trypsinized and resuspended in Hanks Balanced 
Salt Solution (HBSS) with 1% bovine serum albumin (BSA) and 10 µg mL-1 propidium 
iodide to detect cell viability.  To enable direct comparison of the effects of avidity, the 
total amount of Tf was kept constant whether it was in its free form, as AD-PEG5000-Tf, 
or as AD-PEG5000-Tf on the siRNA nanoparticles.  The relative uptake under each 
condition is reported as the ratio of the mean fluorescence of the wells with unlabeled 
competitor to the mean fluorescence of the wells with AF488-Tf alone. 
Method 2:  Live-cell binding assay  
 A live-cell binding assay was used to measure the relative binding of transferrin-
targeted siRNA nanoparticles.  3x105 HeLa cells were resuspended in 100 µL PBS in 
individual microcentrifuge tubes and cooled on ice.  To each microcentrifuge tube were 
added 100 µL PBS containing PEGylated or Tf-targeted nanoparticles formulated with 
Cy3-labeled siRNA such that the final Cy3-siRNA concentration was 100 nM.  After 
incubating for 30 minutes on ice, the microcentrifuge tubes were centrifuged for 5 
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minutes at 200xg to pellet the cells.  100 µL of the supernatant from each microcentrifuge 
tube were added to a well in a black 96-well plate, and the Cy3 fluorescence was 
measured using a Tecan Safire plate reader.  Comparison to a standard curve of Cy3-
siRNA nanoparticles allowed quantification of the amount of Cy3-siRNA in each well, 
and the percent bound (fraction associated with the cell pellet) was determined by 
subtracting the fluorescence remaining in the supernatant from the initial amount added.  
4.3.20 Luciferase knockdown after siRNA transfection 
Functional efficacy of pDNA and siRNA delivered by CDP-Im nanoparticles was 
demonstrated in HeLa cells by co-transfecting the pGL3-CV vector (Promega) containing 
the firefly luciferase gene and a non-targeting control siRNA (siCON1) synthesized by 
Dharmacon or a luciferase-targeting siRNA (siLuc) synthesized by Integrated DNA 
Technologies.  The sequence of the siCON1 siRNA is 
UAGCGACUAAACACAUCAAUU (sense) and UUGAUGUGUUUAGUCGCUAUU 
(antisense).  The sequence of the siLuc siRNA is GUGCCAGAGUCCUUCGAUAdTdT 
(sense) and UAUCGAAGGACUCUGGCACdTdT (antisense).  The Promega Luciferase 
Assay System was then used to quantify the relative luciferase expression in cells that 
had been transfected with 1 µg pGL3-CV alone, 1 µg pGL3-CV and 100 nM siCON1, or 
1 µg pGL3-CV and 100 nM siLuc.  HeLa cells were seeded at 2x104 cells per well in 24-
well plates 2-3 days prior to transfection and grown in medium supplemented with 10% 
FBS and antibiotics (penicillin/streptomycin).  CDP-Im nanoparticles were formulated to 
contain 1 µg pGL3-CV vector and 100 nM siRNA in 200 µL Opti-MEM I.  The growth 
medium was removed from each well and replaced with 200 µL Opti-MEM I containing 
the formulated nanoparticles.  After incubation for 5 h at 37°C and 5% CO2, 800 µL 
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complete growth medium was added to each well.  48 h later, the cells were lysed in 
100 µL 1X Luciferase Cell Culture Lysis Reagent (Promega).  10 µL of the cell lysate 
were added to 90 µL of the luciferase substrate, and bioluminescence was measured 
using a MonoLight (Pharmingen) luminometer.  5 µL of the cell lysate were used in a 
BioRad DC protein assay to determine the protein concentration in each lysate sample.  
Luciferase activities are reported as relative light units per mg protein. 
4.4 Results and discussion 
4.4.1 Particle formation requires a slight excess of positive charge and protects 
siRNA from degradation in serum 
Results from an electrophoretic mobility shift assay (EMSA) demonstrate that 
siRNA nanoparticles completely form at charge ratios (+/-) greater than ~1 to 1.5 (Figure 
4.2A).  At sufficiently high charge ratios, the band corresponding to the free nucleic acid 
becomes undetectable since the nucleic acid remains associated with the nanoparticles 
that have greatly reduced electrophoretic mobility.  To determine what portion of the 
polycations (CDP) added during formulation actually are incorporated into the 
nanoparticles, the free polycations were separated from the nanoparticles after 
formulation.  Regardless of the formulation charge ratio up to 30 (+/-), the charge ratio of 
individual nanoparticles remains ~1 (+/-) (Figure 4.2B).  This is consistent with the 
results shown in Figure 4.2A where charge ratios slightly greater than 1 were required to 
achieve complete nanoparticle formation.  A nuclease stability assay was conducted to 
determine if the formation of nanoparticles could protect the nucleic acid payload from 
degradation by nucleases present in serum.  While naked siRNA degrades rapidly in 
serum, siRNA within nanoparticles is protected from significant degradation even after 4 
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hours in 50% mouse serum (Figure 4.3).  Additionally, the data given in Figure 4.3 show 
(i) there is essentially complete encapsulation of the siRNA by the nanoparticles, and (ii) 
when the nanoparticles exposed to serum are disrupted with SDS, the nucleic acids 
released are still intact siRNA duplexes. 
 
 
Figure 4.2.  Effect of formulation charge ratio (+/-).  (A) Electrophoretic gel mobility shift assay 
demonstrating the effect of formulation charge ratio on siRNA nanoparticle formation.  (B) Individual 
nanoparticle charge ratio as a function of formulation charge ratio. 
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Figure 4.3.  Nuclease stability of siRNA encapsulated within nanoparticles.  For the t = 4 lanes, naked 
siRNA or siRNA within CDP-Im nanoparticles (3 (+/-)) was incubated in 50% mouse serum for 4 h at 
37°C and 5% CO2.  For the t = 0 lanes, serum was added to an equivalent amount of naked siRNA or 
siRNA within CDP-Im nanoparticles immediately before loading into the gel.  Addition of 1% SDS was 
used to displace the siRNA from the nanoparticles to visualize the amount of intact siRNA remaining.  The 
first lane demonstrates that the upper bands are nonspecific bands resulting from the interaction between 
SDS, serum, and the ethidium bromide stain, while the lower bands correspond to the free siRNA. 
 
4.4.2 Formulation conditions affect nanoparticle size and zeta potential 
Transmission electron microscopy (TEM) and atomic force microscopy (AFM) 
were used to visualize the siRNA nanoparticles formulated at a charge ratio of 3 (+/-).  
The images in Figure 4.4 demonstrate that the siRNA nanoparticles assume a roughly 
spherical shape, but the unPEGylated nanoparticles display more variability in size and 
adopt a slightly oblong shape relative to the PEGylated nanoparticles when they are 
visualized by AFM on the mica surface.  While a large fraction of the unPEGylated 
nanoparticles (0.1 g L-1 siRNA) have diameters that exceed 100 nm, PEGylated 
nanoparticles (0.5 g L-1 siRNA) formulated with a 1:1 mole ratio of AD-PEG5000:β-CD 
consistently have diameters <100 nm and are approximately 60-80 nm. 
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Figure 4.4.  Transmission electron microscopy (left panels) and atomic force microscopy (center and right 
panels) images of (A) unPEGylated and (B) PEGylated siRNA nanoparticles formulated at a charge ratio of 
3 (+/-).  Scale bar = 100 nm (left panels) and 200 nm (center and right panels). 
 
To further investigate the effects of formulation conditions, dynamic light 
scattering was used to measure the effective hydrodynamic diameter and zeta potential of 
the nanoparticles.  Consistent with the TEM and AFM images, the results shown in 
Figure 4.5A reveal that the nucleic acid concentration during formulation affects the size 
of the nanoparticles.  Nanoparticles formulated with siRNA, pDNA, and calf thymus 
(CT-DNA) show nearly identical trends of increased size with higher nucleic acid 
concentration.  However, nanoparticles that are formulated in the presence of AD-
PEG5000 (PEGylated nanoparticles formed by the pre-complexation method) do not 
exhibit such a dependence on formulation conditions (Figure 4.5B). 
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Figure 4.5.  Effect of nucleic acid concentration ([NA]) during formulation on the size of (A) unPEGylated 
or (B) PEGylated nanoparticles.  Nanoparticles were formulated at a charge ratio of 3 (+/-) using CDP-Im 
and either siRNA, pDNA, or CT-DNA (calf thymus DNA).  PEGylated nanoparticles were formulated by 
adding a 1:1 mole ratio of AD-PEG5000:β-CD.  Nanoparticle effective diameter was determined using 
dynamic light scattering.  Squares = CDP-Im/siRNA nanoparticles, circles = CDP-Im/pDNA nanoparticles, 
diamonds = CDP-Im/CT-DNA nanoparticles. 
 
These properties allow the delivery vehicles to be fine-tuned with respect to size 
by altering the formulation conditions accordingly (i.e., PEGylation through the pre- or 
post-complexation method).  The zeta potential of unPEGylated nanoparticles ranges 
from 10 (particles ~60 nm in diameter) to 30 mV (particles ~150 nm in diameter), while 
that of PEGylated nanoparticles ranges from 10 to 20 mV for similarly sized 
nanoparticles.  This positive zeta potential implies that the charge ratio of the individual 
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nanoparticles is slightly greater than 1 (+/-).  The AD-PEG5000 conjugates can be further 
modified to contain targeting ligands on the distal end of the PEG chain.  For example, 
transferrin can be conjugated to the AD-PEG5000 molecules to yield AD-PEG5000-Tf (19).  
Because the transferrin protein is negatively charged, inclusion of AD-PEG5000-Tf 
molecules during nanoparticle formulation reduces the zeta potential of siRNA 
nanoparticles in a concentration-dependent manner (Figure 4.6).  Bellocq et al. reported a 
similar trend using nanoparticles made with pDNA (19). 
 
Figure 4.6.  Nanoparticle zeta potential as a function of AD-PEG5000-Tf ligand concentration during 
formulation.  Nanoparticles were formulated at a charge ratio of 3 (+/-) using CDP-Im and siRNA, and the 
AD-PEG5000 or AD-PEG5000-Tf molecules were added after nanoparticle formation (post-complexation).  
The total number of moles of AD-PEG5000-X (AD-PEG5000 and AD-PEG5000-Tf) was equal to the number of 
moles of β-CD, and the mixture of AD-PEG5000 and AD-PEG5000-Tf is defined by the % AD-PEG5000-Tf. 
 
4.4.3 AD-PEG conjugates bind to the surface of nanoparticles through inclusion 
complex formation 
An important property of the cyclodextrin-containing polycations is their ability 
to form inclusion complexes with hydrophobic molecules.  This provides the opportunity 
for modular attachment of different stabilizing molecules or targeting ligands through 
coupling to an adamantane (AD) molecule that forms inclusion complexes with the β-
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cyclodextrin molecules.  Isothermal titration calorimetry was used to investigate the 
thermodynamics of the interaction between AD-PEG molecules and CDP-Im either in its 
free form or within siRNA-containing nanoparticles (Table 4.1). 
 
Table 4.1.  Measured ITC parameters for the binding between AD-PEG5000 and β-CD alone, polycation 
alone (CDP-Im), or CDP-Im/siRNA nanoparticles formulated at charge ratios from 3 to 15 (+/-).  For 
comparison, literature values are provided for the binding between β-CD alone and adamantane carboxylate 
(22). 
 
β-CD + adamantane carboxylate 
 n K (M-1) ∆H (cal M-1) 
β-CD 1 42000 -4440 
β-CD + AD-PEG5000 
 n K (M-1) ∆H (cal M-1) 
β-CD 1.1 30600 -7358 
siRNA nanoparticle + AD-PEG5000 
 n K (M-1) ∆H (cal M-1) 
3 (+/-) 0.34 ± 0.09 5110 ± 730 -15200 ± 4090 
5 (+/-) 0.38 ± 0.04 6320 ± 330 -12600 ± 570 
10 (+/-) 0.48 ± 0.02 8090 ± 620 -10100 ± 520 
15 (+/-) 0.49 ± 0.01 8050 ± 800 -10600 ± 450 
CDP-Im 0.54 ± 0.04 8380 ± 940 -9460 ± 1490 
 
 
Figure 4.7 shows representative ITC data plots for binding between AD-PEG5000 
and CDP-Im formulated with siRNA at a charge ratio of 3 (+/-), CDP-Im formulated with 
siRNA at a charge ratio of 10 (+/-), and CDP-Im alone.  As the charge ratio increases, the 
measured binding parameters approach those of free CDP-Im.  Given the previous results 
showing the actual nanoparticle charge ratio is slightly greater than 1 (+/-), this is 
consistent with the presence of excess free CDP-Im at charge ratios >1.  
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Figure 4.7.  Isothermal titration calorimetry (ITC) plots characterizing the binding between AD-PEG5000 
molecules and free CDP-Im or siRNA nanoparticles.  (A) CDP-Im/siRNA nanoparticle (3 (+/-)) and AD-
PEG5000, (B) CDP-Im/siRNA nanoparticle (10 (+/-)) and AD-PEG5000, (C) CDP-Im and AD-PEG5000. 
 
The value of n represents the fraction of the β-CD molecules available for 
inclusion complex formation with the AD-PEG molecules.  Each β-CD cup can interact 
with a single adamantane molecule, as previous reports have shown a 1:1 binding 
stoichiometry between adamantane molecules and β-CD (22).  While binding between 
individual β-cyclodextrins and AD-PEG5000 conjugates gives the expected n value of ~1, 
binding between CDP-Im and AD-PEG5000 exhibits an n value of ~0.5.  When the AD-
PEG5000 molecule containing a 5000-Da PEG chain binds to a β-CD cup on the CDP-Im 
polymer, it likely provides steric hindrance that impedes binding between other AD-
PEG5000 molecules and nearby β-CD molecules.  Support for this hypothesis comes from 
the observation that the n value for binding between CDP-Im and AD-PEG500 molecules 
containing short 500-Da PEG chains is 0.92 ± 0.05, likely indicating that the shorter PEG 
chains do not interfere to as great an extent with the binding of AD-PEG500 to 
neighboring β-CD molecules.  
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Another interesting pattern is observed with the ∆H values, representing the 
change in enthalpy that results from binding between an AD-PEG molecule and a β-CD 
cup.  These values are all negative, indicating that energy is released upon binding due to 
the favorable interaction between the hydrophobic adamantane and the β-CD cup.  
Notably, ∆H is more negative for AD-PEG5000 binding to the siRNA nanoparticles than it 
is for AD-PEG5000 binding to free CDP-Im.  We hypothesize that this increased 
stabilization energy, in addition to the inclusion complex formation, is a result of 
favorable interactions between the PEG chains themselves when they are grouped 
together on the surface of an siRNA nanoparticle. 
4.4.4 Particle molecular weight can be used to estimate individual nanoparticle 
stoichiometry  
 Determining the individual component stoichiometry of the nanoparticles 
provides important insights into their functional properties.  Centrifugal filtration was 
used to separate unbound components from those bound to the nanoparticles.  As 
discussed previously, it was determined that the individual nanoparticle charge ratio (i.e., 
the ratio of positive charges from the CDP-Im to negative charges from the nucleic acid) 
is slightly greater than 1; we used 1.1 (+/-) for the calculations.  The percent of the total 
AD-PEG5000 or AD-PEG5000-Tf added to the formulation mixture that remains free was 
determined by quantifying the AD-PEG5000 (experiment actually used AD-PEG5000-Lac 
and we assumed that the value for AD-PEG5000 would be approximately the same) or AD-
PEG5000-Tf recovered in the filtrate versus the retentate after centrifugal filtration.  The 
results of these measurements indicated that approximately 3% of the total AD-PEG5000 
and 10% of the total AD-PEG5000-Tf added during formulation remained associated with 
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the nanoparticles.  The greater degree of binding measured for the AD-PEG5000-Tf 
conjugates may be partly due to charge interactions between the negatively charged 
transferrin proteins and the positively charged nanoparticles.  The final piece of data 
needed to estimate the individual nanoparticle stoichiometry is the molecular weight of 
the nanoparticles.  This was determined using multi-angle light scattering.  The results in 
Figure 4.8 show that the molecular weight of nanoparticles formulated with siRNA, 
pDNA, or calf thymus (CT-DNA) scales approximately as r3, where r is the radius of the 
nanoparticle determined by DLS. 
 
Figure 4.8.  Relationship between nanoparticle size and molecular weight (MW) as determined by dynamic 
and multi-angle light scattering.  Nanoparticles were formulated at a charge ratio of 3 (+/-) using CDP-Im 
and either siRNA, pDNA, or CT-DNA.  Effective diameters were measured using dynamic light scattering, 
and molecular weights were determined using multi-angle light scattering.  Squares = CDP-Im/siRNA 
nanoparticles, circles = CDP-Im/pDNA nanoparticles, diamonds = CDP-Im/CT-DNA nanoparticles, solid 
line = r3 scaling dependence of the MW of nanoparticles starting with a MW of 7x107 g mol-1 for a 60-nm 
nanoparticle. 
 
This similarity between all three types of nanoparticles is consistent with the 
trends observed in Figure 4.5, further supporting the interesting result that formulation 
with a variety of nucleic acids leads to nanoparticles with similar physical properties.  An 
unPEGylated nanoparticle with a diameter of 70 nm is expected to have a molecular 
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weight around 1x108 g mol-1 from data given in Figure 4.8.  Inserting this molecular 
weight and an individual nanoparticle charge ratio of 1.1 (+/-) into Equations 1 and 2 
yields 48,800 CDP monomers (or 9,750 CDP chains with a degree of polymerization of 
5) and 2,110 siRNA molecules (with 21 bp per siRNA) per nanoparticle.  For the sake of 
calculation, we can then use this value for #CDP to estimate the number of AD-PEG5000 
and AD-PEG5000-Tf molecules per nanoparticle using Equations 3 and 4.  For example, a 
70-nm siRNA nanoparticle with a molecular weight of 1.3x108 g mol-1 (accounting for 
the added mass from the PEG conjugates) formulated at a charge ratio of 3 (+/-) with 1 
mol% AD-PEG5000-Tf is calculated to contain 9,750 CDP chains, 2,110 siRNA 
molecules, 3,950 AD-PEG5000 molecules, and 133 AD-PEG5000-Tf molecules. 
By approximating each siRNA molecule as a cylinder with a diameter of 2.37 nm 
and a length of 7.14 nm (approximated based on the dimensions of a double-stranded 
DNA helix), each siRNA molecule can be estimated to occupy a volume of 3.15x10-25 
m3.  Therefore, 2,110 siRNA molecules would occupy a minimum volume of 6.7x10-23 
m3; this represents approximately 37% of the total nanoparticle volume of 1.8x10-22 m3 
for a 70-nm sphere.  Therefore, this number of siRNA molecules appears to be reasonable 
given the size constraints of the nanoparticles.  Furthermore, the corresponding surface 
density for the estimated number of AD-PEG5000 chains on a 70-nm nanoparticle is ~43 
pmol cm-2 or 0.26 chains nm-2.  The calculated average distance between PEG5000 
molecules at this surface density is ~2.0 nm, while the Flory radius is ~6 nm.  Since the 
distance between PEG5000 molecules is much less than the Flory radius, the PEG5000 
chains are expected to interact laterally and extend out from the surface in a dense brush 
layer with an estimated thickness of ~12.5 nm.  Hansen et al. further examined the brush 
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scaling laws for polyethylene glycols and predicted that PEG5000 solutions must have 
monomer volume fractions, φ, greater than 0.07-0.09 to be in the brush regime (23).  This 
is satisfied when the PEG5000 surface density exceeds ~26-28 pmol cm-2, again indicating 
that the PEG5000 chains on the nanoparticles are in the brush regime. 
4.4.5 PEGylation provides steric stabilization to the nanoparticles and reduces 
nonspecific interactions 
DLS-based kinetic studies of aggregation were performed to determine whether 
the inclusion of AD-PEG conjugates could help to stabilize the nanoparticles against 
aggregation at physiological salt concentrations.  First, the ratio of AD-PEG5000:β-CD 
(mol:mol) was varied from 0 to 2 to investigate how the surface density of AD-PEG5000 
affects the steric stability of siRNA nanoparticles formulated through the post-
complexation method (Figure 4.9A).  Nanoparticles formulated with AD-PEG5000:β-CD 
(mol:mol) ratios >1 do not exhibit observable aggregation after 15 minutes in 1X PBS.  
At ratios <1, aggregation increases as the ratio of AD-PEG5000:β-CD (mol:mol) 
decreases.  These results with siRNA-containing nanoparticles are consistent with those 
observed by Pun et al. using nanoparticles made with pDNA (24).  The length of the PEG 
molecule in the AD-PEG conjugate also impacts its ability to confer steric stabilization to 
the nanoparticles.  As shown in Figure 4.9B, the stabilization effects increase with the 
length of the PEG chain, with AD-PEG500 (AD-PEG500:β-CD = 1) only slightly slowing 
the aggregation while AD-PEG5000 (AD-PEG5000:β-CD = 1) prevents detectable 
aggregation up to 15 minutes after salt addition.  If the AD-PEG500 chains, like the AD-
PEG5000 chains, also achieve a surface density of ~43 pmol cm-2 (AD-PEG500:β-CD = 1), 
then the average distance between PEG500 chains remains ~2.0 nm.  However, since this 
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is not less than the Flory radius for a PEG500 molecule (~1.5 nm), the PEG500 molecules 
are not expected to form the brush-like layer on the nanoparticle surface that is needed 
for steric stabilization.  Furthermore, modification of up to 1 mol% of the AD-PEG5000 
chains with Tf (AD-PEG5000-Tf) leads to minimal perturbations in the salt stability of the 
nanoparticles.  However, at 5 mol% AD-PEG5000-Tf, gradual nanoparticle aggregation 
becomes apparent during the 15-minute incubation in 1X PBS. 
 
Figure 4.9.  Aggregation of siRNA nanoparticles in physiological salt solutions.  140 µL of a 10X PBS 
solution were added to 1260 µL of the nanoparticles in water after 5 minutes, and dynamic light scattering 
was used to follow the formation of aggregates with time.  (A) Effect of the ratio of AD-PEG5000:β-CD on 
nanoparticle stability.  CDP-Im/siRNA (3 (+/-)) nanoparticles were formulated without AD-PEG5000 (black 
squares) or through the post-complexation method with an AD-PEG5000:β-CD mole ratio of 0.25:1 (black 
triangles), 0.5:1 (inverted black triangles), 0.75:1 (black diamonds), 1:1 (black circles), or 2:1 (black stars).  
(B) Effect of PEG chain length, adamantane conjugation, and Tf targeting ligand density on nanoparticle 
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stability.  CDP-Im/siRNA (3 (+/-)) nanoparticles were formulated without AD-PEG5000 (black squares), 
with a PEG5000 (no adamantane):β-CD mole ratio of 1:1 (open inverted triangles), with an AD-PEG500:β-
CD mole ratio of 1:1 (black triangles), with an AD-PEG5000:β-CD mole ratio of 1:1 (black circles), or with 
a 1:1 mole ratio of AD-PEG5000-X:β-CD where AD-PEG5000-X was composed of 0.1 wt% AD-PEG5000-Tf 
(dark gray circles), 0.1 mol% AD-PEG5000-Tf (gray circles), 1 mol% AD-PEG5000-Tf (light gray circles), or 
5 mol% AD-PEG5000-Tf (open circles) and the remainder AD-PEG5000. 
 
Besides providing steric stabilization to the nanoparticles, PEGylation can help to 
reduce nonspecific interactions.  Specifically, experiments were performed to study the 
interaction between the polycations (or nanoparticles) and erythrocytes (Figure 4.10).  
Significant erythrocyte binding will lead to aggregation that can be observed by visual 
inspection using a light microscope.  While the free CDP or CDP-Im showed negligible 
aggregation at 0.2 g L-1, some aggregation was observed as the concentration increased to 
2 g L-1 (Figure 4.10A-D).  Erythrocyte aggregation was also measured after incubation 
with siRNA nanoparticles that were formulated with CDP-Im and a 1:1 mole ratio of AD-
PEG5000:CDP-Im (Figure 4.10E).  The results demonstrate that PEGylated nanoparticles 
do not lead to any observable aggregation at a total CDP-Im concentration of 0.2 g L-1, 
corresponding to the expected concentration after systemic delivery in vivo (7). 
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Figure 4.10.  Erythrocyte aggregation.  (A) 0.2 g L-1 CDP, (B) 2 g L-1 CDP, (C) 0.2 g L-1 CDP-Im, (D) 2 g 
L-1 CDP-Im, (E) CDP-Im/siRNA (3 (+/-)) nanoparticles at 0.2 g L-1 CDP-Im formulated with a 1:1 mole 
ratio of AD-PEG5000:β-CD, (F) PBS alone.  Scale bar = 20 µm. 
 
4.4.6 PEGylated nanoparticles show minimal complement fixation 
 Complement fixation by polyethylenimine and polylysine was compared to that of 
CDP or CDP-Im.  The CDP and CDP-Im molecules do not show as much complement 
fixation as PEI (branched or linear) or a 36-mer of polylysine, but they do exhibit higher 
complement fixation than a 5-mer of polylysine (Figure 4.11A).  This is consistent with 
the notion that polycation length and charge density can augment complement activation 
(11). 
Because complement fixation was observed at the physiologically relevant 
concentration of 0.2 g L-1, corresponding to the typical concentration of polycations in 
the bloodstream after delivery of nucleic acids at a dose of 2.5 mg kg-1 (a typical dose 
used for in vivo siRNA delivery (7)), experiments were performed to test nanoparticles 
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formulated with calf thymus DNA and stabilized by PEGylation (Figure 4.11B).  
Notably, these formulations showed minimal complement fixation at polymer 
concentrations of 0.2 g L-1. 
 
Figure 4.11.  Complement fixation.  (A) Complement fixation by free polycations.  Asterisks = branched 
PEI, x = linear PEI, black triangles = pentalysine, inverted black triangles = polylysine (36-mer), black 
squares = CDP, black circles = CDP-Im.  (B) Complement fixation by CDP/CT-DNA (3 (+/-)) 
nanoparticles formulated with a 1:1 mole ratio of AD-PEG5000:β-CD (black squares).  The curves for CDP 
(open squares), CDP-Im (open circles), and pentalysine (open triangles) are shown again for comparison. 
 
4.4.7 Particles achieve intracellular delivery of siRNA in vitro 
The uptake of nanoparticles containing fluorescently labeled siRNA was assessed 
using flow cytometry and confocal fluorescence microscopy.  While naked siRNAs do 
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not achieve measurable levels of cellular uptake, formulation into nanoparticles with 
CDP-Im dramatically increases the amount of cell-associated siRNA as measured by 
flow cytometry (Figure 4.12A).  To confirm that the siRNA was being delivered to the 
interior of cells, confocal fluorescence microscopy was used to visualize cells transfected 
with nanoparticles containing fluorescently labeled siRNA (Figure 4.12B).  The 
internalized nanoparticles exhibited a punctate staining and were eventually observed to 
accumulate in the perinuclear region. 
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Figure 4.12.  Uptake of CDP-Im nanoparticles containing fluorescein (FL)-labeled siRNA by HeLa cells.  
(A) Histogram of cell-associated fluorescence measured by flow cytometry.  The left-most peaks 
correspond to the overlapping peaks for HeLa cells incubated with either Opti-MEM I alone or 100 nM 
naked FL-siRNA, while the right-most peak represents the cell-associated fluorescence after transfection 
with CDP-Im/FL-siRNA nanoparticles.  (B) Confocal fluorescence microscopy image of HeLa cells after 
transfection with CDP-Im/FL-siRNA nanoparticles (green) and rhodamine phalloidin staining of F-actin 
(red).  Scale bar = 50 µm. 
 
4.4.8 Targeting ligands enhance cellular uptake of PEGylated nanoparticles 
To verify that attachment of AD-PEG5000-Tf can lead to uptake through 
transferrin receptor (TfR)-mediated endocytosis, the uptake of stabilized (PEGylated) 
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nanoparticles was measured in the presence or absence of free holo-Tf.  While the uptake 
of PEGylated nanoparticles without AD-PEG5000-Tf was not affected by the presence of 
free holo-Tf, the uptake of Tf-targeted nanoparticles was reduced as a result of 
competition with free holo-Tf (Figure 4.13).  Because the nanoparticles can be 
internalized simultaneously by numerous mechanisms including simple pinocytosis, there 
is still significant uptake even without TfR-mediated internalization under these 
conditions. 
 
Figure 4.13.  Uptake of PEGylated and Tf-targeted nanoparticles in the presence of holo-Tf competitor.  
Nanoparticles were formulated at a charge ratio of 3 (+/-) using CDP-Im and siRNA.  PEGylated 
nanoparticles (PEGpart) were formulated with a 1:1 mole ratio of AD-PEG5000:β-CD and Tf-targeted 
nanoparticles (Tfpart) were formulated with a 1:1 mole ratio of AD-PEG5000-X:β-CD where AD-PEG5000-X 
was composed of 99 mol% AD-PEG5000 and 1 mol% AD-PEG5000-Tf.  Nanoparticles containing 100 nM 
siRNA were added to HeLa cells in 200 µL Opti-MEM I in the absence or presence of a 25X (moles holo-
Tf: moles AD-PEG5000-Tf) excess of holo-Tf competitor. 
 
4.4.9 Targeted nanoparticles exhibit avidity effects 
If multiple receptor/ligand interactions can occur simultaneously, then the 
effective affinity of the binding interaction can be enhanced through avidity effects.  
Antibodies or divalent antibody fragments are excellent examples of molecules whose 
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binding affinities are enhanced through avidity effects.  Their divalent interactions allow 
single antibodies to bind two separate receptors, leading to a stronger apparent affinity 
than exhibited by the monovalent antibody fragment (25).  Targeted delivery vehicles 
that contain multiple targeting ligands on the surface should also display these avidity 
effects if multiple targeting ligands can simultaneously interact with the receptors.  A 
typical cancer cell may contain thousands of receptors on its surface (26,27), and the Tf-
targeted delivery vehicles can contain tens or even hundreds of Tf ligands (depending on 
the percent of the AD-PEG5000 molecules with Tf molecules attached to the distal end of 
the flexible PEG5000 chains) decorating each nanoparticle surface.  This arrangement 
should enable multiple Tf molecules to bind to TfR on the surface of the cells.  To test 
whether these avidity effects increase the apparent affinity of the Tf-targeted 
nanoparticles for the TfR on the cell surface, a competitive uptake assay was performed 
using flow cytometry.  The results shown in Figure 4.14A demonstrate that the Tf-
targeted nanoparticles possess enhanced affinity for the TfR relative to individual AD-
PEG5000-Tf molecules.  Additionally, nanoparticles without the Tf targeting ligand had a 
minimal impact on the uptake of the fluorescently labeled holo-Tf.  To determine how 
targeting ligand density affects nanoparticle binding to cell-surface TfR, nanoparticles 
were incubated with HeLa cells in PBS at 4°C to measure the amount of binding in the 
absence of internalization.  The results shown in Figure 4.14B show that Tf targeting 
increases the amount of cell-associated nanoparticles under these conditions, and the 
amount of binding increases with the targeting ligand density. 
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Figure 4.14.  Effect of transferrin targeting ligand density on relative binding affinity.  (A) Competitive TfR 
binding by free holo-Tf (circles), free AD-PEG5000-Tf (triangles), Tf-targeted CDP-Im/siRNA (3 (+/-), 1 
mol% AD-PEG5000-Tf) nanoparticles (squares), and PEGylated CDP-Im/siRNA (3 (+/-)) nanoparticles 
(diamonds) in the presence of 20 nM AlexaFluor488-labeled holo-Tf.  As a control, the PEGylated 
nanoparticles were formulated identically to the Tf-targeted nanoparticles at each concentration except 
without the addition of AD-PEG5000-Tf during formulation.  (B) Live-cell binding assay.  Nanoparticles 
were formulated at a charge ratio of 3 (+/-) using CDP-Im and Cy3-labeled siRNA.  PEGylated 
nanoparticles (PEGpart) were formulated with a 1:1 mole ratio of AD-PEG5000:β-CD and Tf-targeted 
nanoparticles (Tfpart) were formulated with a 1:1 mole ratio of AD-PEG5000-X:β-CD where AD-PEG5000-X 
was composed of the stated % AD-PEG5000-Tf and the remainder AD-PEG5000.  Nanoparticles containing 
100 nM Cy3-siRNA were added to HeLa cells in 200 µL PBS and incubated on ice for 30 minutes.  The 
“percent bound” represents the fraction of nanoparticles associated with the cell pellet after centrifugation. 
 
4.4.10 Particles deliver functional pDNA and siRNA to cells in vitro 
 In addition to achieving intracellular delivery of the nucleic acid-containing 
nanoparticles, the nanoparticles need to release their nucleic acid payload intracellularly 
to allow it to function.  Co-delivery of a luciferase-expressing plasmid and either a 
control or luciferase-targeting siRNA was used to demonstrate the ability of the 
nanoparticles to deliver functional pDNA and siRNA.  The luciferase activity in cell 
lysates was quantified using a luminometer, and relative light units (RLU) were 
normalized to total cellular protein levels.  As shown in Figure 4.15, cells that received 
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CDP-Im nanoparticles containing the plasmid and siRNA against luciferase (siLuc) had 
luciferase activity that was ~50% lower than cells that received CDP-Im nanoparticles 
with either the plasmid alone or the plasmid plus a control siRNA (siCON1). 
 
Figure 4.15.  Luciferase expression 48 h after co-transfection of HeLa cells with nanoparticles containing 
pDNA and siRNA.  Nanoparticles were formulated at a charge ratio of 3 (+/-) by combining CDP-Im with 
pGL3-CV (pGL3 Alone), pGL3-CV and a control siRNA (pGL3+siCON1), or pGL3-CV and an siRNA 
against luciferase (pGL3+siLuc). 
 
4.4.11 Nanoparticles are multifunctional, integrated systems for nucleic acid delivery 
 The results presented here highlight the importance of creating a nanoparticle that 
consists of multiple components that function together as a system, and control over size, 
surface modification, payload protection, and targeting ligand to payload ratio are key 
parameters to consider when designing nucleic acid delivery vehicles for in vivo systemic 
use.  These parameters also represent some of the major advantages of nanoparticle 
composites for delivery of nucleic acids instead of using carrier-free delivery methods.  
Nucleic acid delivery vehicles can help reduce renal clearance while adding features such 
as stabilization against nuclease degradation, cell-specific targeting, and large payload 
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delivery.  These features make them well-suited for the systemic delivery of nucleic acids 
in general, and we have shown that the system investigated here can deliver pDNA, 
siRNA, and DNAzymes in vitro and in vivo (7,17,19,20).   
The capability to fine-tune the delivery vehicle’s properties combined with an 
understanding of how those properties affect its function in biological systems represent 
two key factors necessary for optimization of nucleic acid delivery vehicles.  This study 
demonstrates the importance of a rational approach in delivery vehicle design and lays a 
foundation for further in vivo studies to understand the relationships between the 
properties of nanoparticle delivery systems and their biological function.  The approach 
to designing nanoparticle delivery vehicles that is outlined here can be used for other 
synthetic materials and is thus not limited to the cyclodextrin polymer-based system 
illustrated. 
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5 Noninvasive in vivo imaging using PET and BLI to monitor 
the biodistribution and function of tumor-targeted siRNA 
nanoparticles after intravenous injection in mice† 
 
5.1 Abstract 
Noninvasive in vivo imaging technologies can provide quantitative information 
about the spatiotemporal distribution and function of molecules in living organisms.  
Here, we demonstrate an approach using positron emission tomography (PET) and 
bioluminescent imaging (BLI) to quantify the in vivo biodistribution and function of 
nanoparticles formed with cyclodextrin-containing polycations (CDP) and small 
interfering RNA (siRNA).  Conjugation of the metal chelator, 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), to the 5’ end of the siRNA 
molecules allows labeling with 64Cu for PET imaging.  Since the siRNA molecules target 
luciferase, BLI of mice bearing luciferase-expressing Neuro2A subcutaneous tumors 
before and after PET imaging enabled correlation of functional efficacy with the 
biodistribution data.  Both naked siRNA and siRNA packaged into nanoparticles showed 
rapid blood clearance with significant accumulation in the liver and kidneys.  Despite the 
poor pharmacokinetics of the nanoparticle formulations, both non-targeted and transferrin 
(Tf)-targeted siRNA nanoparticles showed detectable tumor signal (~1% ID/cm3) by PET 
1 d post injection, and the Tf-targeted siRNA nanoparticles reduced luciferase activity by 
~50% relative to non-targeted siRNA nanoparticles after 1 d.  Therefore, the primary 
advantage of targeted nanoparticles may be associated with processes involved in cellular 
                                                 
† This work was performed in collaboration with Helen Su and Isabel Hildebrandt in the laboratory of 
Wolfgang A. Weber, Department of Molecular Medicine and Pharmacology, Jonsson Comprehensive 
Cancer Center, David Geffen School of Medicine, University of California at Los Angeles. 
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uptake rather than overall tumor localization.  Moreover, we propose a physiologically 
based mechanism that could result in nanoparticle disruption primarily within the kidney,
 helping to explain the rapid blood clearance of the nanoparticles after systemic 
administration.  This dissociation mechanism could have broad implications for the 
design of nucleic acid nanoparticles formed through electrostatic interactions and will 
likely facilitate the design of long-circulating nanoparticles. 
5.2 Introduction 
RNA interference (RNAi) is a powerful trigger of sequence-specific gene 
silencing, and its potential therapeutic use for treating diseases such as cancer is being 
widely investigated.  Synthetic small interfering RNA (siRNA) molecules 19-21 bp in 
length can act as the mediators of RNAi if applied exogenously, but they must reach the 
intracellular environment to exert their effect.  Therefore, therapeutic application of 
siRNAs requires their effective delivery into the target cells of interest.  To address the 
challenge of nucleic acid delivery, a variety of approaches have been developed with 
varying success, including covalent attachment of antibodies or cholesterol, liposome 
encapsulation, or nanoparticle formation with cationic lipids or polymers (1-4).  
Nanoparticle encapsulation of siRNAs can help reduce renal clearance while adding 
features such as stabilization against nuclease degradation, tunable cell-specific targeting, 
and large payload delivery.  We previously have described a cyclodextrin-containing 
polycation (CDP) and its interaction with siRNA to form targeted siRNA nanoparticles 
with diameters <100 nm that carry a payload of ~2,000 siRNA molecules (5).  These 
nanoparticles have been used to deliver functional siRNA to tumors in vivo, inhibiting 
tumor growth in a disseminated model of Ewing’s sarcoma (6).  Importantly, these 
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nanoparticles show no clinical signs of toxicity in mice or non-human primates at the 
doses used for in vivo efficacy (7). 
Recently, Medarova et al. described the use of MRI and fluorescence imaging to 
monitor the tumor accumulation and functional activity of magnetic nanoparticles 
covalently linked to siRNAs (8).  This study illustrated the power of multimodality 
imaging approaches to help correlate the biodistribution of therapeutic entities with their 
biological activity.  We attempt to extend this methodology further by employing 
microPET/CT to monitor the real-time, whole-body biodistribution kinetics and tumor 
localization of injected siRNA nanoparticles while concurrently using BLI to measure the 
luciferase knockdown by the delivered siRNA molecules.  By formulating the 
nanoparticles with or without Tf targeting ligands, the effect of cell-specific targeting on 
both biodistribution and function can be studied. 
A recent report by de Wolf et al. examined the effect of polycationic carriers on 
the pharmacokinetics and tumor localization of siRNA (9).  They noted that formulation 
of the siRNA into polycationic carriers had little effect on the biodistribution and tumor 
localization compared to naked siRNA.  Both naked siRNA and siRNA packaged into the 
carriers exhibited rapid blood clearance with tissue distribution mainly to the kidneys and 
liver within the first 15 minutes after injection. 
In an extension of the aforementioned studies, we employ microPET/CT and BLI 
to determine the kinetics of the biodistribution and tumor localization of intravenously 
administered CDP-based siRNA nanoparticles while simultaneously quantifying the 
functional efficacy of the delivered siRNA molecules through luciferase reporter protein 
knockdown.  This methodology represents a generalized procedure for studying any 
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siRNA-based carrier system in vivo, and we believe these results provide important 
insights into the design and optimization of nanoparticle carriers for systemic siRNA 
delivery. 
5.3 Materials and methods 
5.3.1 siRNA sequence 
To create the DOTA-modified siRNA, RNA oligonucleotides were ordered from 
Integrated DNA Technologies.  The antisense strand (5’-
UAUCGAAGGACUCUGGCACdTdT-3’) was ordered unmodified.  The sense strand 
(5’-GUGCCAGAGUCCUUCGAUAdTdT-3’) was ordered unmodified or with a 5' 
Amino Modifier C6 modification to place an amine at the 5’ end of this sense strand.  
The annealed siRNA duplex is designed to target luciferase mRNA. 
5.3.2 Synthesis of DOTA-siRNA 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(N-
hydroxysuccinimide ester) (DOTA-NHS-ester) was ordered from Macrocyclics.  The 
DOTA-NHS-ester reacts with the terminal amine on the amine-modified RNA sense 
strand to form a stable amide bond.  To a microcentrifuge tube were added the RNA 
sense strand with a 100-fold molar excess of DOTA-NHS-ester in Chelex-100-treated 
carbonate buffer (pH 9).  The contents were allowed to react with stirring for ~4 h at 
room temperature.  The DOTA-RNAsense conjugate was ethanol precipitated with 0.1 
volumes of 3M sodium chloride and 2.5 volumes of ethanol followed by incubation 
overnight at -20°C.  The precipitation mixture was then centrifuged, washed with 70% 
ethanol, centrifuged again, and resuspended in water at a concentration of 1 mM.  Finally, 
the purified DOTA-RNAsense was annealed to the unmodified antisense strand to yield 
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DOTA-siRNA.  All liquids were pre-treated with Chelex-100 (Bio-Rad) to remove trace 
metal contaminants. 
5.3.3 Verification of DOTA-siRNA conjugation 
To verify successful conjugation of DOTA to siRNA, a procedure was designed 
to compare the ability of DOTA-siRNA to coordinate gadolinium (Gd3+) relative to free 
DOTA.  To a microcentrifuge tube were added equimolar amounts of gadolinium 
chloride (GdCl3) and either DOTA or DOTA-siRNA in 0.1 M ammonium acetate buffer 
(pH 6).  The microcentrifuge tubes were incubated for 15 min at 75°C for the labeling 
reaction.  Subsequently, half of the labeling reaction was combined with an equal volume 
of 1 mM arsenazo III.  The presence of any free gadolinium ions results in a hypochromic 
shift from 548 nm to 660 nm.  Therefore, the absorbance at 660 nm was measured for 
each sample using a Tecan Safire plate reader.  Comparison to a standard curve allowed 
estimation of the amount of free gadolinium remaining in each sample. 
5.3.4 In vitro transfection 
Neuro2A-Luc cells with constitutive luciferase expression were seeded at 2x104 
cells per well in 24-well plates 2 days prior to transfection and grown in DMEM 
supplemented with 10% FBS and antibiotics (penicillin/streptomycin).  siRNA was 
complexed with Oligofectamine (Invitrogen) according to manufacturer’s instructions 
and applied to each well in a total volume of 200 µL Opti-MEM I (Invitrogen).  
Transfection media was removed and replaced with complete media after 5 h.  The 
kinetics of the luciferase knockdown by unmodified and DOTA-conjugated siRNA were 
determined using the Xenogen IVIS 100 as described previously (10). 
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5.3.5 64Cu labeling of DOTA-siRNA 
64Cu chloride was produced at Washington University (St. Louis, MO).  Upon 
arrival, the 64Cu chloride was mixed with 0.25 M ammonium acetate (pH 7) and 
transferred to a new microcentrifuge tube.  Citrate buffer (pH 5) was added to this 
microcentrifuge tube to achieve a final concentration of 0.1 M citrate buffer.  DOTA-
siRNA in water was added to achieve a final DOTA-siRNA:64Cu ratio of 250:1 for 
labeling.  The contents of the tube were mixed and then allowed to sit for 1 h at 60°C.  
The labeling reaction was purified by gel filtration or ethanol precipitation.  Gel filtration 
was performed using MicroSpin G-25 columns (Amersham Biosciences) according to 
manufacturer’s instructions.  Ethanol precipitation was accomplished by adding 0.1 
volumes of 3M sodium acetate and 2.5 volumes of pre-chilled ethanol followed by 
incubation for ~2 h at -80°C.  The precipitation reaction was then centrifuged to pellet the 
DOTA-siRNA, washed with 70% ethanol, centrifuged again, and resuspended in water to 
yield 64Cu-DOTA-siRNA. 
5.3.6 Nanoparticle formation 
Before addition to the nucleic acid, the CDP was mixed with AD-PEG at a 1:1 
AD-PEG:β-CD (mol:mol) ratio in water.  Targeted nanoparticles contained AD-PEG-
transferrin (AD-PEG-Tf) as a percentage of the total AD-PEG in the mixture.  For 
example, 1 mol% AD-PEG-Tf nanoparticles contained 0.01 moles AD-PEG-Tf for every 
0.99 moles AD-PEG, and 0.1 wt% AD-PEG-Tf nanoparticles contained 0.001 g of AD-
PEG-Tf for every 1 g of AD-PEG.  The mixture of CDP, AD-PEG, and AD-PEG-Tf in 
water was then added to an equal volume of siRNA (or a mixture of unmodified siRNA 
and DOTA-siRNA) in water such that the ratio of positive charges from CDP to negative 
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charges from the nucleic acid was equal to the desired charge ratio of 3 (+/-).  An equal 
volume of 10% (w/v) glucose in water was added to the resulting nanoparticles to give a 
final concentration of 5% (w/v) glucose suitable for injection. 
5.3.7 Dynamic light scattering (DLS) 
Nanoparticle formulations were diluted to a volume of ~1.5 mL, placed in a 
cuvette, and inserted into a ZetaPALS (Brookhaven Instruments Corporation) instrument 
to measure both the size and zeta potential.  Reported effective hydrodynamic diameters 
represent the average values from a total of 5-10 runs of 30 seconds each, while zeta 
potentials represent the average of 10 runs each. 
5.3.8 Serum stability of siRNA nanoparticles 
Nanoparticles were formed in water at a charge ratio of 3 (+/-) with an siRNA 
concentration of 0.5 g/L, and subsequently incubated in 50% mouse serum (Sigma) for 4 
h at 37°C and 5% CO2.  Aliquots of the nanoparticles were removed at the specified time 
points (1 h, 4 h, 17 h, 43 h) and run on an agarose gel to determine the amount of intact 
siRNA remaining.  Nanoparticles that were incubated in water instead of mouse serum 
were loaded as controls for each gel.  Displacement of the nucleic acid from the 
nanoparticles was achieved by adding 1% sodium dodecyl sulfate (SDS) to the sample 
immediately prior to gel loading.  Gel electrophoresis was performed by applying 100 V 
for 30 min, and the siRNA bands were visualized by ethidium bromide staining.  
Quantification of the band intensities was accomplished using ImageJ software. 
5.3.9 Salt stability of siRNA and pDNA nanoparticles 
Nanoparticles were formulated as described above with a 1:1 AD-PEG:β-CD 
(mol:mol) ratio and a charge ratio of 3 (+/-).  Nanoparticles were formed at an siRNA or 
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pDNA concentration of 0.5 g/L.  A portion of the nanoparticle formation (containing 1 
µg siRNA) was added to a microcentrifuge tube and mixed with either 1% SDS or 
sodium chloride (NaCl) at a range of concentrations from 0 to 1.5 M NaCl.  The samples 
were allowed to incubate for 3-5 min at room temperature before being loaded into a 1% 
agarose gel.  Gel electrophoresis was performed by applying 100 V for 30 min (siRNA 
nanoparticles) or 80 V for 60 min (pDNA nanoparticles), and the bands were visualized 
by ethidium bromide staining.  Quantification of the amount of siRNA or pDNA present 
in intact nanoparticles (remaining in the well at the top of the gel) was performed using 
ImageJ image analysis software. 
5.3.10 Animals and tumor formation 
Severe combined immunodeficient (NOD/scid) mice were purchased from 
Jackson Laboratories.  All animal manipulations were performed with sterile technique 
following the guidelines of the UCLA Animal Research Committee.  Neuro2A-Luc cells 
were cultured in DMEM supplemented with 10% FBS, 2 mg/mL glucose, 100 units/mL 
of penicillin, and 100 units/mL of streptomycin.  Exponentially growing Neuro2A-Luc 
cells were removed from the plate with trypsin, resuspended in PBS and Matrigel (BD 
Biosciences), and injected subcutaneously into the right flank of NOD/scid mice at 1-
2x106 cells per mouse.  Animals underwent microPET/CT scanning after tumors had 
grown to an approximate size of 6-7 mm in diameter. 
5.3.11 MicroPET/CT imaging 
MicroPET/CT imaging was performed with a microPET FOCUS 220 PET 
scanner (11) (Siemens Preclinical Solutions) and MicroCAT II CT scanner (Siemens 
Preclinical Solutions).  Mice were placed on a heating pad (30°C) and anesthetized using 
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1.5-2% isoflurane starting 15 min prior to injection.  3.7-11.1 MBq (100-300 µCi) of 64Cu 
was injected via tail vein while the animals were positioned on the scanner bed before a 
dynamic PET study was acquired for one hour.  Mice were then placed in an imaging 
chamber that minimizes positioning errors between PET and CT to less than 1 mm (11).  
PET images were reconstructed by filtered back projection, using a ramp filter to yield an 
image resolution of 1.7 mm.  Immediately after the PET scan, mice underwent a 7-minute 
microCT scan, using routine image acquisition parameters (11).  The microCT scan was 
used for anatomical localization of the tissue concentrations of the 64Cu over time in the 
microPET study.  Static PET scans were acquired the following day (~18-24 h after the 
initial injection) with another CT scan for anatomical co-registration. 
To determine temporal changes of tracer concentration in various organs, 
elliptical regions of interest (ROI) were placed in the area of the organ that exhibited the 
highest 64Cu activity as determined by visual inspection.  To ensure accurate anatomical 
positioning of the ROIs in the various organs, ROIs were placed on fused microPET/CT 
images generated by the AMIDE software (12).  Activity concentrations are expressed as 
percent of the decay-corrected injected activity per cm3 of tissue (can be approximated as 
%ID/g) using the AMIDE software.  The activity in each ROI over time is reported as the 
percent of the decay-corrected injected activity per cm3 (%ID/cm3), and these values 
were normalized to an elliptical cylinder ROI drawn over the entire mouse to correct for 
the actual injected activity. 
5.3.12 Bioluminescent imaging (BLI) 
Bioluminescent imaging was performed using a Xenogen IVIS 100 imaging 
system.  Mice were anesthetized with 2.5% isoflurane and injected i.p. with 0.2 mL of a 
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15 g/L D-luciferin solution in PBS.  Light emission was measured 10 minutes after 
injection of the D-luciferin solution, and bioluminescent signals were quantified using 
Living Image software (Xenogen,). 
5.4 Results 
5.4.1 Synthesis and characterization of DOTA-siRNA 
To verify conjugation of DOTA to the siRNA, a non-radioactive assay was 
designed to quantify the relative ability of DOTA-siRNA and free DOTA to coordinate 
gadolinium.   Incubation with DOTA-siRNA typically yielded gadolinium binding 
efficiencies that were about 50% of that observed for free DOTA. 
Since the DOTA-siRNA is also designed to target the luciferase mRNA, its ability 
to silence luciferase expression in luciferase-expressing cell lines was compared to that of 
unmodified siRNA against luciferase (Figure 5.1).  While the unmodified siRNA is able 
to achieve a maximum luciferase knockdown of >75%, the DOTA-siRNA achieves about 
50% maximum luciferase knockdown, indicating a slight loss in activity after DOTA 
conjugation.  Furthermore, the duration of the knockdown is consistent with an RNAi-
based mechanism (10). 
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Figure 5.1.  Luciferase knockdown by unmodified and DOTA-conjugated siRNA in luciferase-expressing 
Neuro2A-Luc cells.  Luciferase knockdown is reported relative to the luciferase activity from cells 
transfected with equal doses of the siCON control sequence.  Circles = DOTA-siRNA, squares = 
unmodified siRNA.  Error bars = SD. 
 
5.4.2 Formation of nanoparticles containing DOTA-siRNA 
Since conjugation of DOTA to the siRNA molecules may interfere with 
nanoparticle assembly, dynamic light scattering and gel electrophoresis were used to 
analyze the nanoparticles formed with DOTA-siRNA.  The fraction of the total siRNA 
that is modified with DOTA has a negligible effect on nanoparticle zeta potential and 
only a minor effect on nanoparticle size, leading to a slightly larger hydrodynamic 
diameter as the fraction of DOTA-siRNA is increased (Figure 5.2).  Gel electrophoresis 
shows that nanoparticles formed with or without DOTA-siRNA have similar migration 
patterns, and the majority of the siRNA (unmodified or DOTA-conjugated) remains 
bound within the nanoparticles after formation. 
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Figure 5.2.  Effective hydrodynamic diameter (A) and zeta potential (B) of nanoparticles formed with 0 to 
100% DOTA-siRNA.  Error bars = SD. 
 
5.4.3 64Cu-labeling of DOTA-siRNA 
After labeling the DOTA-siRNA with 64Cu, purification was accomplished using 
one of two methods:  gel filtration or ethanol precipitation.  Aliquots of 64Cu-DOTA-
siRNA purified by the two methods were separated by gel electrophoresis and the amount 
of radioactivity in the bands was quantified by a gamma counter.  Relative to the total 
amount loaded per well, 95% and 90% of the radioactivity was associated with the 
siRNA band for the 64Cu-DOTA-siRNA purified by gel filtration and ethanol 
precipitation, respectively.  Estimation of the overall yield of the recovery was made 
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using ImageJ analysis of the band intensities, indicating the total amount of siRNA 
recovered instead of the fraction of the radioactivity in the purification reaction 
associated with the DOTA-siRNA.  According to the relative band intensities, close to 
90% of the initial siRNA in the labeling reaction was recovered after ethanol 
precipitation, whereas only about 30% of the siRNA was recovered after gel filtration. 
5.4.4 Serum stability of DOTA-siRNA nanoparticles 
Nanoparticles were formed with unmodified siRNA or with DOTA-siRNA 
representing either 20% or 50% of the total siRNA in the nanoparticles.  These 
nanoparticles were then incubated in 50% mouse serum for 1 to 43 hours and analyzed by 
gel electrophoresis.  The total amount of siRNA (unmodified or DOTA-conjugated) 
remaining at each time point was quantified by ImageJ analysis of the relative band 
intensities.  All three types of nanoparticles demonstrated essentially equivalent stability 
against nuclease degradation of the encapsulated siRNA, with an estimated half-life of 
~11 h (Figure 5.3).  This indicates that the nanoparticle formulations do provide 
stabilization against siRNA nuclease degradation, since the naked siRNA duplexes 
degrade in mouse serum with a half-life of approximately 1 h (13). 
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Figure 5.3.  Nuclease stability of nanoparticle-encapsulated siRNA after incubation at 37°C and 5% CO2 in 
50% mouse serum.  After gel electrophoresis, band intensities were quantified with ImageJ software and 
plotted versus time to estimate the degradation half-life of the encapsulated siRNA.  Circles = nanoparticles 
formed with unmodified siRNA, diamonds = nanoparticles formed with 20% DOTA-siRNA, squares = 
nanoparticles formed with 50% DOTA-siRNA. 
 
5.4.5 Biodistribution of naked siRNA and siRNA nanoparticles after intravenous 
administration 
MicroPET/CT was used to examine the kinetics of the biodistribution and tumor 
localization of 64Cu-labeled molecules after intravenous injection in mice.  Reconstructed 
microPET/CT images of mice at 1, 10, and 60 min after injection are shown in Figure 
5.4.  The images were quantified using AMIDE software and the %ID/cm3 was 
calculated for each ROI over all time frames.  The resulting time-activity curves shown in 
Figure 5.5 represent the averages from 2 (64Cu, 64Cu-DOTA) or 3 (64Cu-DOTA-siRNA 
,Tf-targeted nanoparticles) independent experiments. 
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Figure 5.4.  Fused microPET/CT images of mice at 1, 10, and 60 min after intravenous injection of free 
64Cu (Cu), 64Cu-labeled DOTA (DOTA), 64Cu-labeled DOTA-siRNA (Naked), and Tf-targeted 
nanoparticles (Tf) containing ~50% 64Cu-labeled DOTA-siRNA.  All images are displayed on the same 
scale (min threshold = 1 %ID/cm3, max threshold = 5 %ID/cm3). 
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Figure 5.5.  Average time-activity curves for the first 60 min after intravenous injection of (A) 64Cu, (B) 
64Cu-labeled DOTA, (C) 64Cu-labeled DOTA-siRNA, and (D) Tf-targeted nanoparticles containing ~50% 
64Cu-labeled DOTA-siRNA.  Regions of interest (ROI) were drawn within each tissue or organ and the 
%ID/cm3 for each ROI was calculated over all time frames using AMIDE software.  Error bars = SE. 
 
64Cu alone accumulates rapidly in the liver, likely a result of binding to serum 
proteins such as albumin or ceruloplasmin (14).  However, when the 64Cu is chelated by 
DOTA and injected systemically in mice, the majority of the injected dose rapidly enters 
the kidney, with some clearing to the bladder.  This importantly shows that the 64Cu is not 
released by the DOTA in the serum, since any free 64Cu would rapidly accumulate in the 
liver.  These results are also consistent with the kidney clearance of other metal chelators, 
such as DTPA (15).  When the DOTA is conjugated to an siRNA molecule and labeled 
with 64Cu (64Cu-DOTA-siRNA), the tissue distribution is different from either the 64Cu 
alone or the 64Cu-DOTA, with biodistribution kinetics characterized by rapid blood 
clearance resulting from both liver accumulation and kidney filtration into the urine.  The 
total siRNA administered per mouse was equal to 2.5 mg/kg, and this 64Cu-DOTA-
siRNA was purified by ethanol precipitation.  Since the labeling efficiency for the 
DOTA-siRNA was approximately 30-50%, the fraction of DOTA-siRNA [DOTA-
siRNA/(DOTA-siRNA+normal siRNA)] was around 50%.  The plasma concentration of 
the 64Cu-DOTA-siRNA was fit using a biexponential decay with an initial elimination 
half-life of 1.8 min and a terminal elimination half-life of 61.9 min.  The rapid initial 
elimination half-life is expected for the siRNA molecules whose small size (~13 kDa) 
allows first-pass renal clearance.  Previously, Soutschek et al. reported an siRNA plasma 
half-life of ~6 min, consistent with the short half-life observed here (1).  Additionally, 
Braasch et al. observed that intravenously injected siRNA accumulated in the kidney and 
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liver, with a peak in the kidney concentration 5 min after injection (16).  Again, these 
observations are consistent with the values obtained here using microPET. 
microPET/CT was also used to examine the kinetics of the biodistribution and 
tumor localization of siRNA nanoparticles after intravenous injection in mice.  Given that 
the total dose of siRNA within the nanoparticles was the same as that used for naked 
siRNA (2.5 mg/kg), the fraction of DOTA-siRNA [DOTA-siRNA/(DOTA-
siRNA+normal siRNA)] was still approximately 50%.  The biodistribution of the 64Cu-
DOTA-siRNA packaged into the Tf-targeted nanoparticles appears very similar to that 
observed for naked 64Cu-DOTA-siRNA, except the nanoparticle formulation led to 
slightly higher liver accumulation and a delayed peak in kidney activity. 
The significant portion of the activity for the Tf-targeted nanoparticles that 
cleared rapidly through the kidneys and was excreted in the urine indicates the possibility 
of the presence of free siRNA.  To investigate whether the free siRNA was present before 
injection, the nanoparticle formulations were analyzed by gel electrophoresis 
immediately before injection (Figure 5.6).  The nanoparticle formulations showed <10% 
free siRNA when analyzed on the gel (Lanes 3 and 5 of Figure 5.6), and this small 
amount of free siRNA could also be an artifact from the gel electrophoresis procedure.  
Moreover, the slight decrease in the amount of migrating free siRNA at higher 
formulation charge ratios did not change the patterns of the time-activity curves after 
microPET/CT imaging.  This supports the notion that any residual free siRNA prior to 
injection is not the dominant factor contributing to the kidney and bladder activity for the 
nanoparticle formulations.  The urine was collected from mice injected with the siRNA 
nanoparticles and analyzed by agarose gel electrophoresis to further investigate whether 
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the activity observed in the kidney and bladder was associated with intact siRNA 
molecules (Figure 5.7).  Visual inspection of the gel reveals a distinct band at the position 
corresponding to the migration distance of free siRNA (Lane 5 of Figure 5.7); however, a 
faint band is also seen at this same position for urine from mice that were not injected 
with any siRNA (Lane 8 of Figure 5.7).  Subsequently, each lane was cut into four pieces 
(top, upper mid, lower mid, bottom) and a gamma counter was used to quantify the 
radioactivity in each region.  At 30 min post injection, ~20% of the total radioactivity 
loaded into the lane was associated with the region corresponding to the migration 
distance of intact siRNA.  This indicates that intact 64Cu-DOTA-siRNA may be 
responsible for at least a portion of the observed kidney and bladder activity. 
 
Figure 5.6.  Gel electrophoresis analysis of 64Cu-DOTA-siRNA nanoparticles prior to injection for 
microPET/CT imaging.  Lane 1 = 64Cu-DOTA-siRNA in water, Lane 2 = 64Cu-DOTA-siRNA + 1% SDS in 
water, Lane 3 = 64Cu-DOTA-siRNA packaged into Tf-targeted nanoparticles (charge ratio (+/-) = 3), Lane 
4 = 64Cu-DOTA-siRNA packaged into Tf-targeted nanoparticles (charge ratio (+/-) = 3) + 1% SDS, Lane 5 
= 64Cu-DOTA-siRNA packaged into Tf-targeted nanoparticles (charge ratio (+/-) = 6), Lane 6 = 64Cu-
DOTA-siRNA packaged into Tf-targeted nanoparticles (charge ratio (+/-) = 6) + 1% SDS. 
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Figure 5.7.  Gel electrophoresis analysis of urine samples from mice injected with 64Cu-DOTA-siRNA 
nanoparticles.  Lane 1 = Naked unmodified siRNA in water, Lane 2 = 64Cu-DOTA-siRNA packaged into 
Tf-targeted nanoparticles (charge ratio (+/-) = 3), Lane 3 = 64Cu-DOTA-siRNA packaged into Tf-targeted 
nanoparticles (charge ratio (+/-) = 3) + 1% SDS, Lane 4 = empty, Lane 5 = 20 µL urine from a mouse 
injected with 64Cu-DOTA-siRNA packaged into Tf-targeted nanoparticles (charge ratio (+/-) = 3), Lane 6 = 
20 µL urine from a mouse injected with 64Cu-DOTA-siRNA packaged into Tf-targeted nanoparticles 
(charge ratio (+/-) = 3) + 1% SDS, Lane 7 = empty, Lane 8 = 20 µL urine from an untreated mouse, Lane 9 
= 20 µL urine from an untreated mouse + 1% SDS. 
 
In an attempt to elucidate a possible physiologically based mechanism for the 
nanoparticle dissociation and release of free siRNA after intravenous administration, gel 
electrophoresis was used to examine the stability of the nanoparticles against dissociation 
when incubated in physiological salt (NaCl) concentrations.  As shown in Figure 5.8, 
incubation of the nanoparticles with increasing salt concentration from 0 to 1.5 M NaCl 
led to a decrease in the intensity of the band at the top of the gel (siRNA within 
nanoparticles) with a corresponding increase in the intensity of the bands corresponding 
to free siRNA (an apparent shift in mobility for free siRNA appears to occur at salt 
concentrations above ~1 M).  Since the nanoparticles are formed by electrostatic 
interactions between the positively charged cationic polymer strands and the negatively 
charged siRNA molecules, high salt concentrations can weaken these interactions and 
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allow release of free siRNA.  This salt-mediated disruption of the nanoparticles would be 
consistent with the slight delay in peak kidney activity observed for the nanoparticle 
formulations relative to naked siRNA.  Such a delay would be indicative of the 
dissociation of the nanoparticles leading to release of the free siRNA that is then rapidly 
cleared by the kidneys.  When the same experiment was conducted using pDNA instead 
of siRNA as the nucleic acid, the nanoparticles were not as easily disrupted by the 
presence of NaCl (Figure 5.8).  These results indicate that the siRNA nanoparticles are 
more susceptible to salt-mediated disruption than pDNA nanoparticles, perhaps owing to 
the smaller polyanion size for the siRNA relative to plasmid DNA. 
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Figure 5.8.  NaCl concentration-dependent disruption of Tf-targeted nanoparticles containing unmodified 
siRNA or pDNA.  (A) Gel electrophoresis of siRNA nanoparticles:  Lane 1 = naked siRNA, Lane 2 = 
nanoparticles + 1% SDS, Lane 3 = nanoparticles in water, Lane 4 = nanoparticles in 1X PBS, Lane 5 = 
nanoparticles in 0.15 M NaCl, Lane 6 = nanoparticles in 0.5 M NaCl, Lane 7 = nanoparticles in 1 M NaCl, 
Lane 8 = nanoparticles in 1.5 M NaCl.  (B) Fraction of intact siRNA nanoparticles based on intensity in the 
wells (corresponding to siRNA within intact nanoparticles).  The change in intensity with increasing NaCl 
concentration was normalized to the intensity for siRNA nanoparticles incubated in water alone (Lane 3).  
Error bars = SD.  (C) Gel electrophoresis of pDNA nanoparticles:  Lane 1 = naked pDNA, Lane 2 = 
nanoparticles + 1% SDS, Lane 3 = nanoparticles in water, Lane 4 = nanoparticles in 0.15 M NaCl, Lane 5 = 
nanoparticles in 0.3 M NaCl, Lane 6 = nanoparticles in 0.5 M NaCl, Lane 7 = nanoparticles in 1 M NaCl, 
Lane 8 = nanoparticles in 1.5 M NaCl.  (D) Fraction of intact pDNA nanoparticles based on intensity in the 
wells (corresponding to pDNA within intact nanoparticles).  The change in intensity with increasing NaCl 
concentration was normalized to the intensity for pDNA nanoparticles incubated in water alone (Lane 3). 
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5.4.6 Tumor localization and function of targeted vs. non-targeted siRNA 
nanoparticles 
A multimodality imaging approach was taken to investigate the biodistribution 
and functional activity of siRNA delivered by Tf-targeted or non-targeted nanoparticles.  
MicroPET/CT was used to analyze the biodistribution and tumor localization of the 
siRNA nanoparticles, while BLI enabled quantification of the luciferase knockdown by 
the delivered siRNA against luciferase.  The tissue distribution of the 64Cu-DOTA-siRNA 
delivered by Tf-targeted and non-targeted nanoparticles was very similar for the first hour 
after injection, with similar blood clearance and tumor accumulation (Figure 5.9). 
 
Figure 5.9.  Tissue distribution of 64Cu-DOTA-siRNA delivered intravenously by Tf-targeted and non-
targeted nanoparticles for the first 60 min after injection.  (A) Fused microPET/CT images of mice at 1, 10, 
and 60 min after injection.  (B) Blood clearance and tumor localization of Tf-targeted and non-targeted 
siRNA nanoparticles for the first 60 min after injection. 
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Figure 5.10 shows the microPET/CT images (1 d post injection) and 
corresponding bioluminescent images (pre injection and 1 d post injection) of two 
representative mice.  The average tumor activity at 1 d post injection measured by 
microPET was 1.1±0.3 %ID/cm3 and 1.4±0.4 %ID/cm3 for Tf-targeted and non-targeted 
nanoparticles, respectively.  Taking advantage of the noninvasive nature of the 
microPET/CT imaging, the same mice were also examined for luciferase activity by BLI 
before injection and 1 d post injection.  The relative luciferase knockdown by the 
delivered siRNA molecules was calculated based on the percent change in the tumor 
luciferase activity (Figure 5.10C).  The relative increase of tumor luciferase activity in 
mice treated with Tf-targeted nanoparticles is 50% lower than that in mice treated with 
non-targeted nanoparticles.  This provides strong evidence suggesting that the Tf-targeted 
nanoparticles are able to deliver more functional siRNA to the tumor cells than non-
targeted nanoparticles.  These data also corroborate our observations showing that tumor 
growth inhibition by a therapeutic siRNA was only observed when the siRNA was 
delivered by Tf-targeted nanoparticles and not by non-targeted nanoparticles (6). 
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Figure 5.10.  Multimodality in vivo imaging of siRNA nanoparticle delivery and function using 
microPET/CT and BLI.  (A) Fused microPET/CT image showing tumor-associated activity 1 d post 
intravenous injection of Tf-targeted and non-targeted nanoparticles containing 64Cu-DOTA-siRNA.  Image 
scale:  min threshold = 0.1 %ID/cm3, max threshold = 1.5 %ID/cm3).  (B) BLI of the same mice shown in 
(A) before injection and 1 d post injection.  (C) Relative change in luciferase expression 1 d after 
intravenous injection of Tf-targeted (n = 7) and non-targeted (n = 4) nanoparticles containing 64Cu-DOTA-
siRNA for simultaneous PET imaging.  p < 0.1 based on a Student's t-Test with a two-tailed distribution. 
 
5.5 Discussion 
This study demonstrates the utility of noninvasive imaging technologies to 
concurrently examine the biodistribution and in vivo efficacy of siRNA nanoparticles.  
Synthesis of DOTA-conjugated siRNA molecules allowed labeling with 64Cu, a positron 
emitting radionuclide, and subsequent imaging by microPET.  The spatiotemporal 
distribution of the injected 64Cu-labeled molecules was determined by co-registration of 
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the microPET images with anatomical information from microCT.  The microPET 
technology allows collection of high resolution, three-dimensional biodistribution of the 
injected radiolabeled molecules over time.  Therefore, the biodistribution of nanoparticles 
containing 64Cu-DOTA-siRNA could be followed after injection in living mice.  
Furthermore, because microPET/CT is noninvasive, BLI was used to measure the tumor 
luciferase activity in these same mice.  By using an siRNA sequence that targets 
luciferase, the relative change in luciferase activity before and after injection serves as an 
indicator for siRNA function within the tumor cells. 
The combination of microPET/CT and BLI represents a novel method to 
concurrently examine the biodistribution and functional efficacy of siRNA nanoparticle 
formulations in living subjects.  Here, we used this methodology to investigate siRNA 
nanoparticles formed using cyclodextrin-containing polycations (CDP), as CDP has 
previously been shown to deliver functional siRNA to tumors in mice after systemic 
administration (6).  Additionally, the CDP-based siRNA nanoparticles can be formulated 
with or without a Tf targeting ligand and can therefore be used to investigate the 
differences in biodistribution and functional efficacy of targeted and non-targeted 
nanoparticles. 
 DOTA-conjugated siRNA molecules targeting luciferase were synthesized by 
reacting DOTA-NHS with an siRNA containing a 5’-NH2.  The resulting DOTA-siRNA 
retained the ability to achieve luciferase knockdown in vitro, although the activity was 
reduced relative to the unmodified siRNA.  Incorporation of DOTA-siRNA into the 
nanoparticles had negligible effects on the size and zeta potential of the resulting 
nanoparticles.  Furthermore, nanoparticles containing 0%, 20%, and 50% DOTA-siRNA 
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all exhibited similar serum stability with an siRNA half-life of approximately 11 h in 
50% mouse serum.  Radiolabeling efficiencies of the DOTA-siRNA with 64Cu were 
typically around 30-50%.  These results all indicate that DOTA-modification of siRNA 
molecules has negligible impact on nanoparticle properties and is therefore a viable 
strategy for creating radiolabeled siRNA nanoparticles for imaging by microPET. 
 The results of the microPET studies indicated that attachment of the transferrin 
targeting ligand to the surface of the nanoparticles had negligible effect on the tissue 
distribution observed by PET.  Both targeted and non-targeted nanoparticles 
demonstrated nearly identical tumor localization kinetics, and at 1 d post injection 
showed similar tumor accumulation representing ~1% ID/cm3.  This is likely due to the 
nonspecific tumor accumulation resulting from the enhanced permeability and retention 
(EPR) effect, which effectively traps large macromolecules in the tumor 
microenvironment regardless of cell-specific binding or internalization.  However, BLI 
was used to examine function in tandem with the tissue distribution studies by microPET, 
and unlike the results with microPET showing that the tissue distribution was 
approximately equal for both targeted and non-targeted nanoparticles, BLI revealed that 
the targeted nanoparticles were more effective in reducing tumor luciferase expression 1 
d post injection.  Previous studies with other targeted delivery systems have also led to 
similar conclusions that the targeting moieties do not necessarily increase the total tumor 
accumulation but instead contribute to enhanced internalization by the tumor cells 
(17,18). 
Even though the Tf-targeted nanoparticles were able to achieve luciferase 
knockdown after systemic administration, the biodistribution by microPET indicated that 
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a significant portion of the injected siRNA dose was rapidly cleared by kidney filtration.  
The possibility that the siRNA nanoparticles dissociate upon injection into the 
bloodstream led to investigation of a physiologically based mechanism to explain this 
observation.  This effect may be most pronounced in the kidney since renal physiology 
provides a reasonable explanation for the observations made in this study and elsewhere 
concerning complexes formed by electrostatic interactions with nucleic acids.  Even if the 
intact nanoparticles are not filtered through the glomerulus on account of their size, they 
still can travel through the nephron of the kidney via the vasa recta.  Because of the 
countercurrent concentrating mechanism utilized by the kidney, NaCl concentrations in 
the vasa recta at the papillary tip of the renal medulla reach approximately 0.4 M (19).  It 
is possible that the greatest dissociation of the nanoparticles takes place here, as the 
electrostatic interactions between the cationic polymer and the siRNA may be 
compromised in such high salt concentrations.  The results in Figure 5.8 indicate ~50% 
dissociation of the siRNA nanoparticles at concentrations of 0.4 M.  Additionally, once 
the free siRNA is released into the complex milieu of the blood, there is little chance for 
it to re-associate with the nanoparticles before being bound by other blood components or 
rapidly cleared by the kidney (through either glomerular filtration on the next pass or by 
active transport by transporters located on the renal proximal tubule cells). 
Several previous studies have demonstrated that increasing amounts of NaCl can 
lead to concentration-dependent dissociation of complexes formed between nucleic acids 
and cationic polymers or lipids (20-22).  Eldred et al. observed that complexes between 
lysine-based peptide oligomers and plasmid DNA showed a sharp rise in the amount of 
unpackaged DNA at ~550 mM NaCl (20).  Additionally, Oupicky et al. examined NaCl-
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mediated dissociation of DNA complexes formed with the cationic polymer, poly-L-
lysine (21).  They showed that when the polyplexes were crosslinked with DTBP 
(dimethyl-3,3’-dithiobispropionimidate), the polyplexes did not exhibit NaCl-dependent 
dissociation.  Furthermore, while the non-crosslinked PEGylated polyplexes exhibited 
rapid clearance from the blood circulation, the crosslinked PEGylated polyplexes showed 
enhanced blood circulation times.  These observations would be consistent with the 
hypothesized mechanism for disruption of the electrostatic nanoparticle interactions 
during blood circulation, particularly in the medulla of the kidney.   
Further studies need to be conducted to confirm whether the conditions reached in 
the kidney medulla may be responsible for the disruption of the siRNA nanoparticles in 
this study.  This disruption mechanism may have broad implications for the general 
design of nanoparticles assembled through electrostatic interactions.  Although the 
siRNA nanoparticles used in this study were still able to deliver sufficient siRNA to 
achieve luciferase knockdown measured by BLI, the microPET experiments 
demonstrated that the majority of the injected dose was cleared rapidly from the blood 
circulation through kidney filtration.  To achieve more efficient systemic delivery of 
siRNA through nanoparticle formulations, it will be imperative to address the short blood 
circulation times observed for the nanoparticle formulations.  For nanoparticles formed 
through electrostatic interaction with nucleic acids, the increased salt concentration 
reached in the kidney (especially in juxtamedullary nephrons) may lead to significant 
nanoparticle dissociation and release of free nucleic acid.  If the nanoparticles are 
stabilized against salt-induced dissociation, then they may begin to exhibit the desired 
property of extended circulation times, especially if the stabilized nanoparticles are 
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coated with a PEG layer to reduce interaction with cells in the reticuloendothelial system.  
Most likely an optimum stability will exist for the nanoparticle formulations that prevents 
excessive release of payload during circulation while still allowing adequate release upon 
cellular internalization. 
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6 Sequence-specific knockdown of EWS-FLI1 by targeted, 
non-viral delivery of siRNA inhibits tumor growth in a 
murine model of metastatic Ewing’s sarcoma† 
 
6.1 Abstract 
Systemic delivery of nucleic acid molecules is one of the major hurdles limiting 
the application of siRNA-based therapeutics for cancer treatment.  Multifunctional 
nanoparticles are being investigated as systemic, nonviral nucleic acid delivery systems, 
and here we describe the use of cyclodextrin-containing polycations (CDP) to interact 
with small interfering RNA (siRNA) molecules to form nanoparticles that can be 
modified with transferrin (Tf) for targeting to transferrin receptor (TfR)-overexpressing 
tumor cells.  Twice-weekly intravenous injections of Tf-targeted nanoparticles formed 
with an siRNA targeting the EWS-FLI1 oncogenic fusion protein are able to achieve 
sequence-specific knockdown of the EWS-FLI1 gene in vivo, leading to tumor growth 
inhibition in a disseminated model of Ewing’s sarcoma.  Removal of the targeting ligand 
or the use of a control siRNA sequence eliminates the anti-tumor effects. Additionally, no 
abnormalities in interleukin-12 and interferon-alpha, liver and kidney function tests, 
complete blood counts, or pathology of major organs are observed after injection of the 
nanoparticles.  These data provide strong evidence for the safety and efficacy of this 
targeted, non-viral siRNA delivery system. 
                                                 
† Adapted from:  Hu-Lieskovan, S., Heidel, J.D., Bartlett, D.W., Davis, M.E. and Triche, T.J. (2005) 
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA 
inhibits tumor growth in a murine model of Ewing's sarcoma. Cancer Res, 65, 8984-8992. 
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6.2 Introduction 
Ewing’s family of tumors (EFT) is a poorly differentiated mesenchymal 
malignancy that arises in bone or soft tissue.  It is the second most common primary 
osseous malignancy in childhood and adolescence (1).  Historical data show that virtually 
all patients die from metastases (e.g., <5% survival after localized therapy (2)).  Systemic 
chemotherapy has improved survival of patients with localized disease, but patients with 
metastatic disease rarely benefit from continued therapy (3).  A major factor contributing 
to this outcome is the development of multi-drug resistance by the time patients are 
treated for metastasis.  The translocation t(11;22) is commonly detected in EFT and 
produces the chimeric EWS-FLI1 fusion gene found in 85% of EFT patients (3).  The 
EWS domain replaces the normal transcriptional activator domain in the 5’ region of the 
FLI1 DNA-binding protein, leading to altered transcriptional activation that contributes to 
the tumorigenic phenotype (1).  Reduction of the EWS-FLI1 protein in EFT cells in vitro 
or in subcutaneous xenograft tumors by antisense oligonucleotides complementary to 
EWS-FLI1 mRNA results in decreased proliferation (4-6), suggesting a potential 
therapeutic intervention directed at this tumor-specific chimeric gene. Small interfering 
RNAs (siRNAs) have recently been shown to silence the EWS-FLI1 gene and suppress 
proliferation of an EFT cell line in vitro (7-9).  To build upon these previous studies, the 
current study explores the use of systemically delivered siRNA against EWS-FLI1 to 
inhibit growth and dissemination of EFT cells in a xenograft model of Ewing’s sarcoma. 
 As discussed in Chapter 4, nanoparticle carriers offer several features that make 
them attractive for systemic siRNA delivery.  Cyclodextrin-containing polycations (CDP) 
can interact with small interfering RNA (siRNA) molecules to form nanoparticles that are 
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approximately 60-80 nm in diameter.  The modular design of these nanoparticles enables 
modification with PEG molecules for steric stabilization and Tf targeting ligands for 
uptake by TfR-overexpressing tumor cells.  The nanoparticles protect the nucleic acid 
payload from nuclease degradation, do not aggregate at physiological salt concentrations, 
and cause minimal erythrocyte aggregation and complement fixation.  Here, we 
investigate their ability to deliver a therapeutic siRNA to tumor cells in vivo after 
intravenous administration. 
The EFT cell line, TC71, is used to create a disseminated model of Ewing’s 
sarcoma in NOD/scid mice.  The TC71 cells engineered to express the luciferase gene 
(TC71-Luc) are injected by low-pressure tail-vein injection to mimic the metastatic 
process.  The most common engraftment sites are lung, vertebral column, pelvis, femur, 
and soft tissue, corresponding to the most frequently observed sites for metastases in EFT 
patients (10).  Live-animal bioluminescent imaging (BLI) is used to noninvasively track 
the growth of metastases in mice.  We test the ability of targeted, non-viral delivery of 
siRNA against EWS-FLI1 to safely limit bulk metastatic tumor growth and prevent 
establishment of bulk metastatic disease from microscopic metastatic disease. We prove 
here the hypothesis that the targeted, non-viral delivery of siRNA can safely abrogate 
EWS-FLI1 expression and inhibit metastatic Ewing’s tumor growth in vivo. 
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6.3 Materials and methods 
6.3.1 siRNA sequences 
siRNA targeting luciferase (siGL3), the breakpoint of EWS-FLI1 (siEFBP2), a 
mutated negative control for siEFBP2 (siEFBP2mut), and a non-targeting control 
sequence (siCON1) were obtained from Dharmacon Research, Inc.. 
siGL3: 
 5’-----CUUACGCUGAGUACUUCGAdTdT 
  dTdTGAAUGCGACUCAUGAAGCU-----5’ 
 
siEFBP2(7): 
 5’---GCAGAACCCUUCUUAUGACUU 
  UUCGUCUUGGGAAGAAUACUG---5’ 
 
siEFBP2mut(7): 
 5’---GCAGAACCAGUCUUAUGACUU 
  UUCGUCUUGGUCAGAAUACUG---5’ 
 
siCON1: 
 5’---UAGCGACUAAACACAUCAAUU 
  UUAUCGCUGAUUUGUGUAGUU---5’ 
6.3.2 In vitro down-regulation of EWS-FLI1 in an EFT cell line 
TC71 cells were grown on 6-well plates in RPMI 1640 with 10% FBS (no 
antibiotics) until they reached 30% confluency. siRNA was complexed with 
Oligofectamine (Invitrogen) according to the manufacturer’s instructions.  The resulting 
formulations were applied to each well at a final concentration of 100 nM.  All transfected 
cells were harvested at 48 h and gene expression was assessed by Western blot analysis.  
Primary monoclonal antibodies against the C-terminal region of FLI1 were obtained from 
BD Biosciences.  Polyclonal antibodies against β-Actin were obtained from Santa Cruz 
Biotechnology.  
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6.3.3 Injection of mice with TC71-Luc cells 
TC71-Luc cells were grown in RPMI 1640 supplemented with 10% FBS and 
antibiotics (penicillin/streptomycin) and subsequently trypsinized and resuspended in 
serum-free RPMI 1640 for injection.  Each mouse was injected with 5x106 TC71-Luc 
cells by tail vein injection of 0.2 mL of the cell suspension.  Mice were treated according 
to the NIH Guidelines for Animal Care and as approved by the Caltech Institutional 
Animal Care and Use Committee. All mice were 6-8 weeks of age at the time of injection.  
6.3.4 Bioluminescent imaging of the mice 
Longitudinal imaging of the mice was performed using the Xenogen IVIS 100 
imaging system.  D-luciferin (Xenogen) was dissolved in PBS at 15 g L-1, and 0.2 mL of 
the 15 g L-1 luciferin solution was injected i.p. 10 minutes before measuring the light 
emission.  Mice were anesthetized with an initial dose of 5% isoflurane followed by a 
maintenance dose of 2.5% isoflurane.  Bioluminescent signals were quantified using 
Living Image software (Xenogen). 
6.3.5 Formulation of non-viral, siRNA-containing nanoparticles for in vivo 
administration 
Before addition to the nucleic acid, the CDP was mixed with AD-PEG at a 1:1 
AD-PEG:β-CD (mol:mol) ratio in water.  Targeted nanoparticles also contained 
transferrin-modified AD-PEG (AD-PEG-Tf) at a 1:1000 AD-PEG-Tf:AD-PEG (w:w) 
ratio.  The mixture of CDP, AD-PEG, and AD-PEG-Tf in water was then added to an 
equal volume of siRNA in water such that the ratio of positive charges from CDP to 
negative charges from the nucleic acid was equal to the desired charge ratio of 3 (+/-).  
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An equal volume of 10% (w/v) glucose in water was added to the resulting nanoparticles 
to give a final concentration of 5% (w/v) glucose suitable for injection. 
6.3.6 Consecutive-day delivery of siRNA to tumors in vivo 
Mice with successful tumor cell engraftment received injection of formulations 
containing siRNA against luciferase (siGL3), EWS-FLI1 (siEFBP2) or a control sequence 
(siCON1) on two or three consecutive days as indicated.  Each mouse (~20 g) received 
0.2 mL of the appropriate formulation, containing 50 µg of siRNA corresponding to a 2.5 
mg/kg dose, by low-pressure tail-vein injection using a 1-mL syringe and a 27-gauge 
needle. 
6.3.7 Real Time Quantitative RT-PCR (Q-RT-PCR) 
Total cellular RNA was isolated using RNA STAT-60 (Tel-Test) from 
homogenized tumors. cDNA was synthesized from 2 µg of DNase I (Invitrogen)-treated 
total RNA in a 42µl reaction volume using oligo–dT and Superscript II (Invitrogen) for 
60 min at 42°C following suppliers’ instructions.  PCR primers were designed with 
MacVector 7.0 (Accelrys).  The sequences are:  
EWS-FLI1, forward, 5’-CGACTAGTTATGATCAGAGCAGT-3’,  
reverse, 5’-CCGTTGCTCTGTATTCTTACTGA-3’;  
β-Actin, forward, 5’-GCACCCCGTGCT GCTGAC-3’,  
reverse, 5’-CAGTGGTACGGCCAGAGG-3’. 
PCR was performed as described previously (11).  PCR conditions were 95°C for 900 s; 
40 cycles of 95°C for 15 s, 60°C for 30 s, 72°C for 30 s; and a final denaturing stage from 
60°C to 95°C.  All PCR products were analyzed on a 1% agarose gel and a single band 
was observed except for negative controls.  The reproducibility was evaluated by at least 
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three PCR measurements.  The expression level of the target gene was normalized to 
internal β-actin and the mean and standard deviation of the target/β-actin ratios were 
calculated for sample-to-sample comparison. 
6.3.8 Long-term delivery of siRNA to tumors in vivo 
Fifty female NOD/scid mice were injected with 5x106 TC71-Luc cells as 
described above.  Immediately after cell injection, each mouse received an additional 
injection of 0.2 mL of one of the following formulations (n = 10 mice per group): 5% 
glucose (group A); naked siEFBP2 (group B); targeted nanoparticles containing siCON1 
(group C); targeted nanoparticles containing siEFBP2 (group D); or non-targeted 
nanoparticles containing siEFBP2 (group E).  Formulations were administered twice-
weekly for four weeks.  Images were taken immediately after the first injections for 
quality control of the injections and twice-weekly immediately before the injection of the 
formulations.  We continued to monitor the tumor signal in the mice receiving targeted 
(group D) and non-targeted (group E) siEFBP2 formulations for an additional three 
weeks or until tumor burden required euthanization of the mice.  
6.3.9 Toxicity, immune response, and pathology studies 
Female C57BL/6 mice (Jackson Laboratories) were 6-8 weeks of age at the time of 
injection.  To measure plasma cytokine levels, blood was harvested from mice 2 h and 24 
h post-injection by cardiac puncture and plasma was isolated using Microtainer tubes 
(Becton Dickinson).  Whole blood was used for complete blood count (CBC) analyses, 
and plasma was used for all liver enzyme and cytokine analyses.  IL-12 (p40) (BD 
Biosciences) and IFN-α levels (PBL Biomedical Laboratories) were measured by ELISA 
according to the manufacturer’s instructions.  Major organs of the NOD/scid mice after 
  
171
long-term treatment studies were collected, formalin-fixed and processed for routine 
hematoxylin and eosin staining using standard methods.  Images were collected using a 
Nikon epifluorescent microscope with a DP11 digital camera.  
6.4 Results 
6.4.1 siRNA mediates down-regulation of EWS-FLI1 in cultured TC71 cells 
Using a previously reported siRNA sequence targeting the EWS-FLI1 breakpoint 
(siEFBP2)(7), we observed comparable and significant (greater than 50%) reduction in 
EWS-FLI1 protein levels after Oligofectamine-mediated transfection (Figure 6.1).  
Delivery of a mutant siRNA sequence (siEFBP2mut) failed to elicit such down-
regulation.  
 
Figure 6.1.  In vitro knockdown of EWS-FLI1 in cultured TC71 cells.  At 48 h post-transfection, cells were 
lysed and total cell protein was denatured, electrophoresed, and transferred to a PVDF membrane that was 
probed with antibodies to EWS-FLI1 or actin (siEFBP2mut: mutant negative control).  Average band 
intensities were determined by densitometry and the ratio of EWS-FLI1 to actin intensities was calculated. 
6.4.2 Formulated siRNA against EWS-FLI1 inhibits tumor growth in vivo 
 Mice with successful engraftment of TC71-Luc cells were randomly selected for 
treatment with targeted nanoparticles containing siEFBP2 on two consecutive days.  
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Assessment of the EWS-FLI1 expression in the tumors treated with two consecutive 
siEFBP2 formulations showed a 60% down-regulation of EWS-FLI1 RNA level 
compared to siCON1-treated tumors (p=0.046). (Figure 6.2).  Therefore, the delivery of 
targeted nanoparticles containing siEFBP2 is able to reduce EWS-FLI1 expression in the 
established tumors. 
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Figure 6.2.  In vivo knockdown of EWS-FLI1 RNA levels in metastasized TC71-Luc tumors in mice.  Tf-
targeted nanoparticles containing 2.5 mg/kg of siEFBP2 or siCON1 were administered intravenously on 
days 19 and 20 after injection of TC71-Luc cells.  Tumors were harvested on the third day.  RNA was 
extracted and EWS-FLI1 level was determined by Q-RT-PCR. 
 
6.4.3 Long-term, twice-weekly administration of targeted, formulated siEFBP2 
inhibits tumor cell engraftment 
 To investigate the potential for tumor growth inhibition as a result of EWS-FLI1 
knockdown, we employed a long-term treatment regimen in which formulations were 
administered twice weekly beginning the same day as injection of TC71-Luc cells.  These 
studies allowed for the more careful investigation of the effects of variations in the 
formulation conditions.  Targeted nanoparticles containing siEFBP2 (group D) 
dramatically inhibited the engraftment of TC71-Luc cells, with only 20% of the mice 
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showing any tumor growth compared to 90-100% in other treatment groups (Figure 6.3).  
Neither the mice receiving naked siEFBP2 (group B) nor those receiving targeted 
delivery of siCON1 (group C) showed any difference in tumor engraftment compared to 
the control group that received only the 5% glucose carrier solution (group A).  
Interestingly, tumors in mice treated with non-targeted nanoparticles containing siEFBP2 
showed a delayed progression of tumor engraftment compared to the control groups.  
Once significant tumors were established, however, the tumors seemed to grow at a rate 
unaffected by continued treatment with the non-targeted nanoparticles containing 
siEFBP2 (Figure 6.4).  The tumor signal was monitored in the mice receiving targeted 
(group D) and non-targeted (group E) nanoparticles containing siEFBP2 for an additional 
three weeks until the tumor burden required euthanization of the mice.  Whereas most of 
the mice receiving non-targeted nanoparticles developed very large tumors, the majority 
of the mice receiving targeted nanoparticles showed little or no tumor signal (Figure 6.3).  
We conclude that treatment with the targeted nanoparticles containing siEFBP2 prevented 
the tumor cell engraftment in these mice and slowed the growth of any tumors that did 
develop. 
  
174
 
Figure 6.3.  Bioluminescent images of the remaining mice from all treatment groups in NOD/scid mice 3.5 
weeks after injection of 5x106 TC71-Luc cells.  Treatment was started on day 0 followed by twice-weekly 
injections of the treatment formulations.  (A) = 5% glucose, (B) = Naked siEFBP2, (C) = Tf-targeted 
nanoparticles containing siCON1, (D) = Tf-targeted nanoparticles containing siEFBP2, (E) = Non-targeted 
nanoparticles containing siEFBP2. 
A
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Figure 6.4.  Median tumor size in NOD/scid mice after injection of 5x106 TC71-Luc cells on day 0 
followed by twice-weekly injections (arrows) of the treatment formulations.  Circles = Tf-targeted 
nanoparticles containing siEFBP2, squares = non-targeted nanoparticles containing siEFBP2, diamonds = 
Tf-targeted nanoparticles containing siCON1, triangles = naked siEFBP2, and asterisks = 5% glucose. 
 
6.4.4 No immune response or major organ damage was observed after treatment with 
targeted nanoparticles 
 Since the ability of the NOD/scid mice to mount a possible immune response to 
these formulations is severely compromised, single tail-vein injections of formulations 
were repeated in immunocompetent mice (C57BL/6) and blood was collected at 2 h or 24 
h after the injections.  Complete blood counts (CBC) of whole blood showed insignificant 
changes in white blood cell (WBC) or platelet (PLT) counts (Figure 6.5).  Levels of 
secreted liver enzymes (AST, ALT), blood urea nitrogen (BUN), and creatinine (CRE) 
were all unchanged, indicating a lack of damage to the liver or kidneys.  No increases, 
resulting from formulations, in plasma interleukin-12 (IL-12) or interferon-alpha (IFN-α) 
at either 2 h or 24 h post-injection were observed (Figure 6.5). 
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Figure 6.5.  Evaluation of toxicity and immune response in mice after a single intravenous administration of 
formulated siRNA.  (A) CBC and liver panel results for female C57BL/6 mice after a single intravenous 
dose of formulated siRNA. At 2 h or 24 h post-treatment, blood was drawn by cardiac puncture and plasma 
was isolated. Whole blood was used for determination of platelet (PLT) and white blood cell (WBC) 
counts. Plasma was used for measurement of aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), alkaline phosphatase (ALKP), creatinine (CRE), and blood urea nitrogen (BUN). The averages of 
triplicate mice for each time point are plotted; error bars represent standard deviations.  (B) Cytokine 
ELISA results for C57BL/6 mice after a single intravenous dose of formulated siRNA.  The plasma levels 
of interleukin-12 (IL-12 (p40)) and interferon-alpha (IFN-α) in mice described above were measured by 
ELISA.  Treatment groups: A = 5% glucose, B = naked siEFBP2, C = Tf-targeted nanoparticles containing 
siCON1, D = Tf-targeted nanoparticles containing siEFBP2, E = non-targeted nanoparticles containing 
siEFBP2, Wild-type = untreated.  2 = blood drawn 2 h after injection, 24 = blood drawn 24 h after injection. 
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We also performed pathological examination of the major organs (liver, kidney, 
brain, heart, lung, and pancreas) from the NOD/scid mice that received long-term 
treatments by hematoxylin and eosin (H&E) staining (Figure 6.6).  No organ damage was 
observed with the nanoparticle formulations when compared to the 5% glucose and naked 
siEFBP2 treatment groups.  Taken together, these results demonstrate the safety and low 
immunogenicity of these CDP-based nanoparticles. 
 
 
 
Figure 6.6.  H&E staining of tissues from mice receiving long-term treatment with (A) 5% glucose, (B) 
naked siEFBP2, and (C) Tf-targeted nanoparticles containing siCON1. 
 
6.5 Discussion 
In this study, we describe the establishment of a highly reproducible and clinically 
relevant metastatic murine model for the Ewing’s family of tumors in NOD/scid mice.  
Additionally, transduction of the EFT cells with the firefly luciferase gene enabled  
noninvasive, in vivo imaging of the mice to follow the fate of the injected tumor cells.  
A 
B 
C 
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The tumor engraftment sites observed (lung, vertebral column, pelvis, femur and soft 
tissue) were comparable to the most common locations of metastases in EFT patients.  
Small interfering RNA (siRNA) duplexes targeting the EWS-FLI1 fusion gene 
(siEFBP2) were formulated with CDP as described in Chapter 4.  Targeted nanoparticles 
contained the transferrin targeting ligand to interact with the high levels of surface 
transferrin receptors expressed on the TC71 cells.  This delivery system self-assembles 
with siRNA to form nanoparticles that are 60-80 nm in diameter. 
Clinically, many tumors relapse after intensive treatment because of systemic 
dissemination of micrometastases.  Nearly all EFT patients already have micrometastases 
at diagnosis, resulting in a >95% relapse rate when treated locally (2), and a 40% relapse 
rate after systemic chemotherapy (3).  Therefore, effective treatment for elimination of 
circulating or dormant metastasized tumor cells after traditional therapy is needed. We 
explored the possibility of using targeted siRNA nanoparticles for this purpose by 
administration of the nanoparticles twice-weekly beginning the same day as injection of 
TC71-Luc cells.  Of the different formulations tests, only the targeted nanoparticles 
containing siEFBP2 were able to achieve long-term tumor growth inhibition (Figure 6.4).  
Neither naked siEFBP2 nor targeted nanoparticles containing a control siRNA sequence 
showed any effect on tumor growth inhibition relative to the control group receiving only 
the 5% glucose carrier fluid.  These results demonstrate the necessity of the delivery 
vehicle for systemic application and the sequence-specificity of the observed inhibition.  
We hypothesize that treatment with the targeted formulation of siEFBP2 assists in the 
prevention of the initial establishment of tumors in these mice from the injected cells and 
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slows the growth of any tumors that develop by downregulating the expression of the 
oncogenic fusion protein EWS-FLI1.  
Notably, mice treated with non-targeted nanoparticles containing siEFBP2 
showed an initial delay in tumor growth.  However, the growth rate of tumors that 
eventually developed were unaffected by continuation of this treatment.  The enhanced 
permeability and retention effect (EPR) leads to the accumulation of macromolecules in 
solid tumors, and both targeted and non-targeted nanoparticles may be able to accumulate 
in the tumors by this mechanism (12).  This tumor accumulation of non-targeted 
nanoparticles was also observed by PET imaging, as discussed in Chapter 5.  While some 
small fraction of the non-targeted nanoparticles may have entered tumor cells after 
accumulation in the tumor microenvironment, the inclusion of the Tf targeting ligand 
likely increases the overall uptake of the nanoparticles through receptor-mediated 
endocytosis.  This increased uptake is likely responsible for the enhanced efficacy of Tf-
targeted nanoparticles relative to non-targeted nanoparticles. 
Recent in vitro reports have shown that siRNA sequences and their method of 
delivery may trigger an interferon response (13,14).  Additionally, in vivo delivery of 
siRNA by lipids has resulted in potent interferon responses (15-17).  Here, single tail-vein 
injections of all of the formulations were performed in immunocompetent (C57BL/6) 
mice to enable measurement of numerous blood markers that are indicative of an immune 
response.  In contrast to results obtained from the injection of poly (I:C), a known 
immunostimulator through interactions with Toll-like receptor 3 (TLR3) (18), none of the 
formulations showed any significant effects on the levels of IL-12, IFN-α, white blood 
cells, platelets, secreted liver enzymes (ALT and AST), BUN, or CRE (Figure 6.5).  All 
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of these observations with formulated siRNA are consistent with previous work showing 
a lack of immune response to naked siRNA (18).  The cyclodextrin-based delivery system 
does not produce an interferon response even when siRNA is used that contains a motif 
known to be immunostimulatory when delivered in vivo with lipids (16) (published 
sequence is within siCON1). These results show the safety and low immunogenicity of 
CDP-containing formulations and demonstrate the attractiveness of this methodology for 
systemic, targeted delivery of nucleic acids.  The in vivo gene silencing effect of siRNA 
by our delivery system is transient, permitting fine-tuning of the intensity and interval of 
the treatment. For example, the frequency of administration can be tuned for use in 
combination with other agents, and the treatment can be terminated within a few days if 
necessary. 
This study demonstrates that, in contrast to naked siRNA delivery, the targeted 
siRNA nanoparticles used here are efficacious at low siRNA doses and do not require 
chemical modification for efficacy in vivo.  Furthermore, the modular design of this 
delivery system enables it to be modified for targeting other tumor types by switching the 
specific targeting ligand attached to the surface of the nanoparticles.  Importantly, the 
siRNA nanoparticles do not elicit a detectable immune response and are well-tolerated at 
the doses required for efficacy.  We believe this treatment has the potential to be 
developed into a useful method for inhibition of metastatic EFT growth and may also 
have broad applicability in cancer therapy. 
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7 Growth inhibition of established subcutaneous tumors in 
mice after intravenous administration of siRNA 
nanoparticles: Impact of tumor-specific targeting and 
dosing schedule 
 
7.1 Abstract 
As nanoparticle carriers for systemic in vivo delivery of small interfering RNA 
(siRNA) near clinical application, the design of suitable dosing schedules will become 
particularly important for their efficacy.  This study addresses issues of practical 
relevance for siRNA nanoparticle delivery by measuring the impact of tumor-specific 
targeting and the effect of dose and dose frequency on the survival of mice bearing 
established subcutaneous tumors.  We have previously shown that cyclodextrin-
containing polycations (CDP) can form siRNA nanoparticles that exhibit desirable 
properties for in vivo application.   Furthermore, we showed that these siRNA 
nanoparticles could inhibit tumor formation in mice when they were injected twice-
weekly beginning immediately after the initial injection of tumor cells in a metastatic 
cancer model.  A major challenge for tumor-targeted siRNA nanoparticle delivery is to 
inhibit tumor growth in established tumors, where issues such as tumor penetration and 
interactions in the tumor microenvironment can become critical factors governing 
efficacy.  Here, we form syngeneic subcutaneous tumors using the Neuro2A 
neuroblastoma cell line.  Three consecutive daily doses of Tf-targeted nanoparticles 
carrying 2.5 mg/kg of two different siRNA sequences targeting ribonucleotide reductase 
subunit M2 (RRM2) slow the growth of tumors that are ~100 mm3 at the beginning of 
treatment; non-targeted nanoparticles are significantly less effective when given at the 
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same dose.  Furthermore, administration of the three doses on consecutive days or every 
three days does not lead to statistically significant differences in tumor growth delay.  
Mathematical model calculations of siRNA-mediated target protein knockdown and 
tumor growth inhibition are used to elucidate possible mechanisms to explain the 
observed effects and provide guidelines for designing more effective siRNA-based 
treatment regimens. 
7.2 Introduction 
Delivery of a therapeutic agent to a desired site in the body after intravenous 
administration often remains the rate-limiting step in the development of novel 
therapeutic entities.  Success hinges upon the ability to finely tune the properties of the 
therapeutic entity so that it can achieve efficacy at the target site at acceptable 
administered doses without inducing unacceptable toxic side effects.  Small interfering 
RNA (siRNA) molecules are no exception, as safe and effective systemic delivery 
remains a major challenge impeding their widespread translation into the clinic (1). 
siRNAs, which are double-stranded nucleic acids approximately 19-21 bp in 
length, are the effectors of RNA interference (RNAi), a naturally occurring mechanism 
for post-transcriptional gene silencing (2,3).  These siRNAs find their cognate mRNAs 
through Watson-Crick base pairing and subsequently trigger the degradation of these 
target mRNAs.  The effect of the mRNA degradation is a reduction in protein expression, 
and this mechanism can be exploited therapeutically to inhibit the expression of disease-
associated targets such as ribonucleotide reductase (RNR).  RNR is an attractive target 
for cancer therapies since it catalyzes the reduction of ribonucleotides into 
deoxyribonucleotides necessary for DNA replication and repair.  Several potent siRNA 
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inhibitors of the M2 subunit of RNR (RRM2) have been identified, and these siRNAs 
have demonstrated the ability to inhibit the growth of tumor cell lines after transfection in 
vitro and transplantation into mice (4).  A recent study by Avolio et al. demonstrated the 
in vitro and in vivo efficacy of an siRNA targeting ribonucleotide reductase (5).  
However, the dearth of suitable methods for in vivo siRNA delivery to tumors has yet 
limited translation of siRNAs for cancer therapy into the clinic. 
Several promising strategies are currently being developed to specifically address 
systemic siRNA delivery.  Covalent attachment of antibodies or cholesterol to the 
siRNAs can improve their pharmacokinetics and tissue distribution, addressing the 
problem of rapid renal clearance of naked siRNAs (6,7).  Nanoparticle-based delivery 
vehicles also can improve the pharmacokinetics and tissue distribution of the delivered 
siRNAs, while providing additional properties such as large payload capacity and tunable 
surface modification.  Stable nucleic acid lipid particles (SNALP) have been shown to 
deliver functional siRNA to the livers of mice and non-human primates leading to 
downregulation of APOB with good tolerability and minimal toxicity (8).  These are non-
targeted nanoparticles that passively accumulate in the liver and release their siRNA 
payload for uptake by the liver hepatocytes.  Targeted nanoparticles attempt to enhance 
the uptake by certain cell populations through interactions with specific cell-surface 
receptors (9).  For example, we have previously described a nanoparticle carrier based on 
cyclodextrin-containing polycations (CDP) that can be modified with transferrin-
targeting ligands, and this system has shown efficacy in delivering functional siRNA to 
tumors in vivo (10-12). 
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In the study presented here, we examine the effects of using a CDP-based 
nanoparticle carrier to deliver therapeutic siRNAs at different dosing schedules to 
established subcutaneous tumors in mice.  Tumor growth is followed by BLI and caliper 
measurements to measure changes in both cell viability and overall tumor burden.  Mice 
are treated by low-pressure tail vein injection of the naked siRNAs or siRNA 
nanoparticles.  Two different siRNAs targeting separate regions on RRM2 mRNA are 
shown to inhibit tumor cell growth in vitro and in vivo, while both an irrelevant control 
and a mismatched variant of one of the potent siRNAs do not show growth inhibition.  
Comparison of Tf-targeted and non-targeted nanoparticles as well as different dosing 
regimens is used to address practical considerations concerning optimal treatment design.  
Mathematical model calculations are used to provide possible explanations for the 
observed effects and to raise important issues for consideration when designing treatment 
regimens especially for cancer therapies that act through a cytostatic mechanism. 
7.3 Materials and methods 
7.3.1 siRNA duplexes 
 The sequences for the siRNA duplexes targeting the RRM2 gene (siR2A+5, 
siR2B+5, siR2B+6) have been previously described (4).  siLuc is designed to target the 
firefly luciferase gene.  These siRNAs were purchased as unmodified RNA duplexes 
from Integrated DNA Technologies.  siCON is an unmodified siRNA bioinformatically 
designed to minimize the potential for targeting any human or mouse genes, and it was 
purchased as an RNA duplex from Dharmacon. 
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siR2A+5: 
sense:      5’- CGAGUACCAUGAUAUCUGGCA –3’ 
antisense:  5’- CCAGAUAUCAUGGUACUCGAU -3’ 
 
siR2B+5: 
sense:      5’- GAUUUAGCCAAGAAGUUCAGA –3’ 
antisense:  5’- UGAACUUCUUGGCUAAAUCGC -3’ 
 
siR2B+6: 
sense:      5’- AUUUAGCCAAGAAGUUCAGAU –3’ 
antisense:  5’- CUGAACUUCUUGGCUAAAUCG -3’ 
 
siLuc: 
sense:      5’- GUGCCAGAGUCCUUCGAUAdTdT –3’ 
antisense:  5’- UAUCGAAGGACUCUGGCACdTdT -3’ 
 
siCON: 
sense:      5’- UAGCGACUAAACACAUCAAUU –3’ 
antisense:  5’- UUGAUGUGUUUAGUCGCUAUU -3’ 
 
7.3.2 In vitro transfection 
Neuro2A-Luc cells with constitutive luciferase expression were seeded at 2x104 
cells per well in 24-well plates 2 days prior to transfection and grown in DMEM 
supplemented with 10% FBS and antibiotics (penicillin/streptomycin).  siRNA was 
complexed with Oligofectamine (Invitrogen) according to manufacturer’s instructions 
and 20 pmol siRNA was applied to each well in a total volume of 200 µL Opti-MEM I 
(Invitrogen).  Transfection media was removed and replaced with complete media after 4 
h.  The kinetics of the luciferase knockdown were determined using the Xenogen IVIS 
100 (Xenogen, Alameda, CA) as described previously (12).  After the final time point, 
phase contrast images of the cells were taken using a Sony CCD-IRIS/RGB video camera 
attached to a Nikon Eclipse TE-300 inverted microscope. 
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7.3.3 Nanoparticle formation 
Before addition to the nucleic acid, the CDP was mixed with adamantane (AD)-
polyethylene glycol (PEG) at a 1:1 AD-PEG:β-CD (mol:mol) ratio in water.  Targeted 
nanoparticles contained AD-PEG-transferrin (AD-PEG-Tf) as a percentage of the total 
AD-PEG in the mixture.  For example, 1 mol% AD-PEG-Tf nanoparticles contained 0.01 
moles AD-PEG-Tf for every 0.99 moles AD-PEG, and 0.1 wt% AD-PEG-Tf 
nanoparticles contained 0.001 g of AD-PEG-Tf for every 1 g of AD-PEG.  The mixture 
of CDP, AD-PEG, and AD-PEG-Tf in water was then added to an equal volume of 
siRNA in water such that the ratio of positive charges from CDP to negative charges 
from the nucleic acid was equal to the desired charge ratio of 3 (+/-).  An equal volume of 
10% (w/v) glucose in water was added to the resulting nanoparticles to give a final 
concentration of 5% (w/v) glucose suitable for injection. 
7.3.4 Dynamic light scattering (DLS) 
Nanoparticle formulations were diluted to a volume of ~1.5 mL, placed in a 
cuvette, and inserted into a ZetaPALS (Brookhaven Instruments Corporation) instrument 
to measure both the size and zeta potential.  Reported effective hydrodynamic diameters 
and zeta potentials represent the average values from a total of 10 runs each. 
7.3.5 Animals and tumor formation 
Female A/J mice were ordered from Jackson Laboratories.  All tumor growth 
studies were performed when mice were 7-9 weeks old.  Neuro2A-Luc cells were grown 
in DMEM supplemented with 10% FBS and antibiotics (penicillin/streptomycin) and 
subsequently trypsinized and resuspended in serum-free DMEM for injection.  Each 
mouse was injected with 1x106 Neuro2A-Luc cells in the right flank to form a 
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subcutaneous tumor.  Tumor growth was monitored by caliper measurements of tumor 
volume (0.5 × l × w2) and bioluminescent imaging of total emitted ph/s from the tumor 
region of interest.  Treatments were commenced when the tumors had reached 
approximately 100 mm3. 
7.3.6 Intravenous administration of siRNA formulations 
Naked siRNA or siRNA nanoparticles were mixed with an equal volume of 10% 
(w/v) glucose in water to yield a 5% (w/v) glucose (D5W) carrier solution suitable for 
injection.  Each mouse was injected via lateral tail vein with 0.2 mL of the formulation in 
a 5% glucose solution. 
7.3.7 Bioluminescent imaging (BLI) 
Cell culture plates or mice were imaged using the Xenogen IVIS 100 imaging 
system (Xenogen).  D-luciferin (Xenogen) was dissolved in PBS at 15 g L-1.  For in vitro 
assays in 24-well plates, 50 µL of the 15 g L-1 luciferin solution was added to each well 
containing 1 mL of media.  Light emission was measured 2-3 minutes after addition of 
the luciferin.  For in vivo experiments, 0.2 mL of the 15 g L-1 luciferin solution was 
injected i.p. 10 minutes before measuring the light emission.  Mice were anesthetized 
with an initial dose of 5% isoflurane followed by a maintenance dose of 2.5% isoflurane.  
Bioluminescent signals were quantified using Living Image software (Xenogen). 
7.3.8 Histology and confocal immunofluorescence microscopy 
A/J mice bearing subcutaneous Neuro2A-Luc tumors were injected via tail vein 
with Tf-targeted nanoparticles carrying 2.5 mg/kg Cy3-siLuc.  18 h after injection, the 
mice were euthanized and the tumors were harvested, immediately placed in OCT 
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(TissueTek), and frozen on dry ice.  Samples were stored at -80°C until sectioning.  5-µm 
thick cryosections were stained with hematoxylin and eosin (H&E) for histological 
analysis.  To prepare for immunofluorescence staining, 5-µm thick cryosections were 
thawed and then fixed with acetone at -20°C for 15 min.  Fixed cryosections were 
blocked with normal donkey serum (Jackson ImmunoResearch) for 1 h at room 
temperature, washed with PBS, and then placed in a humidity chamber for incubation 
with the primary antibodies in PBS + 1% BSA for 2 h at room temperature.  A rat anti-
mouse CD31 primary mAb (Pharmingen) was used at a dilution of 1:25, and a goat anti-
luciferase primary pAb (Promega) was used at a dilution of 1:50.  After washing with 
PBS, the cryosections were placed in a humidity chamber for incubation with the 
secondary antibodies in PBS for 1 h at room temperature.  An AF488-conjugated donkey 
anti-rat secondary antibody (Invitrogen) was used at a dilution of 1:200, and a Cy5-
conjugated donkey anti-goat secondary antibody (Jackson ImmunoResearch) was used at 
a dilution of 1:200.  After washing with PBS, the slides were mounted using Biomeda 
Gel/Mount.  Confocal microscopy was performed using a Zeiss LSM 510 Meta laser-
scanning confocal microscope. 
7.3.9 Determination of treatment efficacy 
 Quantification of the relative efficacy of various treatments was accomplished by 
calculating the time for the tumor to reach a luciferase signal of 1x1010 ph/s or a volume 
of 1000 mm3.  To facilitate comparison between treatment groups, the growth curves for 
each group were time-shifted using linear regression of the log-transformed initial growth 
curves so that the value at day 7 (pre-injection) for each group was 100 mm3 (or 1x109 
ph/s).  The time to endpoint (TTE) was then calculated by linear regression of a log-
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transformed growth curve created from the final time point and the three previous time 
points.  Mice whose tumors never reached the end point size were assigned a TTE value 
equal to the final day of the study.  Statistical significance of the difference in TTEs 
between treatment groups was assessed using log-rank tests with two-tailed p values.  
TTEs based on the luciferase signal endpoint of 1x1010 ph/s are designated “TTE luc.”  
7.3.10 Tolerability 
 Mouse body weight was determined every 2-3 days during the course of 
treatment.  Acceptable toxicity for each treatment group was defined as a mean body 
weight loss of no less than 20% at any point during or after treatment. 
7.3.11 Mathematical modeling 
We added a cell death parameter to the mathematical model of siRNA-mediated 
gene silencing described previously to enable simulation of treatment with a therapeutic 
siRNA (12).  The differential equation governing cell growth was modified so that the 
cell growth rate would be reduced by a factor of P/Po where P is defined as the target 
protein concentration and Po is defined as the initial steady-state protein concentration in 
the cell.  The equation was also modified such that the growth rate would be reduced to 0 
when P/Po is reduced below an arbitrary threshold of 0.5.  No parameters were included 
to account for possible cell death in addition to reduction in growth rate; however, such 
modifications could be easily incorporated if knockdown of a certain target protein is 
known to directly induce cell death.  Furthermore, no modifications were added to 
account for the length of time the target protein is reduced below the threshold of 0.5, 
although it could be imagined that this might be physiologically relevant.   The protein 
degradation rate, kdegprot, was adjusted to reflect the RRM2 protein half-life of 6.3 h 
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(13).  The extracellular elimination rate constant, kelimec, was adjusted to 0.06 h-1 since 
the observed stability of the siRNA particles when incubated in serum is approximately 
11 h, as shown in Chapter 5.  The partition parameter governing the amount of the 
injected dose that reaches the tumor was adjusted to 1.5x10-2.  Finally, tumor growth was 
modeled with a logistic growth equation where the maximum number of cells was limited 
to 1000× the initial number of injected cells.  The remaining parameters were left 
unchanged from those described previously (12). 
7.4 Results 
7.4.1 In vitro growth inhibition by siRNAs targeting RRM2  
Demonstration of the efficacy and sequence-specificity of the siRNA duplexes 
was first performed in cultured Neuro2A-Luc cells.  The luciferase expression of the 
Neuro2A-Luc cells was monitored longitudinally using the Xenogen live-cell imaging 
system.  Our previous work has shown that the luciferase knockdown in the Neuro2A-
Luc cells lasts approximately 1 week with the greatest knockdown occurring 1-2 days 
after transfection (12).  However, a different situation is observed when siRNAs that 
inhibit cell growth are applied.  Instead of being used to follow the changes in luciferase 
expression, BLI is used to noninvasively measure the relative growth rates of the 
luciferase-expressing cells.  The results in Figure 7.1 show the relative growth rates of 
cells transfected with siR2A+5, siR2B+5, siR2B+6, and siCON, and a phase contrast 
image of the cells in each treatment group after the final time point is shown to confirm 
the growth inhibition.  The sequences for siR2A+5 and siR2B+5 were chosen based on 
their ability to reduce RRM2 protein levels in vitro and their complete sequence 
homology to mouse and human RRM2 (4).  Furthermore, they target two separate sites 
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on the RRM2 mRNA.  The sequence for siR2B+6 displayed reduced potency for RRM2 
protein reduction relative to siR2A+5 and siR2B+5, even though it shares nearly 
complete homology to the siR2B+5 sequence, indicating the highly specific nature of the 
RNAi mechanism (4).  Finally, siCON served as an irrelevant control sequence.  
Consistent with the expected reductions in RRM2 protein levels, both siR2A+5 and 
siR2B+5 inhibit cell growth relative to siR2B+6 and siCON.  At the final time point, a 
two-tailed Student’s t-Test was used to assess the significance of the cell growth 
inhibition by each treatment group.  The growth inhibition by siR2B+5 relative to all 
other treatment groups was highly significant (p<0.005), inhibition by siR2A+5 was 
highly significant (p<0.005) relative to siCON and not quite significant relative to 
siR2B+6 (p=0.05), and inhibition by siR2B+6 was not significant (p>0.1) relative to 
siCON. 
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Figure 7.1.  In vitro growth inhibition of Neuro2A-Luc cells after treatment with siCON (a), siR2B+6 (b), 
siR2A+5 (c), and siR2B+5 (d).  Growth curves were measured for 6 consecutive days after treatment using 
live-cell bioluminescent imaging, and phase contrast images of cells from each of the four treatment groups 
were acquired after the final time point. The growth curves represent the mean luciferase signal from one 
(siR2A+5) or two (siR2B+5, siR2B+6, siCON) experiments with triplicate wells each.  Error bars = SE. 
 
7.4.2 Schedule dependence of tumor growth inhibition in vivo by siRNA 
nanoparticles 
 Based on the in vitro growth inhibition studies, siR2A+5 and siR2B+5 possess the 
capability to inhibit cell growth once they are internalized into the Neuro2A-Luc cells.  
When the siRNAs are administered intravenously in mice using the CDP-based 
nanoparticle carriers, however, only a small percent of the injected siRNA dose even 
reaches the tumor location, let alone is internalized by the target cells (as shown in 
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Chapter 5).  Therefore, a systematic exploration of dose, dose frequency, and targeting 
ligand density was performed to determine what conditions may lead to sufficient 
delivery of the siRNAs into the Neuro2A-Luc tumor cells in mice to affect tumor growth 
rates.  
 Our previous work has shown that delivery of 2.5 mg/kg siRNA by the CDP-
based nanoparticles was sufficient to achieve knockdown of a target gene in mouse 
tumors (11).  Therefore, this dose was chosen as the initial dose for the investigations 
described here.  The first set of experiments was conducted to determine the impact of 
dosing schedule.  The rapid growth of the Neuro2A-Luc subcutaneous tumors provides 
the opportunity to conduct these experiments on a reasonable time scale, but it also limits 
the available dosing window since the length of time between the appearance of palpable 
tumors and their reaching the IACUC size limit is approximately 2 weeks.  Figure 7.2 
shows the effect of dosing schedules of qd×1, qd×3, or q3d×3 for doses of 2.5 mg/kg 
siRNA (siR2B+5 [n = 5], siR2B+6 [n = 5], and siCON [n = 4-5]) formulated into Tf-
targeted (1 mol% Tf) nanoparticles.  The data are represented as median luciferase signal 
(ph/s) measured by BLI.  At all dosing schedules, siR2B+5 showed greater tumor growth 
inhibition than either siR2B+6 (p<0.1 for qd×1, p<0.05 for qd×3, and p<0.1 for q3d×3) or 
siCON (p<0.1 for qd×1, p<0.15 for qd×3, and p<0.1 for q3d×3).  Although there was no 
statistically significant difference between the three dosing schedules of siR2B+5, the 
schedule of qd×3 (median TTE luc = 26.9 d) led to a greater delay in tumor growth 
relative to schedules of qd×1 (median TTE luc = 16.9 d) or q3d×3 (median TTE luc = 
15.4 d).  A single dose (qd×1) or three doses given every three days (q3d×3) yielded 
similar changes in the median tumor growth.  The tumors may have grown to such a large 
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size by the time the last two doses of the q3d×3 schedule were given that the injected 
dose was unable to reach enough cells with an efficacious dose to impact tumor growth; 
therefore, this schedule had similar efficacy to a single dose.  Three consecutive daily 
doses, however, may lead to sufficient siRNA accumulation at the tumor site and within 
the cells to have the desired impact on growth inhibition. 
 None of the treatments led to any overt signs of toxicity, and the mean body 
weight loss after treatment was ≤5% for all dosing schedules with siR2B+5, siR2B+6, 
and siCON.  The body weight loss was transient with a maximum loss usually occurring 
within the 1-2 days immediately after treatment and a recovery to pre-treatment body 
weights thereafter. 
 
Figure 7.2.  Effect of siRNA nanoparticle dosing schedule on the in vivo growth inhibition of established 
subcutaneous Neuro2A-Luc tumors in A/J mice.  Tf-targeted nanoparticles containing 2.5 mg/kg of 
siR2B+5 (circles, n = 5), siR2B+6 (squares, n = 5), or siCON (diamonds, n = 4-5) were injected 
intravenously once (qd×1, white markers), on three consecutive days (qd×3, black markers), or once every 
three days (q3d×3, gray markers).  Tumor growth was monitored by BLI, and the median luciferase signal 
is shown for each treatment group over the entire study period beginning with the initial injection of the 
cells.  The first treatment was started around day 7 when the tumors achieved a luciferase signal of 
approximately 1x109 ph/s (~100 mm3). 
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7.4.3 Correlation between tumor bioluminescence (BLI) and tumor volume (caliper 
measurement) 
One advantage of using a subcutaneous tumor model for these studies is that the 
tumor growth can be quantified by either BLI or caliper measurement of tumor volume.  
Since the goal of these studies was to examine the tumor growth inhibition by the 
delivered siRNAs, it was necessary to verify that the changes in luciferase expression 
correlated with changes in physical tumor volume.  Tumor luciferase signal (ph/s) as a 
function of tumor volume (mm3) is shown in Figure 7.3.  These data represent the 
compilation of the luciferase signal and size measurements for several hundred tumors, 
since each data point represents the mean value for one of the treatment groups (typically 
n = 5) of mice at a given time after injection.  The best fit (r2 = 0.89) was obtained using a 
power law regression with an exponent of 0.9.  This shows that BLI ph/s and caliper 
tumor volume are highly correlated, and there is nearly a linear correlation over 4 orders 
of magnitude.  The accuracy of the correlation is highest for tumors with volumes >100 
mm3, an observation also made by Paroo et. al using a luciferase-expressing HeLa cell 
line (14).  Furthermore, the correlation holds for mice treated with the therapeutic 
siRNAs, showing that treatment does not hinder the capability of BLI to follow changes 
in tumor volume in this tumor model.  Consistent with our ex vivo analysis of the tumors 
in this study, Smrekar et al. observed very little necrosis in Neuro2A tumors.  As necrotic 
regions could affect the correlation between luciferase signal and tumor volume, their 
minimal presence in the Neuro2A tumors may contribute to the good correlation 
observed in Figure 7.3. 
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Figure 7.3.  Correlation between tumor bioluminescence and tumor volume.  Tumor luciferase signal (ph/s) 
as a function of tumor volume (mm3) is shown for data from several hundred independent measurements 
(each data point represents the mean value for one of the treatment groups [n = 3-5] of mice at a given time 
after injection).  The dashed line represents the power law regression line (r2 = 0.89) that provided the best 
fit to the data. 
 
However, a higher variability in bioluminescent imaging was observed compared 
to caliper measurements, especially when tracking the growth curves over time.  Tumors 
(especially at early time points) which were placed deeper under the skin showed lower 
luciferase signal even though the physical size was identical to tumors located closer to 
the surface.  BLI was therefore affected by variability in tissue penetration of light as well 
as differences between animals in luciferin injection and tumor uptake.  Although both 
BLI and caliper measurements were still used to follow tumor growth in all of the 
experiments described here, the remaining results are reported as mean tumor volume 
(mm3) owing to the reduced variability for caliper measurement of tumor volume.  
Notwithstanding, BLI can prove invaluable for tracking tumor growth in regions 
inaccessible to caliper measurement, such as sites of tumor metastasis, but such 
advantages are not apparent in a subcutaneous tumor model. 
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7.4.4 In vivo efficacy of naked siRNA vs. siRNA nanoparticles 
 The next set of experiments attempted to determine the effect of varying the 
siRNA formulation conditions while maintaining the qd×3 dosing schedule.  The results 
in Figure 7.4A demonstrate the impact of variations in siRNA formulation conditions on 
the mean tumor volume, while the survival curves (time to 1000 mm3) for each treatment 
group are shown in Figure 7.4B.  
 
Figure 7.4.  Effect of siRNA nanoparticle formulation on the in vivo growth inhibition of established 
subcutaneous Neuro2A-Luc tumors in A/J mice after intravenous injection of naked siRNA or siRNA 
nanoparticles for three consecutive days (qd×3).  (A) Mean tumor volume.  Error bars = SE.  (B) Survival 
curves based on the endpoint of 1000 mm3.  Tf-targeted nanoparticles carrying 2.5 mg/kg of siR2B+5 were 
formulated without Tf targeting ligand (white circles, n = 5), with 0.1 wt% Tf (dark gray circles, n = 5), or 
with 1 mol% Tf (black circles, n = 5).  Comparison is also made to Tf-targeted (1 mol%) nanoparticles 
carrying 5 mg/kg of siR2B+5 (light gray circles, n = 5), Tf-targeted (1 mol%) nanoparticles carrying 2.5 
mg/kg of siR2B+6 (black squares, n = 5), Tf-targeted (1 mol%) nanoparticles carrying 2.5 mg/kg of siCON 
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(black diamonds, n = 4), 2.5 mg/kg of naked siR2B+5 (black triangles, n = 5), or no treatment (inverted 
black triangles, n = 3).  The first treatment was started around day 7 when the tumors were ~100 mm3. 
 
Duxbury et al. reported that twice-weekly systemic administration of naked 
siRNA inhibited subcutaneous tumor growth in mice, and Avolio et al. showed 
subcutaneous tumor growth inhibition after thrice-weekly injection of naked siRNA 
(5,15).  To test whether the same tumor growth inhibition was observed with naked 
siRNA as with the nanoparticle formulations in the Neuro2A subcutaneous tumor model 
studied here, 2.5 mg/kg of naked siR2B+5 (n = 5) was administered at the dosing 
schedule of qd×3 and the growth of tumors was followed over time.  As with the 
nanoparticle formulations, the mice treated with naked siRNA showed a transient 
reduction in body weight ≤5%.  The results in Figure 7.4 show that tumor growth in mice 
treated with naked siR2B+5 (median TTE = 12.9 d) was similar to that in untreated mice 
(n = 3, median TTE = 12.9 d).  On the other hand, all treatments with the Tf-targeted 
nanoparticle formulations led to significant (p<0.05) changes in TTE relative to untreated 
mice or naked siR2B+5.  
7.4.5 In vivo efficacy of targeted vs. non-targeted siRNA nanoparticles 
Since the nanoparticle formulations appeared to be important for the efficacy of 
the delivered siRNA in the subcutaneous Neuro2A tumors, mice were treated with 
siR2B+5 at 2.5 mg/kg qd×3 formulated into nanoparticles containing 1 mol% Tf (n = 5), 
0.1 wt% Tf (n = 5), or no Tf (non-targeted, n = 5) to assess the impact of Tf targeting 
ligand density.  No adverse health events were observed after treatment with these 
formulations, and the transient body weight loss immediately after treatment was ≤5%.  
The data in Figure 7.4 indicate that nanoparticles with 1 mol% Tf were the most effective 
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for inhibiting tumor growth (median TTE = 17.6 d), while both non-targeted 
nanoparticles (median TTE = 15.7 d) and those with only 0.1 wt% Tf (median TTE = 
15.0 d) showed less inhibition of tumor growth relative to untreated mice (median TTE = 
12.9 d).  However, both the 1 mol% Tf and 0.1 wt% Tf formulations showed a 
statistically significant (p<0.05) change in TTE relative to untreated mice, while the non-
targeted formulation did not (p>0.3).  The targeting ligand likely helps to enhance the 
intracellular uptake of the injected siRNA nanoparticles.  In a metastatic xenograft model, 
we previously showed efficacy using Tf-targeted (0.1 wt%) siRNA nanoparticles (11).  
The greater efficacy observed here using the higher targeting ligand density (1 mol%) 
may reflect the reduced, but not negligible, affinity between the human Tf and the mouse 
TfR on mouse Neuro2A cells, or the use here of a subcutaneous instead of a metastatic 
tumor model.  Further studies will be needed to optimize nanoparticle targeting ligand 
density, and the optimal density may depend on factors such as the cell line, tumor 
location, and tumor size. 
Finally, mice were treated with the Tf-targeted (1 mol%) nanoparticles qd×3 with 
an siRNA dose of 5 mg/kg (n = 5).  Treatment at the 5 mg/kg dose led to a transient 
decrease in mean body weight of ~11%, approximately twice that observed for 
formulations at 2.5 mg/kg; however, no other adverse health effects were observed.  
Relative to untreated mice, there was a highly significant change in TTE (p<0.005).  
However, as shown in Figure 7.4, there was no advantage for tumor growth inhibition 
with a dose of 5 mg/kg (median TTE = 15.9 d) relative to a dose of 2.5 mg/kg (median 
TTE = 17.6 d).  This may indicate that the 2.5 mg/kg dose is sufficient to reduce the 
RRM2 protein levels below the value necessary to inhibit cell growth; therefore, if the 
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higher dose does not reach a higher percentage of the tumor cells, no phenotypic 
difference would be observed.  It is possible that the nanoparticles may have restricted 
access to different cell populations within the tumor that inherently limit the efficacy of 
the delivered siRNA, although these important effects of intratumoral nanoparticle and 
siRNA distribution have yet to be extensively tested for this system. 
7.4.6 Tumor growth inhibition in vivo correlates with in vitro cell growth inhibition 
  Although the siR2A+5, siR2B+5, siR2B+6, and siCON sequences had different 
effects on Neuro2A-Luc cell growth in vitro, it remained to be shown whether these same 
trends would be observed after nanoparticle-mediated delivery to subcutaneous 
Neuro2A-Luc tumors in vivo.  The results in Figure 7.5 show the mean tumor volume 
(mm3) for mice treated qd×3 with Tf-targeted (1 mol%) nanoparticles containing 2.5 
mg/kg of siR2A+5 (n = 5), siR2B+5 (n = 5), siR2B+6 (n = 5), or siCON (n = 4).  
Corroborating the correlation between BLI and physical tumor volume presented in 
Figure 7.3, the trends for mean tumor volume are the same as for median tumor light 
output (ph/s) shown in Figure 7.2; however, Figure 7.5 also contains the data for mice 
treated with Tf-targeted nanoparticles containing siR2A+5.  Like siR2B+5, the siR2A+5 
sequence leads to significant tumor growth delay relative to untreated mice (p<0.005).  In 
vivo tumor growth inhibition by the delivered siRNAs parallels their in vitro efficacy, 
with the potency of in vivo growth inhibition following the trend of siR2B+5 (median 
TTE = 17.6 d) > siR2A+5 (median TTE = 17.0 d) > siR2B+6 (median TTE = 14.3 d) > 
siCON (median TTE = 13.1). 
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Figure 7.5.  In vivo growth inhibition of established subcutaneous Neuro2A-Luc tumors in A/J mice after 
treatment with three independent sequences targeting RRM2 mRNA and an irrelevant control sequence.  
Tf-targeted (1 mol%) nanoparticles containing 2.5 mg/kg of siR2B+5 (circles), siR2B+6 (squares), siCON 
(diamonds), or siR2A+5 (triangles) were injected intravenously on three consecutive days (qd×3) once the 
tumors had reached a size of ~100 mm3. 
 
7.4.7 Histology and confocal immunofluorescence microscopy 
 To investigate the intratumoral distribution of siRNA after systemic delivery, 
H&E-staining and confocal immunofluorescence (IF) microscopy were used to examine 
cryosections of subcutaneous Neuro2A-Luc tumors excised from mice 18 h after tail-vein 
injection with Tf-targeted nanoparticles carrying 2.5 mg/kg Cy3-labeled siLuc (Figure 
7.6).  The H&E staining revealed the aggressive form of the Neuro2A-Luc tumors, 
characterized by densely packed tumor cells.  However, IF staining for blood vessels 
using an anti-CD31 antibody showed that the tumors are also well-vascularized.  This 
characteristic is particularly important to therapeutics that are applied intravenously and 
therefore require transport to the tumor through the blood vessels.  Because of the 
extensive tumor vascularization, even intact nanoparticles that may have poor tissue 
penetration owing to their size (~70 nm) can potentially access a significant portion of the 
tumor cells.  Cy3-labeled siLuc can be seen within the tumor cryosections in Figure 7.6, 
  
205
although the intratumoral distribution of the siRNA molecules is highly heterogeneous.  
Moreover, IF-staining for luciferase expression within the tumor cryosections indicated a 
visible reduction in luciferase staining in the vicinity of the Cy3-labeled siLuc.  This 
would be consistent with functional activity of the delivered Cy3-siLuc that is designed 
to inhibit luciferase expression.  These results indicate that although the Tf-targeted 
nanoparticles can deliver functional siRNA to the subcutaneous Neuro2A-Luc tumors, 
their heterogeneous intratumoral distribution may limit the fraction of the tumor cells that 
can be treated (Figure 7.6B). 
 
Figure 7.6.  H&E staining (A) and confocal immunofluorescence microscopy (B) of Neuro2A-Luc tumor 
cryosections.  Tumors were harvested 18 h after tail-vein injection of Tf-targeted nanoparticles containing 
Cy3-labeled siLuc (2.5 mg/kg).  (A) H&E staining; images of the same tumor region are shown at 4X, 10X, 
and 40X magnification.  (B) Confocal immunofluorescence microscopy of three different regions within 
the same tumor; green = anti-CD31, blue = anti-luciferase, red = Cy3-siLuc, and scale bar = 20 µm. 
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7.4.8 Mathematical model simulations and insights for siRNA-based treatment 
design 
Based on our observations that a higher dose or a q3d×3 dosing schedule did not 
improve tumor growth inhibition, it may be that within the time frame of these 
experimental dosing schedules the nanoparticles essentially access the same region of 
tumor cells after each dose.  Under such circumstances, there is no advantage to 
delivering more siRNA to the same region of cells once sufficient siRNA has been 
delivered to inhibit the growth of a given tumor cell.  This is particularly important for 
therapeutic siRNAs which act to arrest cell growth or elicit cell death, since a threshold 
may exist beyond which further knockdown no longer achieves any advantage (i.e., the 
cell is already growth-arrested or dying).  In these situations, multiple doses may not be 
needed for any given cell.  On the other hand, multiple doses might be important if new 
cells are reached that either have not internalized any siRNA or have not internalized 
sufficient siRNA to pass beyond the threshold required for the phenotypic effect such as 
cell death.  These concepts are illustrated in Figures 7.7 and 7.8 using a mathematical 
model to account for siRNA knockdown of a therapeutic target followed by cessation of 
cell growth if a threshold knockdown is achieved. 
The duration of target knockdown after siRNA treatment is an important factor to 
consider when designing treatments.  Figure 7.7 shows the expected duration of RRM2 
protein knockdown after treatment (beginning on day 7) with 2.5 mg/kg qd×1 (I), 2.5 
mg/kg q3d×3 (II), 2.5 mg/kg qd×3 (III), or 5 mg/kg qd×3 (IV).  The only difference 
between Figures 7.8A and 7.8B is the rate of cell division of the tumor cells.  In Figure 
7.7A, the tumor cell doubling time is fixed at 1.5 d, so neither the maximum number of 
cells (logistic growth) nor target protein knockdown (even if the threshold knockdown is 
  
207
surpassed) slow this growth.  As expected, the knockdown lasts slightly longer than one 
week (12).    In Figure 7.7B, however, the tumor cell growth rate is reduced as a result of 
target protein knockdown (proportional to relative protein level, P/Po), and growth is 
halted if P/Po < 0.5.  Although the logistic growth equation is also applied in Figure 
7.7B, it has a minimal impact on the expected protein knockdown in these simulations 
since removal of the maximum carrying capacity term does not significantly change the 
observed target knockdown curves.  Therefore, these simulations demonstrate that the 
reduction in cell growth rate can lead to significantly longer target knockdown because of 
the reduced dilution from cell division.  In the absence of cell division, target knockdown 
after siRNA delivery can last at least several weeks and even more than one month 
(8,12,16).  This effect may represent a particularly important consideration in light of the 
increased use of cytostatic agents in oncology.  If the treatment does not immediately 
induce cell death but rather slows or inhibits cell growth, then the siRNA-mediated target 
knockdown can persist for a substantial period after a single efficacious dose without the 
need for further dosing of the cells. 
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Figure 7.7.  Model simulations showing the effect of tumor growth rate on the protein knockdown after 
siRNA nanoparticle treatment with dosing schedules of 2.5 mg/kg qd×1 (I), 2.5 mg/kg q3d×3 (II), 2.5 
mg/kg qd×3 (III), or 5 mg/kg qd×3 (IV).  (A) Protein knockdown in tumor cells with a constant doubling 
time of 1.5 d.  (B) Protein knockdown in tumor cells with a growth rate that is slowed in proportion to 
protein knockdown and stopped once the protein knockdown passes the threshold of 50% protein 
knockdown. 
 
The simulations in Figure 7.8 present an important caveat to the conclusions 
drawn from Figure 7.7.  Although the target knockdown in any given cell may persist for 
a prolonged period if the tumor cell growth rate is reduced, it is highly unlikely that any 
treatment reaches all of the cells in the tumor, as illustrated by the heterogeneous 
intratumoral distribution of Cy3-siRNA shown in Figure 7.6.  Particularly for relatively 
large therapeutic entities such as the siRNA nanoparticles, access to certain regions 
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within the tumor can be limited.  Even if multiple doses are given, this does not ensure 
that new cells are reached within the tumor.  In fact, Figure 7.8A shows what would 
happen if no new cells are reached even with subsequent doses.  Treatment (beginning on 
day 7) with 2.5 mg/kg qd×1 (I), 2.5 mg/kg q3d×3 (II), 2.5 mg/kg qd×3 (III), or 5 mg/kg 
qd×3 (IV) all lead to essentially identical tumor growth inhibition.  This is because the 
additional doses do not provide any therapeutic benefit since the target protein is already 
reduced below the threshold required for cessation of growth (Figure 7.7B).  In such a 
situation where no new cells are reached with each treatment, multiple doses (or higher 
doses) will only be advantageous if additional reduction in target protein levels leads to 
further therapeutic benefit (i.e., a greater reduction in cell growth rate or induction of 
apoptosis at sufficiently low target protein levels). 
For comparison, the simulations in Figure 7.8B assume that each additional dose 
reaches 50% new cells.  After three doses, this predicts that there will be populations of 
cells that have been reached with a single dose, two doses, or all three doses.  This ability 
to reach new cells leads to a greater total fraction of the tumor cells that receive 
therapeutic doses of the siRNA, and the benefit is clearly seen in Figure 7.8B.  Under 
these conditions, the dosing schedules of 2.5 mg/kg qd×3 (III) or 5 mg/kg qd×3 (IV) are 
the most effective, owing to the faster reduction in target protein levels leading to cell 
growth inhibition.  Because the tumor is growing rapidly, the number of cells to be 
reached increases with time.  Therefore, if more cells need to be reached, then an 
equivalent total dose of siRNA may not be as effective in a large tumor as it is in a small 
tumor (if 50% of the total tumor cells are reached in each case).  Alternatively, to achieve 
the same intracellular levels of siRNA in the larger tumor, a lower fraction of the total 
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tumor cells must be reached.  Either scenario will lead to lower overall efficacy.  The 
q3d×3 dosing schedule (II) in Figure 7.8B illustrates this point since the target protein 
levels in a portion of the cells that are reached at later time points are not reduced below 
the 50% threshold to stop cell growth. 
 
Figure 7.8.  Model simulations comparing tumor growth inhibition after siRNA nanoparticle treatment in 
situations where (A) no new cells are reached or (B) 50% new cells are reached with each additional dose.  
Comparison is made between simulated siRNA nanoparticle treatment with dosing schedules of 2.5 mg/kg 
qd×1 (I), 2.5 mg/kg q3d×3 (II), 2.5 mg/kg qd×3 (III), or 5 mg/kg qd×3 (IV). 
 
7.5 Discussion 
 In the present study, we demonstrated the ability of Tf-targeted siRNA 
nanoparticles to inhibit the growth of established subcutaneous Neuro2A tumors in a 
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syngeneic mouse model.  The siRNAs were designed to target the M2 subunit of 
ribonucleotide reductase (RRM2), a crucial enzyme involved in preparing nucleotides for 
DNA replication (17).  Three separate siRNAs targeting different regions on the RRM2 
transcript were tested for their ability to inhibit the growth of Neuro2A-Luc (luciferase 
expressing) cells in vitro relative to cells transfected with an irrelevant control sequence 
(siCON).  Consistent with previously reported RRM2 protein knockdown by these 
sequences, the order of potency for cell growth inhibition was siR2B+5 > siR2A+5 > 
siR2B+6 (4).  While siR2A+5 and siR2B+5 target completely distinct regions in the 
RRM2 mRNA transcript, siR2B+5 and siR2B+6 are shifted by only 1 base pair.  
Moreover, siR2A+5 and siR2B+5 show complete homology to mouse RRM2 mRNA, but 
siR2B+6 contains a single mismatch at the last nucleotide of the target region in mouse 
RRM2 mRNA.  These examples support the exquisite sensitivity of RNAi while also 
providing support that the observed effects are due to specific RRM2 protein knockdown. 
These same trends in potency are observed in vivo after intravenous 
administration of Tf-targeted nanoparticles carrying the siRNAs.  siRNA nanoparticle 
dosing schedules of 2.5 mg/kg qd×1, 2.5 mg/kg qd×3, and 2.5 mg/kg q3d×3 were 
compared, and the 2.5 mg/kg qd×3 led to the most pronounced growth inhibition.  
Increasing the siRNA dose to 5 mg/kg did not yield greater tumor growth inhibition.  
Importantly, non-targeted nanoparticles given at a dose of 2.5 mg/kg qd×3 were less 
effective at achieving tumor growth inhibition.  Several groups have reported similar 
trends showing that inclusion of a targeting ligand is necessary for achieving therapeutic 
efficacy, most likely by enhancing the intracellular delivery of the nanoparticle payload 
(18,19). 
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A particular concern with siRNA-based therapies is the possibility of nonspecific 
effects, such as immune stimulation, that could mask the sequence-specific effects of the 
siRNA (20).   Toxicity studies in cynomolgus monkeys have been conducted after 
intravenous administration of Tf-targeted nanoparticles formed using the CDP delivery 
vehicle and the siR2B+5 sequence at siRNA doses up to 27 mg/kg (21).  At siRNA doses 
up to 9 mg/kg, the Tf-targeted nanoparticles were well-tolerated with no overt signs of 
toxicity; importantly, there was a lack of significant complement activation or immune 
response at these doses.  This indicates that the efficacy observed here is not related to 
non-specific effects from immune stimulation. 
 These results provide several important insights into systemic siRNA delivery 
using nanoparticle formulations.  According to the in vitro data shown in Figure 7.2, a 
single dose of siRNA can be sufficient to achieve the phenotypic effect of cell growth 
arrest, presumably because a single dose can inhibit the RRM2 target long enough so that 
the rapidly dividing cells will attempt to divide during the window of inhibition, 
triggering the growth arrest or even cell death.  With targets that disrupt cell division, for 
example, prolonged inhibition in any cell may not be needed, so the criteria used to 
choose the dosing intervals should not be designed to necessarily prolong inhibition in a 
given cell.  Instead, multiple doses should be designed to maximize the fraction of cells 
reached with a sufficient siRNA dose for efficacy.  The surprising observation that a 
higher siRNA dose did not lead to greater tumor growth inhibition can possibly be 
explained by the threshold hypothesis illustrated by the simulations in Figures 7.7 and 
7.8.  Essentially, if the target is already knocked down sufficiently in a cell, and the 
higher dose does not reach any greater fraction of the total tumor cells, then giving a 
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higher dose will provide no therapeutic advantage.  This effect is magnified by the 
prolonged duration of target knockdown expected if cell growth is inhibited after 
treatment.  These criteria would not be expected to apply for other therapeutic 
applications, such as infectious diseases or metabolic disorders, where the target may 
have to be continuously repressed to achieve the therapeutic effect.  In such applications, 
multiple dosing schedules must be designed to maintain the silencing within a given cell.  
As we showed previously, this dosing schedule will be largely governed by the doubling 
time of the target cell (12). 
In conclusion, these studies address issues of practical relevance for siRNA 
nanoparticle delivery including the impact of tumor-specific targeting and the effect of 
dose and dose frequency.  The results emphasize the importance of rationally designing 
dosing schedules based on the characteristics of the therapeutic target, since the duration 
of gene inhibition in a given cell required for therapeutic efficacy will vary.  Compared to 
systemically delivered naked siRNA molecules, tumor-targeted siRNA nanoparticle 
formulations were shown to be significantly more effective in slowing the growth of 
subcutaneous tumors.  This increased efficacy may be attributed at least partly to the 
capability of nanoparticles to deliver thousands of individual siRNA molecules per 
cellular uptake event, increasing the chance for therapeutic efficacy within a cell.  
Furthermore, targeted nanoparticles are shown to be more effective than non-targeted 
nanoparticles, indicating that inclusion of a targeting ligand may be critical for uptake by 
the desired cell population after localization to the tumor microenvironment.  These 
results emphasize the need to incorporate both tumor-specific (e.g., accessibility, number 
of target cells, and growth rate) and treatment-specific (e.g., threshold knockdown 
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required, cytostatic vs. cytotoxic, and duration of therapeutic effect after a given dose) 
parameters into the design of siRNA-based treatments for cancer therapy. 
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8 Future directions 
 
The aim of this thesis is to help develop a rational approach for the application of 
siRNA therapeutics for cancer treatment.  Through a methodical and quantitative analysis 
of siRNAs and their formulation into nanoparticles for systemic delivery, several 
observations were made that can help direct future research in the field. 
A consistent theme throughout the thesis work was the emphasis on studying the 
dynamics of biological processes instead of merely looking at individual snapshots in 
time.  It is apparent that the information obtained from time-course studies, as 
exemplified by the live-cell and live-animal imaging studies, provides unique insights 
into the behavior of the biological systems.  Additionally, the tumor growth inhibition 
studies highlighted how these insights can be applied to design more effective siRNA-
based cancer treatments.  Future studies examining the kinetics of the knockdown of 
therapeutic targets, and not just the luciferase reporter gene, will be critical for optimizing 
the dosing schedules of siRNA therapeutics.  Moreover, these studies must correlate the 
target knockdown with the observed phenotypic changes.  For example, determination of 
a threshold knockdown or duration of knockdown required to achieve efficacy, as 
mentioned in Chapter 7, would provide more rigorous criteria for achieving successful 
therapeutic response with siRNAs. 
Additional studies are also needed to further probe the mechanism and in vivo 
behavior of nanoparticle carriers for nucleic acids such as siRNA.  In Chapter 5, the use 
of PET and BLI to study the in vivo biodistribution and function of siRNA nanoparticles 
raised several intriguing questions concerning their biological activity.  Even though a 
significant portion of the injected siRNA appears to dissociate rapidly from the 
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nanoparticles after systemic administration, nanoparticle formulation still appears to 
facilitate the delivery of functional siRNA to the target cells.  This is confirmed by the 
observations in Chapters 6 and 7 where targeted siRNA nanoparticles were shown to be 
more effective at achieving tumor growth inhibition than non-targeted siRNA 
nanoparticles or naked siRNAs alone.  Elucidating the mechanism for these differences 
will be essential for designing treatments based on the targeted siRNA nanoparticles. 
In Chapter 5, a mechanism was proposed whereby nanoparticles formed by 
electrostatic interactions with nucleic acids can be dissociated in the high salt 
environment within the bloodstream, particularly in the kidney.  Studies will need to 
examine the factors responsible for making some nanoparticles more susceptible to 
dissociation in the presence of competing electrolytes.  The electrostatic interactions may 
be more stable for polycations with higher molecular weight, but these polycations also 
may exhibit greater toxicity through mechanisms such as complement activation (as 
shown in Chapter 3).  The short length of siRNAs may also contribute to the reduced 
strength of the electrostatic interactions within the nanoparticles.  Future work must be 
done to explore how these interactions can be stabilized to keep the nanoparticles intact 
until reaching the desired target cell population after intravenous administration.  
Methods such as reversible crosslinking, as mentioned previously, may be required to 
achieve long circulation times while still allowing intracellular release of the nucleic acid 
payload.  
A more thorough examination of the intratumoral distribution of the nanoparticles 
after intravenous administration will be important to the field of nanoparticle delivery.  A 
fundamental issue to address is whether or not intact nanoparticles are responsible for the 
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observed therapeutic effects, or whether the siRNA payload is first released within the 
extracellular environment of the targeted cells.  The results from Chapter 3 comparing the 
activity of unmodified and nuclease-stabilized siRNAs may be utilized to explore this 
question.  It was shown that nuclease-stabilized siRNAs show significantly greater 
efficacy than unmodified siRNAs only if the siRNAs must first be exposed to a nuclease-
rich extracellular environment; once the siRNAs are internalized into the cells, there is no 
observable difference in the persistence or magnitude of gene inhibition.  Therefore, 
comparison of gene inhibition after delivery with unmodified and nuclease-stabilized 
siRNAs can indicate whether or not the siRNA is released prior to cellular internalization.  
If the siRNAs are only released after cellular internalization, then their efficacies would 
be expected to be very similar.  However, extracellular release of the siRNAs may lead to 
an enhanced potency observed for the nuclease-stabilized siRNAs owing to their reduced 
degradation upon exposure to the nuclease-rich extracellular environment.  Incomplete 
nuclease protection of the siRNA payload despite nanoparticle encapsulation can 
confound the conclusions from these studies, but the magnitude of this complication will 
be unknown until such studies are performed.  
If intact nanoparticles are observed to accumulate at the target site, then another 
question to be explored is the impact of surface decoration with different targeting 
ligands.  In the field of antibody therapeutics, the binding-site barrier effect limits the 
penetration of high-affinity antibodies.  This same barrier may be particularly relevant to 
targeted nanoparticles, especially in light of the avidity effects conferred by the 
multivalency of multiple targeting ligands decorating the nanoparticle surface.  If such a 
barrier does exist, then modifications of the targeting ligand density or the affinity of the 
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attached targeting ligands may be used to modulate the tumor penetration of the injected 
nanoparticles.  However, the size of nanoparticles may mask these binding-site barrier 
effects if diffusion limitations dominate.  These questions remain to be answered for 
nanoparticle formulations. 
Although not presented in this thesis work, initial studies were performed to develop 
a high-affinity targeting ligand based on a single-chain antibody fragment against the 
transferrin receptor.  The antibody fragment was cloned from a parent plasmid containing 
the anti-TfR scFv donated by Dr. David FitzGerald at the National Cancer Institute.  It 
was modified to contain a C-terminal cysteine residue to allow conjugation with PEG 
conjugates for attachment to the nanoparticle surface.  Conjugation of a fluorophore to 
this C-terminal cysteine residue enabled the use of flow cytometry to examine the 
binding properties of the anti-TfR scFv.  It was shown to strongly bind to human TfR on 
the HeLa human cancer cell line, but it exhibited no cross-reactivity to the mouse TfR on 
the Neuro2A mouse cell line.  Furthermore, competitive uptake experiments showed that 
the binding of the anti-TfR scFv was not affected by the presence of Tf.  As such, the 
nanoparticles targeted with anti-TfR scFv, unlike those targeted by Tf, will not be 
competed by endogenous Tf that is naturally present in the bloodstream.  The parental 
5e9 mAb from which the anti-TfR scFv is derived has a Kd of ~2x10-9 M, whereas Tf has 
a Kd of ~3x10-8 M.  Therefore, the anti-TfR scFv also possesses a much higher affinity 
for the TfR than Tf.  These scFv-targeted nanoparticles should exhibit extremely high 
binding affinities for cells expressing the TfR owing to the higher affinity of the anti-TfR 
scFv for the TfR, the absence of competition from free Tf, and the multivalency effects of 
multiple surface targeting ligands. 
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Altogether, these proposed studies will provide important information concerning the 
design of nanoparticle carriers for systemic siRNA delivery.  The work presented in this 
thesis provides a foundation upon which these other studies can be built.  The practical 
nature of the topics explored and their direct relevance to clinical application will 
hopefully expedite the development of more effective cancer therapies using siRNA.   
